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Cancer
Cancer is an international public health problem. A total of 1,665,540 new cancer cases and 585,720 
cancer deaths are projected to occur in the United States in 2015. Although the combined cancer 
death rate (deaths per 100,000 population per year) has been continuously declining for two 
decades, from a peak of 215 in 1991 to 172 in 2010, cancer is still a big health problem (1).
Head and neck squamous cell carcinoma
Head and neck cancer represents the sixth most common malignancy worldwide. The vast 
majority of these patients are diagnosed with head and neck squamous cell carcinoma (HNSCC) 
(Figure 1). HNSCC and its treatment can result in cosmetic deformity and functional impairment 
of vital functions, including breathing, swallowing, speech, phonation, taste, hearing, and smell. 
The estimated yearly incidence worldwide is half a million people. Nearly 50% of patients die due 
to tumor-related complications (2,3). The disease ranks age dependently among the leading types 
of solid cancer and is responsible for more than 65,000 deaths annually in Europe (4,5). More than 
50% of patients suffering from HNSCC sustain local relapses after primary treatment while up to 
25% develop distant metastases (6). Despite significant improvements in treatment options of 
these cancers, with combinations of radiotherapy (RT), surgery and systemic therapy, the five-year 
disease-free survival of those patients remains unacceptably poor (7). 
Figure 1. Squamous cell carcinoma on the left side of the tongue.
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For many years, the main prognostic factors of HNSCC have been the conventional grading, 
staging, and site of the tumor (8,9). Since the human genome project has been finished and a 
better understanding of the molecular basis of cancer has resulted, an enormous scientific field 
has arisen. Nowadays, an important goal of basic science research is to define the tumor “biological 
fingerprint” and to find key molecular components that are involved in carcinogenesis. An example 
is the epidermal growth factor receptor (EGFR). EGFR is a transmembrane tyrosine kinase receptor 
belonging to the HER/erbB family, it is overexpressed in up to 90% of HNSCC patients (10). High 
EGFR gene copy number has been reported in 10% - 58% of HNSCC. In HNSCC, in contrast to other 
cancers such as lung cancer, activating EGFR mutations are rare. Overexpression of EGFR and high 
EGFR gene copy number are associated with poor prognosis and radioresistance (11-16). EGFR is 
a relevant target in HNSCC since cetuximab, an immunoglobulin G1 (IgG1) monoclonal antibody 
targeting EGFR, improves overall survival (OS) when combined with RT or chemotherapy. However, 
only a minority of patients will benefit from anti-EGFR monoclonal antibodies, and the objective 
response rate in monotherapy is between 6% and 13% (17,18). The goal of research nowadays is 
to be able to treat the majority of patients with individualized cancer therapy by elucidating the 
major genetic and epigenetic changes per tumor. Thus, further research is necessary for this still 
deadly disease to expand the array of targeted therapies. An in-depth understanding of head and 
neck tumorigenesis and new developments in molecular biology may lead to personalized cancer 
treatment with improved overall outcomes.
Squamous cell carcinoma related oncogene (SCCRO a.k.a. DCUN1D1)
In an attempt to elucidate the biological background of HNSCC, low-resolution mapping studies 
utilizing comparative genomic hybridization (CGH) and spectral karyotyping (SKY) were performed 
and refined a region of frequent amplification to 3q25-27 (19-21). Several tumor types originating 
from mucosal squamous cell epithelium demonstrated a similar recurrent gain of the long arm of 
chromosome 3, including squamous-type non-small-cell lung cancer (NSCLC), and cancer of the 
uterine cervix (19). FISH-based fine-resolution mapping of a region of maximal amplification at 
3q26.3 in head and neck cancer cell lines identified squamous cell carcinoma related oncogene 
(SCCRO a.k.a. DCUN1D1) as a candidate oncogene within this region of frequent amplification. 
SCCRO gene amplification correlated significantly with mRNA and SCCRO protein overexpression 
in tissue and cell lines derived from head and neck and lung cancers. In primary human tumors, 
highly significant overexpression of SCCRO mRNA relative to normal tissue controls was detected 
in 36% of HNSCC, 44% of cervical carcinoma, and 48% of NSCLC tested. SCCRO overexpression is 
shown to correlate negatively with cause-free survival in non-small cell lung cancer (22). Functional 
evidence of SCCRO’s oncogenic activity came from experiments in which SCCRO was transgenically 
overexpressed in mouse fibroblasts and human immortalized keratinocytes. SCCRO-transfected 
keratinocytes gained anchorage-independent growth, while stably SCCRO overexpressing 
fibroblasts showed dedifferentiated morphology, increased proliferation, serum-independent 
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growth, enhanced invasiveness and tumorgenicity in nude mice (22). Altogether, these data 
established SCCRO as a potential novel oncogene. The next step was to characterize the molecular 
function of SCCRO. At that time, completion of the human genome sequencing project revealed 
that SCCRO was known as Defective in Cullin Neddylation 1 (DCUN1D1) in the gene database. 
During that same period, Kurz and colleagues showed that in the nematode Caenorhabditis 
elegans Defective in Cullin Neddylation (DCN-1) and in the yeast Saccharomyces Cerevisiae Dcn1p, 
both homologs of the human SCCRO/DCUN1D1, were required for the covalent modification of 
cullin proteins by the ubiquitin-like protein Nedd8 (23). This led the focus of our research, described 
in this thesis, to SCCRO’s involvement in the neddylation pathway, a pathway known to regulate 
protein ubiquitination. 
Ubiquitination
The ubiquitination of proteins involves the hierarchical action of three ubiquitin enzymes (Figure 
2). An E1 enzyme must first activate ubiquitin (Ub), a highly conserved 76 amino acid polypeptide. 
The thioesterified ubiquitin passes from the E1 active site to the next member of the cascade, the 
E2 or ubiquitin-conjugating enzyme. Finally, the E3 ubiquitin ligase binds to both the E2-bound 
ubiquitin and the protein substrate, promoting the transfer of ubiquitin onto the substrate. There 
are several hundred different ubiquitin pathway E3 ligases (24). Cullin-Ring ubiquitin ligases (CRL’s) 
comprise the largest known category of ubiquitin ligases. Eukaryotic species contain multiple 
cullins. Each cullin forms a distinct class of CRL complex with distinct adaptors and/or substrate-
recognition subunits. Despite this diversity, each of the classes of CRL complexes is subject to 
similar regulatory mechanisms (25). 
Figure 2 shows the neddylation and ubiquitin pathway.
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In the ubiquitin pathway proteins can either be conjugated to one ubiquitin monomer, 
referred to as mono-ubiquitination, or to several ubiquitins to form a poly-ubiquitin chain. Mono-
ubiquitination modifies proteins, changes their activity and in that way mediates downstream 
effects. Proteins conjugated to chains of ubiquitin may be directed to the 26S proteasome where 
they then become degraded or undergo alteration of their activity. Degradation occurs through 
the ubiquitin-proteasome system (UPS), a highly complex process (26). The ubiquitin system plays 
important roles in a variety of basic cellular processes. Among these are regulation of cell cycle 
and division, apoptosis, transcription, modulation of the immune and inflammatory responses and 
development and differentiation (27). The association between ubiquitination and cancer is evident 
from the multiple tumor suppressor genes and oncogenes that are regulated in this manner (27). 
Neddylation 
Like ubiquitination, neddylation results from an enzymatic cascade involving the sequential 
activity of a dedicated E1 (APPBP1/Uba3), E2 (Ubc12), and E3 enzyme (Figure 2) (27,28). Covalent 
modification of cullins by the ubiquitin like protein (UBL) Nedd8 regulates protein ubiquitination 
by promoting the assembly of CRL E3 complexes, thus activating protein ubiquitination. Nedd8 
modification of cullins is crucial for CRL dependent ubiquitination (30,31). Most UBL’s don’t target 
their substrates for degradation, but rather change their activity by, for example, providing a (new) 
binding surface for interaction partners (26,32).
SCCRO family
Completion of the human genome sequencing project revealed that SCCRO is a member of 
a protein family that contains four other highly conserved paralogs in higher organisms, all 
of which contain a conserved C-terminal potentiating of neddylation (PONY) domain with a 
variable N-terminal region. SCCRO paralogs are subdivided into three subfamilies on the basis 
of the N-terminal sequence: SCCRO and SCCRO2 (a.k.a. DCUN1D2) contain a ubiquitin associated 
(UBA) domain, SCCRO3 (a.k.a. DCUN1D3) contains a myristoylation sequence and SCCRO4 (a.k.a. 
DCUN1D4) and SCCRO5 (a.k.a. DCUN1D5) contain a nuclear localization sequence (NLS) (Figure 3). 
Like SCCRO (at 3q26), its paralogs are located in chromosomal loci that are recurrently amplified 
in human cancers (SCCRO2 at 13q34, SCCRO4 at 4q12, and SCCRO5 at 11q22) (33-40). Therefore, 
we sought to unravel their molecular function and their clinical relevance and to evaluate their 
potential roles in carcinogenesis. 
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Figure 3. Phylogenetic analyses of the SCCRO gene family.
Evolutionary tree showing the inferred evolutionary relationships among various biological species – their 
phylogeny based upon similarities and differences in their physical or genetic characteristics. Here shown the 
phylogenetic or evolutionary tree of the SCCRO/DCUN1D genes. Numbers: boot strap comparison. 
a, Anopheles gambiae ; ce, C.elegans; dm, Drosophila melanogaster; h, Homo sapiens; m, Mus musculus; Sc, 
S. cerevisiae. 
Translational relevance
Targeted therapy based on common molecular aberrations consitutes the future of cancer therapy. 
In this regard, the characterization of SCCRO in the neddylation pathway is not only important in 
the understanding of basic cellular biology, but also for oncogenesis. The observation that changes 
in protein homeostatis drive human cancer pathogenesis has led to the discovery of several 
important anticancer therapies. In this regard, the ubiquitin proteasome system is of significance, as 
Chapter 1
14
there is a high prevalence of aberrations among the components of this pathway. The link between 
abnormal CRL activity and dysregulation of proteins involved in neddylation in human cancers has 
only recently been appreciated (41). These observations have led to the development of a small 
molecule inhibitor of neddylation E1, MLN4924. Inhibition of neddylation by the Nedd8 activating 
enzyme (NAE) inhibitor MLN4924 has shown statistically significantly suppressed proliferation, 
survival, migration and motility of lung cancer cells in vitro and tumor formation and metastasis in 
vivo and has shown promise in preclinical and early human trials (42). Also, the therapeutic potential 
of inhibition of the ubiquitin proteosome system (UPS) has been validated with the first-in-class 
proteasome inhibitor, Bortezomib, which is approved for the treatment of multiple myeloma and 
the treatment of relapsed mantle cell lymphoma (43,44). 
Altogether, this underscores the importance of elucidating the function of the ubiquitin and 
neddylation pathways. In this thesis we solve a piece of this puzzle by characterizing the role of the 
human SCCRO gene family in the neddylation pathway and in carcinogenesis.
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Outline of the thesis
In this thesis we have set the first steps in understanding the molecular function of the human 
SCCRO gene family in neddylation and in carcinogenesis.
Chapter 2 describes the molecular function of SCCRO in the neddylation pathway. We show 
that SCCRO binds to the components of the neddylation pathway (Cullin-ROC1, Ubc12, and CAND1) 
and augments, but is not required for cullin neddylation in reactions using purified recombinant 
proteins. We show that SCCRO enhances recruitment of Ubc12~Nedd8 to the CRL complex and is 
necessary to dissociate CAND1.
In chapter 3 we define the contribution of the N-terminal UBA domain to SCCRO’s function. We 
show that binding of polyubiquitin chains to the UBA domain inhibits SCCRO’s neddylation activity 
by inhibiting SCCRO-promoted nuclear translocation of neddylation components. We suggest that 
the UBA domain of SCCRO functions as a negative regulator of SCCRO’s function. 
Chapter 4 describes the function of SCCRO3. We find that SCCRO3 is often underexpressed in 
various human cancers and we attempt to define the cause of decreased expression of SCCRO3. We 
show by structure-function and cell based assays that SCCRO3 may function as a tumor suppressor. 
Our findings suggest that SCCRO3 antagonizes SCCRO mediated neddylation and oncogenic 
activity by blocking nuclear localization of cullins and hence cullin neddylation. 
In chapter 5 we elucidate the role of SCCRO5 as a target that drives selection for 11q22 
amplification in human cancers. Gene expression levels and protein levels are assessed and clinical 
correlations are described. The molecular mechanism is unraveled by showing its function in the 
neddylation pathway and further explored by cell based assays. 
Finally, chapter 6 further illustrates the translational importance of this basic science research as 
we examine the role of the SCCRO family of genes in various human cancers and describe a novel 
biochemical assay to look for ubiquitination activities in human tissue and use this in a subset of 
thyroid cancer. 
In chapter 7 we recapitulate the role of the human SCCRO gene family, the importance of 
neddylation and ubiquitination in cell function and in carcinogenesis. Finally, topics for further 
investigation are discussed in this chapter. 
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Abstract
Covalent modification of cullins by the ubiquitin-like protein Nedd8 (neddylation) promotes 
protein ubiquitination by fostering the assembly of cullin-RING ligase (CRL) E3 complexes. Like 
ubiquitination, neddylation results from an enzymatic cascade involving the sequential activity of a 
dedicated E1 (APPBP1/Uba3), E2 (Ubc12) and an ill-defined E3. We show that SCCRO (a.k.a. DCUN1D1) 
binds to the components of neddylation pathway (Cullin-ROC1, Ubc12, and CAND1) and augments 
but is not required for cullin neddylation in reactions using purified recombinant proteins. We also 
show that SCCRO recruits Ubc12~Nedd8 to the CAND1-Cul1-ROC1 complex, but that this is not 
sufficient to dissociate CAND1 or overcome its inhibitory effects on cullin neddylation in purified 
protein assays. In contrast to findings in cellular systems, we show that SCCRO and CAND1 can bind 
to the neddylated Cul1-ROC1 complex in assays using purified recombinant proteins. Although 
neddylated (not unneddylated) Cul1-ROC1 is released from CAND1 upon incubation with testis 
lysate from SCCRO+/+ mice, the addition of recombinant SCCRO is required to achieve the same 
results in lysate from SCCRO-/- mice. Combined, these results suggest that SCCRO is an important 
component of the neddylation E3 complex that functions to recruit charged E2 and is involved in 
the release of the inhibitory effects of CAND1 on CRL E3 complex assembly and activity.
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Introduction
Post-translational modification of proteins by ubiquitin (Ub) regulates diverse cellular functions 
including protein turnover, differentiation, apoptosis, cell cycle and transcription (1-5). Given its 
essential role, ubiquitination is a highly regulated process that involves the sequential action of 
three enzymes termed as E1, E2 and E3. In this enzymatic cascade, E1 initiates the process by forming 
a high energy thioester bond with Ub in an ATP coupled reaction. The Ub is then transferred to E2 
as a thioester intermediate. Finally, E3s serve as the targeting arm in the ubiquitination process 
mediating the transfer of Ub from E2 to the target protein to create an isopeptide bond between 
the c-terminal glycine in Ub and a lysine residue on the substrate protein. Once attached, the 
Ub itself can be modified to generate poly-ubiquitin chains on the target protein (6). The signal 
initiated by ubiquitination is influenced by the chain length and the residue on the Ub to which 
the chain is attached. Poly-ubiquitination promotes the translocation to the 26S proteosome 
for degradation. Other functional effects of mono- and poly-ubiquitination include protein 
translocation, interaction and activation.
Although there is only one known E1 (except in plants) and relatively few E2s, E3s exist in 
multiple forms to allow for specific protein targeting (6). In general, E3s are modular multiprotein 
complexes that can be divided into two broad categories based on the presence of either a HECT 
(homologous to E6-AP carboxy terminus) or RING (Really Interesting New Gene) finger domain 
containing protein at their core. While HECT E3s form a thioester intermediate with the Ub before 
its transfer, RING containing complexes serve as scaffolds to facilitate the direct transfer of Ub from 
E2 to the target protein. 
Cullin RING ligases (CRLs) constitute the largest class of E3s in mammals (7,8). All CRLs are 
anchored by cullins, a highly conserved protein family with 7 known isoforms in humans (Cul1, 
Cul2, Cul3, Cul4a, Cul4b, Cul5, and Cul7). A small RING protein (ROC1) and a variable substrate 
recognition subunit bind to the cullin core to form the CRL complex. The SCF (SKP1 cullin1 F-box) 
complex is the prototypic CRL E3 complex and is made up of ROC1 bound to the C-terminus and 
SKP1 adaptor protein bound to the N-terminus of Cul1. SKP1 in turn binds to a host of different 
F-box containing proteins to confer target specificity and ROC1 binds to E2 to form the catalytic 
core of the SCF complex.
Assembly of CRL complexes serves as a key regulatory step for ubiquitination. Cullins normally 
exist as part of two mutually exclusive complexes in cells. The majority of cullins are in complex 
with CAND1 (Cullin Associated Nedd8 Dissociated-1) which sterically inhibits assembly of CRL 
complexes. The covalent modification of cullins with the ubiquitin like protein (Ublp) Nedd8, 
in a process termed neddylation, dissociates CAND1 and promotes assembly of CRL complexes 
(9-12). In addition, cullin neddylation also enhances CRL activity through the recruitment of 
ubiquitin E2s to the complex and possible facilitation of cullin heterodimer formation (13-15). 
Conversely, deneddylation of cullins, principally by the COP9 signalosome, promotes dissociation 
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of CRL complexes and binding to CAND1. Several studies suggest that cycling of neddylation and 
deneddylation is required for normal CRL function. (8,16,17). Neddylation occurs by mechanisms 
analogous to Ub or Ublp conjugation, involving the sequential activity of a dedicated E1, E2 and 
E3. While APPBP1/Uba3 functions as the E1 and Ubc12 as the E2, the precise components of the 
neddylation E3 remain to be established. Using a positional cloning strategy, we identified SCCRO 
(Squamous Cell Carcinoma Related Oncogene) within a recurrent amplification peak at 3q26.3 in 
squamous cell carcinomas (18). Here we show that SCCRO interacts with known cullin isoforms 
as well as ROC1, Ubc12 and CAND1. SCCRO preferentially binds to Ubc12~Nedd8 thioester and 
augments cullin neddylation in both lysate and purified systems. Although SCCRO is not essential 
in a purified system, lack of neddylation in extracts made from SCCRO-/- mice suggest that it plays 
an important role in vivo. Details of the SCCRO knock-out mouse construction and characterization 
will be published elsewhere (Kaufman et. al., manuscript in preparation). Although purified 
recombinant SCCRO on its own does not overcome CAND1 inhibition of cullin neddylation, lysate 
from SCCRO+/+ mice and not SCCRO-/- mice could dissociate CAND1. These findings suggest that 
SCCRO plays an essential role in neddylation and supports its inclusion as a component of the E3 
complex for neddylation.
Experimental procedures
Alignment and sequence analyses
Database and Blast searches were carried out at NCBI (http://www.ncbi.nlm.nih.gov).  Multiple 
sequence alignments were performed using the ClustalW program. 
Reagents
All constructs were generated by standard PCR-ligation based methods and verified by automated 
sequencing. Proteins were expressed as GST fusions in E. coli and induced overnight at 18oC with 
the addition of 1 mM IPTG, purified by passing through Glutathione Sepharose 4B beads (GE 
Healthcare, WI) followed by thrombin cleavage where required.  Cul1-ROC1 was expressed and 
purified from E. coli essentially as described (19). APPBP1/Uba3, Ubc12 and Nedd8 were obtained 
from a commercial source (Boston Biochem, MA).
cDNAs for mammalian transfection were cloned into pUSEamp or pCMV-HA vector (Clontech, 
DE). Anti-SCCRO RNAi, and scrambled RNAi were generated, validated and used as previously 
described (18). Transfection was carried out with Lipofectamine 2000 (Invitrogen, CA) or FuGene 
(Roche, NJ) using manufacturer’s specifications. 
All cell lines used in this study were obtained from ATCC (American Type Culture Collection, 
Rockville, MD) and grown at 37oC in 5% CO2 . HeLa cells were maintained in minimal essential media 
(MEM) supplemented with 10% fetal calf serum (FCS) containing antibiotics.
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The following antibodies were used in this study: anti-Cul1 (Zymed, CA), anti-Cul2 (Abcam, 
MA), anti-Cul3 (BD Biosciences, CA), anti-Cul4, anti-Cul5 (Santa Cruz, CA), anti-ROC1 (Abcam, MA), 
anti-SKP1 (Abnova, Taiwan), anti-Ubc12 (Rockland, MA), anti-Nedd8 (Invitrogen, CA), anti-CAND1 
(BD Biosciences, CA), anti-α-tubulin (CalBiochem, WI), anti-HA (Abcam, MA), and Anti-Flag (Sigma, 
MO). Anti-SCCRO (rabbit polyclonal) antibody was produced and utilized as described previously 
(Sarkaria et al., 2006). Secondary antibodies conjugated to horseradish peroxidase (Santa Cruz, CA) 
were used according to the manufacturers’ specifications. 
GST pull down assay
GST tagged proteins were bound to Glutathione Sepharose beads by gentle rocking at 4oC for 30 
minutes. The beads were washed three times with EBC buffer (50 mM Tris-HCl pH (7.5), 2.5 mM 
MgCl2, 150 mM NaCl, and 0.5% NP40) at 20x bead volume. The beads were incubated with 500 μg 
of HeLa cell lysate or purified proteins as indicated at 4oC for 1 hour followed by three washes with 
EBC buffer at 20x bead volume. Bound proteins were eluted by the addition of 6x Lamelli buffer, 
resolved on SDS-PAGE and analyzed by western blot. For mass spectrometric analysis, the resolved 
proteins were stained with Coomassie R250. Bands were excised and subjected to matrix-assisted 
laser-desorption/ ionization reflectron time-of-flight (MALDI-reTOF) mass spectrometric analysis.
Immunoprecipitations
Immunoprecipitations were performed essentially as described earlier (18). In brief, all cells were 
lysed using mammalian cell lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
μg/ml leupeptin (Cell Signaling, MA). One mg of cell lysate was incubated with HA antibody bound 
to agarose beads by gentle rocking at 4oC for 2 hours. The same wash and detection sequence was 
used as for the GST pull down assay. 
Thioester reactions
Reactions were performed at room temperature in a buffer (50 mM Tris-HCl (pH 7.6), 50 mM NaCl, 
10 mM MgCl2, 0.5 mM DTT) with 4 mM ATP, 80 nM APPBP1/Uba3, 800 nM Ubc12 and 9 μM Nedd8. 
Reactions were quenched with 3x non-reducing Lamelli buffer (without DTT) and the presence of 
Ubc12~Nedd8 thioester complexes were verified by western blot for Ubc12 and/or Nedd8 in the 
presence and absence of 50 mM DTT. Time course experiments showed that incubation times greater 
than 10 minutes resulted in the formation of a small fraction of Nedd8 bound to Ubc12 that was not 
reducible by DTT. Accordingly, all thioester reactions were carried out for 10 minutes or less. For use 
in binding assays, the reaction mix was quenched with the addition of EDTA to a final concentration 
of 50 mM and purified on a G-50 micro spin desalting column. For competition experiments, 
reaction conditions were identical except for the addition of a gradient of free Ubc12 to the purified 
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thioester reaction mix. For thioester reaction involving the competition between E1 and SCCRO for 
Ubc12, all components were added simultaneously and loading of Nedd8 to Ubc12 was assessed 
by western blotting. Reaction conditions for HeLa transfected with HA-Ubc12 or HA-Ubc12Δ1-26 
was the same, except a longer incubation time (30 min) was employed for HA-Ubc12Δ1-26. 
In vitro neddylation
The source of Cullin-ROC1 substrate for in vitro neddylation reactions was either HeLa lysates or 
bacterially derived (see above). For reactions using HeLa derived Cullin-ROC1 complexes, 100 µg of 
lysates (estimated Cul1 concentration is 20 fmol) were added to reactions containing 0.2–2 pmol of 
APPBP1/Uba3, 1–12.5 pmol Ubc12, and 150 pmol of cold Nedd8 or 32P-Nedd8, in neddylation buffer 
(100 mM Tris-HCl, pH 7.8, 150 mM NaCl, 2.5 mM DTT, and 5 mM MgCl2). Reactions were incubated 
at 30oC and stopped with the addition of 6x Lamelli buffer.  Reactions with bacterially derived 
substrate were performed at 30oC in neddylation buffer containing 20 nM Cul1-ROC1, 4 mM ATP, 10 
nM of APPBP1/Uba3, 20 nM Ubc12, and 0.9 μM of Nedd8. In reactions containing CAND1, Cul1-ROC1 
was preincubated with the indicated amounts of CAND1 for 15 min at room temperature. Proteins 
were resolved on an SDS-PAGE and subjected to autoradiography and/or western blot analysis. For 
quantification, western blots were imaged using MultiImage Light Cabinet and quantified using 
AlphaEaseFC v3.2.1 (Alpha Innotech Corp., CA). 
Assay for binding to neddylated and unneddylated cullins
Neddylation reactions were performed on purified Cul1-ROC1 at 30oC for the indicated time. The 
reactions were stopped by the addition of EDTA to a final concentration of 50 mM and the products 
purified on a G-50 micro spin desalting column. A small aliquot of the flow-through was subjected 
to western blot analysis for Cul1 to establish the level of cullin neddylation. The remaining flow-
through was incubated with GST-SCCRO and/or GST-CAND1 (at limiting concentrations) at room 
temperature for 20 minutes, followed by the addition of Glutathione Sepharose beads and 
incubation with gentle rocking at 4oC for 45 minutes. After three 20x bead volume washes with 
EBC wash buffer, 6x Lamelli buffer was added to the beads and bound proteins were resolved on 
an SDS-PAGE and analyzed by western blot for Cul1. To assess the effects of lysate on release of 
cullins from CAND1, neddylated or unneddylated Cul1-ROC1 was incubated with GST-CAND1 at 
room temperature for 20 minutes and rocked at 4oC for 30 minutes. SCCRO, SCCRO-D241N and/or 
testis lysate from SCCRO+/+ or SCCRO-/- mice was added onto the beads and rotated at 4oC for 1 hour, 
followed by three 20x bead volume washes with EBC buffer. 6x Lamelli buffer was added to the 
beads and bound proteins were analyzed by western blot for Cul1. 
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Results
SCCRO interacts with components of the neddylation pathway
We identified SCCRO by fluorescent in situ hybridization (FISH)-based fine resolution mapping of 
a recurrent amplification at 3q26.3 that is present in multiple human cancers (18,20-22). As a step 
towards understanding the molecular function of SCCRO, we sought to identify interacting proteins. 
GST-SCCRO pull down from HeLa lysates identified two unique bands relative to GST alone (Fig. 1A). 
These bands were excised and subjected to mass spectrometric analysis (MALDI-ReTOF) identifying 
CAND1 and members of the cullin family of proteins (Cul1, Cul2, Cul3, and Cul4) as putative binding 
partners (Fig. 1A). We confirmed these interactions by GST-SCCRO pull down from HeLa lysates 
followed by western blot for each of the identified proteins. In addition, we found that SCCRO also 
binds to Cul5 and ROC1 (Fig. 1B). GST pulldown assays using purified proteins showed that SCCRO 
directly binds to ROC1 consistent with findings in yeast (data not shown) (23). Since they are soluble 
only as a complex with ROC1, we could not assess if SCCRO can also bind to cullins directly.
Given the established role of CAND1 and the cullin family of proteins in neddylation, we assessed 
for binding to other proteins in the neddylation pathway, including Nedd8, APPBP1/Uba3, and 
Ubc12 and found that SCCRO interacts with Ubc12 (Fig. 1B, lane 2). The co-immunoprecipitation 
of SCCRO with each of its putative binding partners in HA-SCCRO transfected HeLa cells confirmed 
that the observed interactions occur in cells (Fig.1C, lane 2). SCCRO does not bind to Ubc9 (an E2 for 
sumolation), SKP1 or SKP2, suggesting that its interactions are specific to the components of the 
neddylation pathway (data not shown). To confirm these interactions occur in vivo, we performed 
immunoprecipitation experiments using a SCCRO monoclonal antibody that is highly sensitive and 
specific for SCCRO. Western blots on the immunoprecipitates showed that SCCRO binds to Cul1, 
ROC1, and CAND1 (Fig.1D, left panel). Similarly, reciprocal immunoprecipitation for ROC1 followed 
by Western blotting confirmed the interaction with SCCRO as well as CAND1, Cul1 and SKP2 (Fig. 1D, 
right panel). While SCCRO did not interact with SKP2, ROC1 bound, as expected.
To map binding domains we created a series of SCCRO deletions and point mutants as GST 
fusions, including those involving the N-terminal UBA (aa 8-45) and C-terminal DCUN1 domain (aa 
60-259) (Fig. 1B,C, and E, and supplemental Fig.2). Whereas the N-terminal deletions (SCCROΔ1-33, 
SCCROΔ1-45, and SCCROΔ1-82) retained binding, C-terminal deletions (SCCROΔ151-259 and 
SCCROΔ210-259) lost detectable binding to CAND1, Cul-ROC1 and Ubc12, suggesting that these 
proteins interact with the C-terminal 49 amino acids within the DCUN1 domain of SCCRO (Fig. 1B 
and C, lane 3 and 4, and E). Point mutations were generated in highly conserved residues within 
the C-terminal region of SCCRO and tested for binding to cullins, CAND1 and Ubc12. SCCRO-D241N 
lost detectable binding to CAND1 and Cul-ROC1 complex, but not to Ubc12 suggesting that Ubc12 
and CAND1/Cul-ROC1 bind to different regions within the C-terminus of SCCRO (Fig. 1B, lane 6). Our 
findings using a biochemical approach are consistent with results from structure based analyses of 
C. elegans and S.cerevisiae DCN-1/Dcn1p where mutations in a similar residue (D259) also resulted 
in loss of binding to cullin-ROC1 (23-25).
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 Figure 1. SCCRO Interacts with Cullins, CAND1 and Ubc12. 
(A), Coomassie-stained SDS-PAGE gel showing GST (lane 1) and GST-SCCRO (lane 2) pulldown products from 
HeLa extracts. Unique bands from GST-SCCRO pulldown assays were excised and subjected to tandem mass 
spectroscopy analysis (MALDI-ReTOF) revealing the 120-kDa band as CAND1 and the 80–90-kDa bands as 
cullins 1–4. (B), Western blot on the pulldown products of GST-SCCRO and GST-SCCRO mutants from HeLa 
extracts probed with indicated antibodies showing SCCRO binds to CAND1, cullins 1–5, ROC1, and Ubc12 (lane 
2). The C-terminal (SCCRO∆210–259; lane 4) but not the N-terminal deletion of SCCRO (SCCRO∆1–33; lane 3) or 
the N-terminal point mutant of SCCRO (SCCRO_L30A; lane 5) lost interaction with the Cullin-ROC1, CAND1, 
and Ubc12. SCCRO-D241N lost interaction with the Cullin-ROC1 and CAND1 while retaining binding to Ubc12 
(lane 6). The level of the various GST-tagged proteins used in the pulldown experiment was confirmed by 
probing a Western blot with anti-GST antibody (bottom panel). (C), Western blot showing products from an HA 
immunoprecipitation (IP) of lysates from HeLa cells transfected pCMV-HA-SCCRO or selected SCCRO deletions/ 
mutants probed with indicated antibodies showing SCCRO maintains binding to neddylation components in 
vivo (lane 2). SCCRO∆210–259 (lane 4) and SCCRO-D241N (lane 6) lose binding to cullins, ROC1, and CAND1. (D), 
Western blot on immunoprecipitates from HeLa extract prepared with anti- SCCRO (left panel; lane 2) anti-
ROC1 (right panel; lane 2) or preimmune serum (PIS; lane 1) probed with indicated antibodies showing in vivo 
interaction between native SCCRO and CAND1, Cul1, and ROC1 but not SKP2 (left panel), whereas ROC1 binds 
to CAND1, Cul1, SCCRO, and SKP2 (right panel). (E), summary of results from pulldown assays using GST-SCCRO 
or SCCRO deletions/mutations showing binding of CAND1, Cul-ROC1, and Ubc12 requires C-terminal 50 amino 
acids. SCCRO-D241N loses binding to CAND1 and Cul1-ROC1 but retains binding to Ubc12.
 GST-SCCRO
    100kD
A 
GST 
  50kD
 CAND1 
Cullin 1,2,3,4
G
ST
 
G
ST
-S
C
C
R
O
Coomassie stain
B
αCAND1 
αCul1 
αCul2 
αCul3 
αCul4 
αROC1
αCul5 
G
ST
 
SC
C
R
O
Δ
1-
33
Δ
21
0-
25
9
L3
0A
D
24
1N
αGST 
αUbc12 
Western blot
pC
M
V
-H
A
 
H
A
-S
C
C
R
O
Δ
21
0-
25
9
H
A
-S
C
C
R
O
αCAND1 
αCul1 
αCul3 
αCul2 
αROC1
H
A
-S
C
C
C
R
O
Δ
1-
33
H
A
-S
C
C
R
O
-L
30
A
H
A
-S
C
C
R
O
-D
24
1N
HA-IP
C 
SCCRO Mutants Cul-ROC1 Ubc12 CAND1
Wild type + + + 
Δ1-33 + + + 
Δ1-45 + + + 
Δ1-82 + + + 
Δ151-259 - - -
Δ210-259 - - -
L30A + + + 
D218N + + + 
D231N + + + 
E232Q + + + 
D231N, E232Q + + + 
G234E + + + 
V238A + + + 
I240F + + + 
D241N - + -
D242A + + + 
E
1     2     3     4      5     61                 2 1        2        3       4        5       6
D 
IP-Western
αCAND1 
αCul1 
αSCCRO
αROC1
IP-Western
αCAND1 
αCul1 
αROC1
αSCCRO
1         2 1         2
α Skp2 α Skp2
D E
B C
Chapter 2
28
SCCRO augments cullin neddylation
Recently it was reported that DCN-1/Dcn1p, the C. elegans and S.cerevisiae orthologs of SCCRO, 
facilitate cullin neddylation (23-25). To test if the human ortholog also promotes cullin neddylation, 
we performed in vitro neddylation assays in the presence of varying concentrations of SCCRO. 
Reactions containing Nedd8, recombinant APPBP/Uba3 (E1), Ubc12 (E2), ATP and whole cell lysate 
from HeLa cells (as a source of cullin-ROC1 substrate) showed a dose dependent increase in cullin 
neddylation with SCCRO (Fig. 2A and B). A time course reaction showed that SCCRO also enhances 
the rate of cullin neddylation (Fig. 2C and D). 
To determine if binding is required for the observed functional effects, we supplemented 
neddylation reactions with SCCRO or selected SCCRO deletions. Whereas the N-terminal deletion 
(SCCROΔ1-33)  enhanced the rate of Cul3 neddylation to levels similar to SCCRO, the C-terminal 
deletion (SCCROΔ210-259) that loses binding to Ubc12 and Cul-ROC1 failed to augment cullin 
neddylation beyond basal levels (Fig. 2C and D). These findings suggest that the effects of SCCRO 
on cullin neddylation require its interaction with Cul-ROC1 and/or Ubc12 and implicate it is a 
component of the neddylation E3.
Furthermore, cullin neddylation increased with transient expression of HA-SCCRO and decreased 
with knockdown of SCCRO by RNAi (Fig. 3B and D). The decrease in cullin neddylation as a result 
of SCCRO protein knockdown by RNAi was rescued by the addition of recombinant SCCRO to the 
lysate (Fig. 3D).
SCCRO is not required for neddylation in vitro
Several in vitro studies suggest that ROC1 functions as an E3 ligase and is sufficient to promote 
neddylation by itself (26-29). To determine the effect of SCCRO on cullin neddylation, we 
performed a time course reaction using recombinant purified components (E1, E2, ATP, Nedd8 
and Cul1-ROC1). Although Cul1 neddylation occurred in its absence (Fig. 2F, lanes 2,3,4), addition 
of SCCRO enhanced the rate of cullin neddylation (Fig. 2F, compare lanes 2,3,4 with 6,7,8). This is 
consistent with published reports showing cullin neddylation occurs in the absence of SCCRO in 
vitro (26,28). However, neddylation is absent in testis lysates from SCCRO knockout mice (Fig. 3E, 
right panel) (Kaufman et al., unpublished data). Similar findings are also reported in C. elegans and 
S. cerevisiae where DCN-1/Dcn1p knockouts also lose neddylation activity (24). Combined these 
findings suggest that although SCCRO is not required for neddylation in vitro, it is essential in vivo. 
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Figure 2. SCCRO augments Cullin neddylation in vitro. 
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(A) and (B), plot showing levels of Cul1 (A) and Cul3 (B) (mean ± S.E.) neddylation quantified by densitometry 
of Western blots from three independent in vitro neddylation reactions containing HeLa extract (as a source of 
cullin substrate), E1, E2, ATP, Nedd8, and a concentration gradient of SCCRO. The fraction of neddylated Cul1 
(A) and Cul3 (B) increased with increasing SCCRO concentration. Representative Western blots from in vitro 
neddylation reactions are shown as insets. (C), a plot showing the fraction of neddylated Cul3 (means ± S.E.) 
against time in minutes from three independent neddylation assays. SCCRO but not SCCRO-D241N enhances 
neddylation efficiency. (D), representative Western blot from C showing Cul3 neddylation in presence of 
SCCRO or SCCRO-D241N. (E), results from in vitro neddylation reaction supplemented with SCCRO (lanes 2 and 
3) or SCCRO deletions showing SCCRO∆1–33 (lanes 4 and 5) but not the C-terminal deletion SCCRO∆210–259 
(lanes 6 and 7) retained neddylation activity. (F), Western blot for Cul1 from a time course in vitro reaction 
containing purified, bacterially expressed Cul1-ROC1 showing SCCRO enhances efficiency but is not required 
for neddylation.
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Figure 3. SCCRO augments cullin neddylation in vivo. 
(A), Western blot on HeLa lysates showing elevated SCCRO protein levels in SCCRO transfected (lane 3) relative to 
untransfected (lane 1) or vector-transfected (lane2) cells. (B), Western blot showing a higher level of neddylated 
cullins in lysates from SCCRO transfected (lane 2) relative to vector-transfected cells (lane 1). Western blot on 
HeLa lysates from B after addition of neddylation components (E1, E2, Nedd8, and ATP) showing increased 
neddylated Cul1 levels in SCCRO-transfected (lane 4) relative to empty vector (lane 3)-transfected cells. (C), 
Western blot on lysates from SCC15 cells showing a decrease in SCCRO protein levels in cells transfected with 
specific RNAi against SCCRO (lane 3) relative to untransfected (lane 1) or scrambled RNAi-transfected cells (lane 
2). (D), in vitro neddylation reaction of the same lysates showing decreased Cul1 neddylation in SCCRO-RNAi 
transfected (lane 3) compared with untransfected (lane 1) or scrambled RNAi (lane 2)-transfected cells. The 
addition of recombinant SCCRO to the lysate from SCCRO RNAi-transfected SCC15 cells (lane 6) recovers Cul1 
neddylation to levels observed in controls (lanes 4 and 5). (E), Western blot showing the absence of detectable 
SCCRO protein in testis lysates from SCCRO-/- mice (left panel, lane 2) in contrast to a SCCRO-/- (left panel, lane 1) 
litter mate control. The same lysates were subjected to neddylation assays (right panel) showing a significant 
decrease in neddylated Cul3 levels in SCCRO-/- mice (lane 2).
SCCRO preferentially interacts with Ubc12 thioester intermediate
The mechanisms and reaction processivity involved in the conjugation of Ub and Ublp are 
highly conserved. A mutually exclusive interaction between E1 and E3 with E2 is a key aspect in 
maintaining reaction processivity. Accordingly, an E2 conjugating enzyme must dissociate from 
its cognate E1 before binding to E3 (30). One way this is achieved is the differential affinity of E1 
and E3 for free and conjugated E2. Several studies show that the affinity of E2 for E1 (and E3 to E2) 
SCCRO is an essential component of the E3 complex for neddylation
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is higher when the latter is loaded with Ub or Ublp (13,31,32). If SCCRO functions as a component 
of the neddylation E3, it should have greater affinity for Ubc12~Nedd8 thioester over free Ubc12. 
GST-SCCRO pull down from a Ubc12 thioester reaction followed by western blot for Ubc12 showed 
that SCCRO preferentially binds to Ubc12~Nedd8 thioester even in the presence of large excess 
of free Ubc12 (Fig. 4A, lane1,3). To quantify the differences in binding affinity of SCCRO for Ubc12 
and Ubc12~Nedd8, competition experiments were performed. GST-SCCRO pull downs from 
a mixture containing Ubc12~Nedd8 (generated and purified as discussed in the experimental 
procedures section) and a gradient of free Ubc12 followed by westernblot showed that SCCRO 
preferentially binds to Ubc12~Nedd8 even in the presence of ≥ 20-fold excess of free Ubc12 (Fig. 
4B, lane 3). Similarly, when lysates from HA-SCCRO transfected HeLa cells that were subjected to 
in vitro thioester reaction (Fig. 4C, top and middle panel) were immunoprecipitated with anti-HA 
antibody and probed for Ubc12, preferential binding of SCCRO to Ubc12~Nedd8 was detected 
(Fig. 4C, bottom panel). The preferential interaction with Ubc12~Nedd8 thioester over free Ubc12 
suggests that SCCRO conforms to the conserved processivity paradigm of Ub and Ublp pathway 
and supports its role as a component of the E3 complex for neddylation. 
SCCRO interacts with the unique N-terminus of Ubc12
A second mechanism ensuring processivity in Ub and Ublp conjugation results from the presence 
of overlapping binding sites on E2 for E1 and E3, making their interactions mutually exclusive (30). 
Like all E2s, Ubc12 contains a ~150 residue catalytic core domain. However, it is distinguished from 
other E2s by the presence of a unique N-terminal extension (33). Studies have shown that both 
the N-terminal extension and the catalytic core domain of Ubc12 are involved in its interaction 
with the Nedd8~E1 (33). ROC1 binds to the catalytic core domain of Ubc12, with no known role 
for the N-terminal extension in the Ubc12-ROC1 interaction (11,34). To determine if SCCRO 
binds to the unique N-terminal region of Ubc12 or to the catalytic core domain, we performed 
HA-immunoprecipitation on lysates from HeLa cells transfected with either HA-Ubc12 or HA-
Ubc12∆1-26 (N-terminal deleted Ubc12) and probed for SCCRO on a western blot. Since SCCRO 
preferentially interacts with the Ubc12~Nedd8 thioester, we performed a thioester reaction on 
the lysate to generate Nedd8 loaded HA-Ubc12 and HA-Ubc12∆1-26 prior to immunoprecipitation 
(Fig. 4D, top). As the efficiency of thioester formation is lower for Ubc12∆1-26 deletion, we allowed 
the reaction adequate time to run to completion so as to generate an equivalent amount of the 
Nedd8 thioester.  Even though longer incubation time was required to generate HA-Ubc12∆1-
26~Nedd8, this interaction was reducible with DTT, suggesting the presence of a thioester bond 
(data not shown). Despite equal loading of Nedd8 to Ubc12 and Ubc12Δ1-26 (Fig. 4D, top), only 
HA-Ubc12 pulled down SCCRO (Fig. 4D, middle). However, ROC1, which is known to interact with 
the conserved core domain of Ubc12, bound to both HA-Ubc12 and HA-Ubc12Δ1-26 (Fig. 4D, 
bottom). These observations suggest that the binding site of SCCRO on Ubc12 (E2) overlaps with 
the Nedd8~E1. Moreover, unlike ROC1 which interacts with the conserved core domain of Ubc12 
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(E2), SCCRO interacts with its unique N-terminal extension, raising the possibility that SCCRO-
Ubc12 interaction is specific to the neddylation pathway. This is further strengthened by lack of 
interaction between SCCRO and other E2s (Ubc9) in GST pull down assays (data not shown). Taken 
together, these observations suggest that SCCRO conforms to the conserved reaction processivity 
paradigms, further supporting its candidacy as a component of the E3 complex.
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(A), Western blot for Ubc12 after a thioester reaction showing generation of Ubc12~Nedd8 thioester (top panel, lane 
1, upper band). GST (lane 2) and GST-SCCRO (lane 3) pulldown on the same reaction products showing preferential 
interaction of SCCRO with Ubc12~Nedd8 despite a large excess of free Ubc12 (top panel, lane 3). Autoradiograph 
of products from a thioester reaction containing E1, E2, ATP, and 32P-labeled PK-Nedd8 showing Ubc12~Nedd8 
(bottom panel, lane 1, upper band) and free Nedd8 (bottom panel, lane 1, lower band). GST (lane 2) or GST-SCCRO 
(lane 3) pulldown assays on thioester reaction components showing SCCRO binds to Ubc12~Nedd8 but not to free 
Nedd8 (bottom panel, lane 3) (B), Western blot showing levels of Ubc12~Nedd8 and Ubc12 from a thioester reaction 
supplemented with varying concentrations of free Ubc12 after quenching with EDTA (see “Experimental Procedures”; 
top panel). The same reactions were subjected to pulldown assays using limiting amounts of GST-SCCRO (70 pM) 
showing preferential binding to Ubc12~Nedd8 even in the presence of 20-fold excess of free Ubc12 (bottom panel). 
Figure 4. SCCRO interacts with the unique N terminus of Ubc12~Nedd8. 
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(C), Western blots for Nedd8 (top panel) and Ubc12 (middle panel) on thioester reactions with and without ATP in 
lysates from HeLa cells transfected with pCMV or pCMV-SCCRO showing lower levels of Ubc12~Nedd8 in reactions not 
containing ATP (compare first and third lanes with the second and fourth lanes).HAimmunoprecipitation of the same 
reaction mix showing preferential binding of SCCRO (in limiting concentrations) to Ubc12~Nedd8 (bottom panel, 
third and fourth lanes), even in the presence of a large excess of free Ubc12 (bottom panel, third lane).(D), Western 
blot forHAafter thioester reactions on HeLa cell lysates transfected with HA-Ubc12 or HA-Ubc12∆26 showing equal 
amounts of Nedd8 thioester formation after 10 and 30 min of incubation, respectively. HA immunoprecipitation on 
the same reaction products followed by Western blot with the indicated antibody showing SCCRO interacts with full-
length Ubc12~Nedd8 but not with Ubc12∆26~Nedd8, whereas ROC1 interacts with both (bottom right).
SCCRO binds CAND1 only when it is in complex with Cul1-ROC1
Reflecting the increasing complexity of protein regulation, the neddylation pathway is also more 
complex in higher organisms. For example, in contrast to S. cerevisiae where CAND1 is absent, 
in higher organisms unneddylated cullin-ROC1 exists almost exclusively in complex with CAND1 
(11,35,36). Binding to CAND1 inhibits cullin neddylation and subsequent ubiquitination E3 complex 
assembly. Once neddylated, cullin-ROC1 is released from CAND1 and forms active E3 ubiquitination 
complexes. Analysis of the crystal structure shows that CAND1 binds to Cul1-ROC1 in a head to tail 
arrangement burying the otherwise solvent exposed lysine residue on Cul1, making it inaccessible 
to the neddylation machinery. In contrast, a β-hairpin motif from CAND1 directly binds to two 
helices in Cul1 that are involved in its interaction with SKP1. In this arrangement, it is possible for 
neddylation of cullins to proceed if modifications expose the target lysine, while binding to SKP1 
would require dissociation of CAND1. 
Given that SCCRO interacts with Cul-ROC1 and CAND1, we aimed to determine if SCCRO binds 
to CAND1 directly or indirectly through its interaction with Cul-ROC1. To begin to define the steric 
interactions, we looked for the presence of SCCRO in exclusive complexes with either Cul1-ROC1 or 
CAND1 in cellular systems using gel filtration analyses. SCCRO was not found in fractions containing 
significant amounts of CAND1, Cul1 or ROC1, suggesting that the majority of endogenous cellular 
SCCRO is not stably associated with CAND1 or cullin-containing complexes, thereby limiting our 
ability to draw conclusions about the individual protein interactions (data not shown). GST-SCCRO 
pull down assays using purified proteins showed that CAND1 only interacts with SCCRO when 
in complex with Cul1-ROC1 (Fig. 5A, compare lanes 1 and 3). A deletion of CAND1 (CAND1∆604-
1230), which loses binding to Cul1-ROC1, does not interact with SCCRO (Fig. 5A, lane 4 and 5). In a 
reciprocal pull down assay, GST-CAND1 only pulls down SCCRO when the latter is in complex with 
Cul1-ROC1 (Fig. 5B, lane 3 and 4). These findings suggest that the interaction of SCCRO with CAND1 
is mediated by Cul1-ROC1. Moreover, the binding stoichiometry between SCCRO and Cul1-ROC1 
was not altered by the presence of CAND1 (data not shown). Given that, in cells, unneddylated 
cullins exist exclusively as ternary complexes with CAND1 and ROC1, and that SCCRO preferentially 
interacts with unneddylated cullins (see below), it is likely that SCCRO binds to the cullin-ROC1 
complexes before they are released by CAND1. These observations raised the possibility that 
SCCRO may be involved in overcoming CAND1 inhibition of cullin neddylation. 
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Figure 5. SCCRO does not overcome the inhibitory effects of CAND1 on neddylation. 
(A), Western blot on GST-SCCRO pulldown products after incubation with purified, bacterially expressed Cul1-
ROC1 and CAND1 showing CAND1 is pulled down by SCCRO only when it is complexed with Cul1-ROC1 (lanes 
1 and 3). A CAND1 deletion (CAND1∆604–1230) that loses binding to cullins is not pulled down by SCCRO (lane 
4 and 5). (B), Western blot from reciprocal GST-CAND1 pulldown assay showing interaction of CAND1 with 
SCCRO requires Cul1-ROC1 (lanes 2–4). (C), Western blot for Cul1 following in vitro neddylation reaction using 
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SCCRO does not overcome inhibition of cullin neddylation by CAND1
Given the observed binding interactions, we wanted to determine if SCCRO can overcome the 
inhibitory effects of CAND1 on cullin neddylation. We confirmed previous findings that CAND1 
inhibits cullin neddylation in an in vitro purified recombinant system (Fig. 5C) (12,35). To assess 
the ability of SCCRO to overcome CAND1 inhibition, we preincubated Cul1-ROC1 with the minimal 
concentration of CAND1 required to completely inhibit cullin neddylation. Addition of up to five-
fold molar excess of SCCRO failed to overcome the inhibitory effects of CAND1 on cullin neddylation 
(Fig. 5D). To determine if the effects of CAND1 on cullin neddylation were related to recruitment 
of Ubc12~Nedd8, we performed pull down assays. We found CAND1-Cul1-ROC1 is able to bind 
to Ubc12~Nedd8. This binding is enhanced by the addition of SCCRO (Fig 5E, lane 3). However, 
assembly of these proteins was not sufficient to overcome CAND1 inhibition. As expected, this 
complex was not detected in HeLa lysates where its assembly should lead to efficient transfer of 
the Nedd8 to cullins and dissociation of CAND1 (data not shown). These observations suggest that 
SCCRO is not sufficient to overcome the inhibitory effects of CAND1 and raise the possibility of 
additional factors involved in CAND1 release. 
purified recombinant components showing complete inhibition of neddylation in the presence of 2-fold or 
higher molar excess of CAND1. (D), Western blot on products from an in vitro neddylation reaction confirming 
increasing Cul1 neddylation with increasing amounts of SCCRO (lanes 2–4). The addition of CAND1 inhibits Cul1 
neddylation (lane 5), which is not rescued even by 5-fold molar excess of SCCRO (lane 6; same blot, excess lanes 
removed). (E), Western blot showing GST-CAND1 pulldown products after incubation with purified, bacterially 
expressed Cul1-ROC1, Ubc12~Nedd8, and SCCRO. CAND1 interacts with Ubc12~Nedd8 only when Cul1-ROC1 
is present (lanes 1 and 2), and this interaction is enhanced by the presence of SCCRO (lane 3). (F), Western blot 
on lysates from HA-SCCRO-transfected HeLa cells subjected to neddylation reaction showing an increase in 
cullin neddylation with the addition of ATP (lanes 1 and 2). HA immunoprecipitation (IP) of the same reaction 
products showed SCCRO preferentially interacts with unneddylated cullins (lanes 3 and 4). (G), Western blot on 
products from an in vitro neddylation reaction using purified recombinant components showing an increase 
in the fraction of neddylated Cul1 with increasing reaction time (top panel). Western blot on the same reaction 
after GST-SCCRO (middle panel) and GST-CAND1 (bottom panel) pulldown assays showing that SCCRO and 
CAND1 interact with both free and neddylated cullins (same blot, excess lanes removed). (H), Western blot on 
products from pulldown assays after GST-CAND1 complexed with either Nedd8-Cul1-ROC1 or free Cul1-ROC1 
was incubated with increasing amounts of testis lysate from SCCRO-/- mice showing release of Nedd8-Cul1-
ROC1 but not unneddylated Cul1-ROC1. (I), Western blot on products from pulldown assays after GST-CAND1 
complexed with either Nedd8-Cul1-ROC1 or free Cul1-ROC1 was incubated with increasing amounts of testis 
lysate from SCCRO-/- mice showing release of Cul1-ROC1-Nedd8 only with addition of SCCRO and not  SCCRO-
D241N (same blot, excess lanes removed).
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Neddylated Cul1 can bind to CAND1 and SCCRO in vitro
To assess if SCCRO binding to Cul1-ROC1 is affected by neddylation, lysates from HeLa cells 
transfected with HA-SCCRO were subjected to in vitro neddylation reaction with and without ATP 
(Fig. 5F, left panel). Western blot analysis showed increased cullin neddylation in reactions containing 
ATP. When HA-immunoprecipitation was performed on these lysates, only unneddylated cullins 
were pulled down (Fig. 5F, right panel). In contrast, binding assays using purified proteins showed 
that both neddylated and unneddylated Cul1-ROC1 were pulled down by GST-SCCRO and GST-
CAND1 (Fig. 5G). These results suggest that neddylation of cullins may not be sufficient by itself to 
dissociate CAND1. Since we could not detect any binding between neddylated cullins and CAND1 
in lysates, a factor in the lysate may be required to release neddylated cullins. To address this issue, 
GST-CAND1 complexed with either neddylated or unneddylated Cul1-ROC1 was incubated with 
lysate. Incubation with HeLa lysate or SCCRO+/+ mice testis lysate resulted in the dissociation of 
neddylated but not un-neddylated cullins from CAND1 (Fig. 5H). This dissociation was not due to 
competition with native cullin complexes, as these complexes were not detected on the GST-CAND1 
pull down assays. In contrast, incubation with testis lysate from SCCRO-/- mice failed to dissociate 
GST-CAND1 from neddylated Cul1-ROC1. Addition of recombinant SCCRO but not SCCRO-D241N to 
the SCCRO-/- lysate allowed dissociation of neddylated Cul1-ROC1 from CAND1 (Fig. 5I). These data 
suggest that neddylated cullins are dissociated from CAND1 by a factor in lysate and that SCCRO 
may be required for this dissociation.
Discussion
Hershko and Ciechanover define ubiquitin ligases as enzymes that bind, directly or indirectly, to 
specific protein substrates and promote the transfer of Ub, directly or indirectly, from a thioester 
intermediate to amide linkages with proteins or poly-ubiquitin chains (1). Our data suggest that 
SCCRO is part of a complex that functions as the E3 for neddylation. The neddylation E3 ligase 
complex (Cul-ROC1-SCCRO) shares a modular architecture similar to CRL-containing ubiquitin 
ligases. CRL complexes have a constant catalytic module (ROC1 bound to E2 thioester) that 
is conserved in the neddylation E3 complex. SCCRO has a unique regulatory role by helping to 
recruit the Ubc12~Nedd8 thioester to the neddylation E3 complex. Since SCCRO promotes 
cullin neddylation, which serves as a signal for assembly of ubiquitination E3 complexes, factors 
controlling SCCRO likely regulate ubiquitination by CRL-containing E3 complexes. Given the 
diversity of proteins regulated by CRL-containing E3s, it is not surprising that dysregulation of 
Dcn1p/DCN-1 results in severe developmental defects in S. cerevisiae and C. elegans and that SCCRO 
appears to be a key target activated by amplification in a vast array of human cancers (18). 
Assembly of E3 complexes is a key regulatory mechanism. CAND1 affects the assembly of both 
the neddylation E3 complex as well as the CRL complexes. Several studies, as well as our own 
SCCRO is an essential component of the E3 complex for neddylation
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findings, suggest that unneddylated cullins exist almost exclusively in complexes with CAND1, while 
neddylated cullins are predominantly in active ubiquitination E3 complexes (10-12). Although it is 
accepted that neddylation serves as a signal for CAND1 dissociation from Cul1-ROC1 and subsequent 
assembly of ubiquitination E3 complexes, the precise mechanisms leading to the release remain ill 
defined. The finding that only endogenous Cul1-ROC1 (immunoprecipitated from cells) and not 
the recombinant protein bound to CAND1 can undergo neddylation leads to speculation that (a) 
factor(s) in lysate allow(s) release of CAND1 inhibition (10,12). Several experimental observations 
from our studies may begin to help explain the mechanisms involved in CAND1 release. First, we 
found that the entire E3 neddylation complex (including Ubc12~Nedd8 and SCCRO) can assemble 
onto purified Cul1-ROC1 while it is in complex with CAND1. However, this is neither sufficient to 
promote cullin neddylation nor to induce CAND1 dissociation, suggesting that the assembly of 
the neddylation E3 complex by itself is not sufficient to overcome the inhibitory effects of CAND1 
and the subsequent CRL assembly. However, the  CAND1-Cul1-ROC1-Ubc12~Nedd8  complex is 
not detectable in lysates, consistent with the fact that the assembly of SCCRO and Ubc12 onto the 
CAND1-Cul1-ROC1 results in rapid neddylation and dissociation of the complex. This is consistent 
with the increase in neddylation of endogenous cullins with the addition of Ubc12 and/or SCCRO 
to lysates. Given that SCCRO is not required for neddylation in purified systems, but is essential in 
SCCRO-/- mice (Kaufman, et al., manuscript in preparation) and DCN-1/Dcn1p knockouts in C. elegans 
and S. cerevisiae, raises the possibility that SCCRO may be required to overcome CAND1 associated 
inhibition of cullin neddylation in lysates where unneddylated cullins are in complex with CAND1. 
Consistent with this hypothesis, the addition of recombinant SCCRO, but not Ubc12~Nedd8 can 
rescue neddylation in lysates from both DCN-1/Dcn1p and SCCRO knockouts in C. elegans, S. 
cerevisiae and mice (Kaufman A, et. al., manuscript in preparation), respectively. 
The prevailing theory has been that neddylation makes the binding between CAND1 and cullins 
unfavorable. This led to speculation that either neddylation serves as a signal for the release or 
occurs after dissociation from CAND1. We found that in contrast to cellular lysates where they exist 
in exclusive complex with unneddylated cullins, CAND1 and SCCRO can bind to both neddylated 
and  unneddylated cullins in assays using recombinant proteins. This raises the possibility that 
neddylation by itself, although required, may not be sufficient for CAND1 dissociation. When 
incubated with HeLa or SCCRO+/+ mouse testis lysates, CAND1 is dissociated from neddylated 
Cul1-ROC1, but not unneddylated Cul1-ROC1, suggesting that cellular factors are involved in the 
release of neddylated cullins from CAND1. In contrast, neddylated Cul1 was not released by CAND1 
when incubated in lysates from SCCRO-/- mice unless supplemented with recombinant SCCRO 
(but not SCCRO-D241N). Factors that compete for binding of neddylated cullins (i.e. SKP1/SKP2) 
dissociate CAND1 from Cul1-ROC1 only in lysates (which contains wild type SCCRO), but not in 
purified protein systems, suggesting that SCCRO is required for release. The combined results from 
these experiments suggest that SCCRO plays a critical role in both cullin neddylation and CAND1 
release. Our findings suggest that SCCRO by itself is not sufficient for cullin neddylation and CAND1 
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release and factor(s) in lysate are required in these processes. Goldberg and colleagues suggest 
that this factor may be a small molecule that binds the CAND1-Cul1-ROC1 complex to modify its 
structure, exposing the neddylation site on Cul1 (12). Because CAND1 binds to both neddylated 
and unneddylated cullins with equal affinity, neddylation in itself, although required, may not be 
sufficient for CAND1 release. We propose that neddylation occurs through the assembly of the 
competent neddylation E3 complex onto cullin-ROC1-CAND1, including SCCRO, Ubc12~Nedd8 and 
an unidentified CAND1 opening factor present in lysate. In this model, neddylation serves as a 
signal for recruitment of release factors required to dissociate CAND1. The release factor remains to 
be defined but can include a novel binding protein or posttranslational modifications in reaction 
components. Although provocative, further studies are required to validate this model.
The other critical question that remains is what is downstream of SCCRO. Katanin is a key target 
in C.elegans and yeast, as its levels are altered in DCN1/DCN1p knockouts. The identification of CRL 
target downstream of SCCRO is more complex given the presence of multiple paralogs that retain 
neddylation activity and the complex phenotype in SCCRO knockout mice.
SCCRO is an essential component of the E3 complex for neddylation
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Supplemental figure 1.
In vitro thioester reactions containing E1 (APPBP1/Uba3), E2 (Ubc12), Nedd8 and ATP were stopped at the 
indicated time by the addition of Lamelli buffer with (R) or without (NR) 50mM DTT. Western blots showing 
reduction of the reaction products by DTT in reactions up to 10 minutes (compare R to NR), suggesting that 
Ubc12~Nedd8 thioester was generated. Longer incubation (15 min) resulted in products resistant to reduction 
by DTT, suggesting the formation of Ubc12-Nedd8 isopeptide.
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Supplemental figure 2. 
(A), figure showing the two functional domains in SCCRO: a UBA-like domain and a DCUN1 domain. (B), 
sequence alignment showing SCCRO has a high degree of sequence conservation in the C-terminal region 
(shown). Conserved residues mutated for binding studies (see Fig.1E) are indicated by an asterisk. Residue 
D241, which is important for SCCRO’s interaction with Cul-ROC1 and CAND1, is boxed.
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Abstract
Amplification of SCCRO activates its function as an oncogene in a wide range of human cancers. 
SCCRO’s oncogenic activity requires its PONY domain, which regulates its E3 activity for neddylation. 
Contribution of the N-terminal ubiquitin-associated (UBA) domain to SCCRO’s function remains to 
be defined. We found that the UBA domain of SCCRO preferentially binds to polyubiquitin chains 
in a linkage-independent manner. Binding of polyubiquitin chains to the UBA domain inhibits 
SCCRO’s neddylation activity in vivo by inhibiting SCCRO-promoted nuclear translocation of 
neddylation components and results in a corresponding decrease in cullin-RING-ligase promoted 
ubiquitination. The results of colony-formation and xenograft assays showed mutation in UBA 
domain of SCCRO that reduces binding to polyubiquitin chains significantly enhances its oncogenic 
activity. Analysis of 47 lung and head and neck squamous cell carcinomas identified a case with a 
frame-shift mutation in SCCRO that putatively codes for a protein that lacks a UBA domain. Analysis 
of data from The Cancer Genome Atlas (TCGA) showed that recurrent mutations cluster in the UBA 
domains of SCCRO, lose binding to polyubiquitinated proteins, and have increased neddylation 
and transformation activities. Combined, these data suggest that the UBA domain functions as 
a negative regulator of SCCRO function. Mutations in the UBA domain lead to loss of inhibitory 
control, which results in increased biochemical and oncogenic activity. The clustering of mutations 
in the UBA domain of SCCRO suggests that mutations may be a mechanism of oncogene activation 
in human cancers. 
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Introduction
Posttranslational modification by ubiquitin regulates the activity of proteins involved in a wide 
range of essential cellular processes. Although ubiquitin modifications primarily target proteins 
for degradation by the 26S proteasome, they can also signal for nonproteolytic effects on protein 
function. The pleiotropic effects of the ubiquitin signal are encoded for by variations in length 
and linkage of the ubiquitin chain. In general, Lys48-linked polyubiquitin chains signal for protein 
degradation, whereas monoubiquitin and non–Lys48-linked polyubiquitin chains signal for 
nonproteolytic effects (Lys6, Lys11, Lys27, Lys29, Lys33, Lys63) (1-5). However, the same ubiquitin 
linkage can have varying consequences: for example Lys11-linked chains can promote degradation 
of the targeted proteins by either the proteasome or the endoplasmic reticulum, as well as promote 
endocytosis and nondegradative activities that lead to NF-κB activation (6). The diversity of effects 
imparted by the ubiquitin signal are mediated by motifs that bind to ubiquitin and/or ubiquitin 
chains and transduce their effects, analogous to the role played by binding of phosphorylated 
proteins to phospho-binding domains (7-10). Collectively known as ubiquitin-binding domains 
(UBDs), these motifs comprise more than 20 different families. The ubiquitin-associated (UBA) 
domain, the prototypic and most common type of UBD, is composed of a motif of 40 residues 
that are arranged in three tightly packed α-helices that share structural homology with coupling 
of ubiquitin conjugation to ER degradation (CUE)-type UBDs (9,11-14). It is estimated that more 
than 79 proteins contain UBA domains. The majority of UBA domains recognize a canonical Ile44/
Val70-binding patch on ubiquitin and preferentially bind to polyubiquitin chains (15,16). However, 
the affinities of individual UBA domains vary considerably, binding to ubiquitin chains of different 
lengths and linkages (10). UBA  domains are thought to limit ubiquitin chain elongation and to 
help with localization of the bound ubiquitinated proteins to the 26S proteasome for degradation. 
Recent studies show that UBA domains can also transduce for a variety of other consequences, 
including modulation of protein interactions and subcellular localization, as well as nonproteasomal 
turnover of the ubiquitinated proteins and/or the UBA domain-containing proteins (9,17,18).
The presence of a UBA domain in SCCRO (aka DCUN1D1), a protein that functions as an E3 in 
neddylation (conjugation of the ubiquitin-like protein Nedd8), raises several intriguing possibilities 
about its function. In contrast to ubiquitination, only a limited number of proteins are subject 
to neddylation, with the cullin protein family (Cul1, Cul2, Cul3, Cul4, Cul5, and Cul7) being the 
best-characterized targets (19). Cullins serve as the scaffold for assembly of cullin-RING-ligase 
(CRL) type E3 ligases, the most common type of ubiquitination E3s (20,21). Neddylation of cullins 
promotes assembly of the CRL complex and optimizes its conformation to allow efficient transfer of 
ubiquitin from the E2 to the substrate protein. In its role in promoting neddylation, SCCRO activity 
regulates levels of ubiquitination activity in cells: an increase in SCCRO activity increases levels of 
ubiquitinated proteins by promoting CRL activity, whereas a decrease in SCCRO activity has the 
opposite effect (22-27).
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So what is the role of the UBA domain in SCCRO? The high degree of conservation and the existence 
of splice forms of the SCCRO orthologue DCN1 in lower organisms and SCCRO paralogs in higher 
organisms that lack a UBA domain suggest that, although it is not required, the UBA domain 
plays an important role in SCCRO’s function. In vitro studies confirm that the UBA domain is not 
required for SCCRO’s neddylation activity (26). Our finding that SCCRO regulates neddylation in 
vivo by promoting nuclear translocation of the neddylation components (27)—combined with 
recent reports that the UBA domain promotes monoubiquitination of SCCRO, leading to its nuclear 
export (28)—suggests that the UBA domain may regulate SCCRO’s neddylation activity in vivo. In 
this report, we show that binding of polyubiquitin chains to the UBA domain inhibits the activity of 
SCCRO, a core protein in the ubiquitin-proteasome pathway. In this role, the UBA domain serves as 
a feedback regulator of SCCRO’s in vivo neddylation and oncogenic activity. Moreover, clustering 
of mutations in the UBA domain of SCCRO that mitigate binding to polyubiquitinated proteins 
suggests that it is a mechanism for oncogene activation. Moreover, the presence of mutations in 
the UBA domain of many other proteins suggests this may be an underappreciated mechanism of 
oncogene activation in human cancers. Given the conserved binding characteristics of the UBA 
domain, targeting it may have therapeutic benefit in the treatment of human cancer. 
Experimental procedures
Alignment and sequence analyses
Database and BLAST searches were performed at the National Center for Biotechnology Information. 
Sequence alignments were performed using the ClustalW program. 
Reagents
All mutants were generated by PCR mutagenesis and verified by sequencing. Proteins were 
expressed as GST fusions in Escherichia coli using the pGEX4T3 vector. The proteins were purified 
using glutathione-Sepharose 4B beads (Amersham Biosciences, Piscataway, NJ), followed by 
thrombin cleavage, where required. Cul1-ROC1 was expressed and purified from E. coli as described 
previously (29). APPBP1/Uba3, Ubc12, Nedd8, and all ubiquitin chains were obtained from a 
commercial source (Boston Biochem, Cambridge, MA). The proteasome inhibitor Z-Leu-Leu-Leu-
al (here referred to as MG132) was purchased from Sigma-Aldrich (St. Louis, MO). The following 
antibodies were used in this study: anti-Cul1 (Zymed Laboratories, South San Francisco, CA); anti-
Cul3 (BD Biosciences, San Jose, CA); anti-Ubc12 (Rockland Immunochemicals, Gilbertsville, PA); anti-
Nedd8 (Invitrogen); anti-CAND1 (BD Biosciences); anti-αTubulin (Calbiochem, Billerica, MA); anti-
HA, anti-6xHis, and anti-ROC1 (Abcam, Cambridge, MA); and anti-Myc and anti-Ubiquitin (Santa 
Cruz Biotechnology, Dallas, TX). Anti-SCCRO (rabbit polyclonal) antibody was produced and used 
as described previously (30). Anti-SCCRO monoclonal antibody was raised against an N-terminal 
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region of the protein in SCCRO–/– mice. This antibody was found to be highly sensitive and specific 
(data not shown). All cell lines used in this study were obtained from American Type Culture 
Collection (Manassas, VA) and maintained as recommended. 
cDNAs for mammalian transfection were cloned into the pBABE-puro vector (Addgene, 
Cambridge, MA) or pUSE-amp (Clontech, Mountain View, CA). NIH 3T3 cells were doubly exposed 
to virus in the presence of 7 ug/mL Polybrene (Sigma-Aldrich) for 24 h each. Infected cells were 
selected for by use of puromycin (Sigma-Aldrich). pUSE-amp transfection was performed using 
Lipofectamine 2000 reagent (Invitrogen, Grand Island, NY), in accordance with the manufacturer’s 
specifications. 
In vitro neddylation
Cullin-ROC1 substrate for in vitro neddylation reactions was derived from either HeLa cell lysates 
or bacteria (see above). For reactions using HeLa-derived Cullin-ROC1 complexes, 50 µg of lysate 
(Cul1 concentration, ~20 fmol) was added to reactions containing 10 nM APPBP1/Uba3, 4 nM Ubc12, 
and 0.9 µM Nedd8 in neddylation buffer (50 mM Tris-HCl [pH 7.5], 55 mM NaCl, and 5 mM MgCl2). 
Reactions were incubated at 30°C and stopped with the addition of 6x Laemmli buffer. Reactions 
with bacterially derived substrate were performed at 30°C in neddylation buffer containing 27 nM 
Cul1-ROC1, 4 mM ATP, 10 nM APPBP1/Uba3, 20 nM Ubc12, and 0.9 µM Nedd8. Proteins were resolved 
on SDS-PAGE gels and subjected to Western blot analysis. For quantification, Western blots were 
imaged using ImageJ software (NIH).
GST pull-down assay and immunoprecipitation
GST-tagged proteins were bound to glutathione-Sepharose beads by gentle rotation at 4°C for 45 
min. The beads were washed 5 times with EBC buffer (50 mM Tris-HCl [pH 7.5], 2.5 mM MgCl2, 150 
mM NaCl, and 0.5% Nonidet P-40) at 20x bead volume. The beads were incubated with HeLa cell 
lysate or purified proteins, as indicated, at 4°C for 1 h, followed by 5 washes with EBC buffer at 20x 
bead volume. Bound proteins were eluted by the addition of 6x Laemmli buffer, were resolved on 
SDS-PAGE gels, and were analyzed by Western blot. GST-tagged proteins were visualized by use 
of Coomassie R250 staining (Sigma-Aldrich). Immunoprecipitations were performed essentially as 
described previously (30). In brief, 1 mg of whole-cell lysate was incubated with antibody bound to 
agarose beads by gentle rocking at 4°C for 2 h. The wash and detection were the same as described 
above for the GST pull-down assay. 
Immunofluorescence
Rhodamine-conjugated anti-Myc and FITC-conjugated anti-HA antibodies were obtained from a 
commercial source (Jackson ImmunoResearch Laboratories, West Grove, PA). Cells transfected with 
plasmid(s) were seeded in 6-well plates with cover glass. Forty-eight hours after transfection, cells 
The UBA domain of SCCRO protein serves as a feedback regulator of biochemical and oncogenic activity
49
Ch
ap
te
r
3
were washed with PBS and fixed in 4% formaldehyde for 10 min. The fixed cells were permeabilized 
with 0.5% Triton X-100 for 5 min, incubated in blocking buffer (PBS containing 10% FCS) for 30 
min, and stained overnight at 4°C with fluorochrome-conjugated antibodies. The cells were 
washed 3 times with PBS, counterstained with DAPI, covered with ProLong Gold Antifade Reagent 
(Invitrogen, Carlsbad, CA), and examined with a Leica inverted confocal microscope fitted with 
appropriate fluorescence filters.
Colony formation and xenograft assays
Soft agar assay was performed essentially as described previously (30). Xenograft assays were 
performed as described previously and in accordance with Institutional Animal Care and Use 
Committee guidelines. In brief, NIH 3T3 cells (5 x 106) were implanted into the flanks of 8-week-old 
female BALB/c SCID (severe combined immunodeficiency) mice (Taconic, Hudson, NY). Tumor size 
was measured every 3 days by a single observer and analyzed using Microsoft Excel and GraphPad 
Prism 5 software. According to institutional guidelines, mice were sacrificed when tumor burden 
impeded normal feeding and movement.
UBA mutation analysis
Sixty-four human UBA domain–containing proteins from SMART (http://smart.embl.de/smart/
do_annotation.pl?DOMAIN=SM00165) and 15 UBA domain–containing proteins from the literature 
were analyzed. Of these proteins, 28 were included in the TCGA data set. These 28 proteins were 
assessed for presence and location of mutations against 29 cancer types by use of the cBioPortal 
for Cancer Genomics (http://www.cbioportal.org/public-portal/). 
Statistical analysis
Paired t tests were used to compare the means ± SD of soft agar colony formation counts by 
use of SPSS 19 software (IBM, Armonk, NY). Survival curves were generated using the Kaplan-
Meier method and were compared using the log-rank test, by use of Graphpad Prism (Graphpad 
Software, La Jolla, CA). Disease-free survival was defined as the time from primary treatment of 
cancer to development of recurrence. Survival outcomes were censored for patients who died of 
intercurrent disease or who survived to the end of the study. A two-tailed P≤0.05 was considered 
to indicate statistical significance.
Results
The UBA domain of SCCRO binds polyubiquitin chains in a linkage-independent manner
Results of sequence and structural analyses show that the UBA domain of SCCRO is composed of a 
three-helical bundle architecture that shares homology with several other UBA and CUE 
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Figure 1. The UBA domain of SCCRO binds polyubiquitin chains in a linkage-independent manner. 
(A) Schematic depiction of the domain structure of SCCRO (top panel) and sequence analysis of the UBA 
domain of SCCRO with several other UBA and CUE domains (bottom panel). Highlighted are conserved 
hydrophobic residues critical for binding to ubiquitinated proteins. (B) SCCRO preferentially binds Ub4 over 
Ub or Ub2. K48-linked ubiquitin chains (Ub2 and Ub4) were synthesized in vitro. Pictured is a size-exclusion 
chromatogram showing that SCCRO was co-eluted with Ub4 but not with Ub or Ub2. (C) Pull-down assay using 
GST-SCCRO and its mutants on K48 or K63 ubiquitin chains or HeLa cell lysates, followed by Western blot 
analysis for ubiquitin, showing that SCCRO binds to the ubiquitin chain in a linkage-independent manner. 
(D) Pull-down assay using GST-SCCRO on serially diluted K48 or K63 ubiquitin chains, showing SCCRO has 
preferential binding toward K63-linked ubiquitin chains. (E) and (F) Immunoblot analysis of lysates from U2OS 
cells transfected with Myc-SCCRO and selected mutants probed with antibody against ubiquitinated proteins 
following immunoprecipitation for Myc showing that conserved hydrophobic residues in the UBA domain of 
SCCRO are critical for binding to ubiquitin chains. EV, empty vector.
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domains (26,31). Hydrophobic residues that are critical for interactions with ubiquitin chains 
in structurally related domains are highly conserved in the UBA domain of SCCRO (Figure 1A). 
Whereas previous studies have shown that the UBA domain of the yeast orthologue of SCCRO 
(DCN1) binds to monoubiquitin, structurally related domains preferentially bind to polyubiquitin 
chains and have a low affinity for monoubiquitin (16,22). To define the binding preferences, we 
used in vitro synthesized K48-linked ubiquitin chains (Ub2 and Ub4) and assessed their binding to 
SCCRO by size-exclusion chromatography. The results showed a preferential 1:1 co-elution of the 
Ub4-SCCRO complex, even in the presence of excess Ub or Ub2 (Figure 1B). To validate these binding 
preferences and precisely map the residues involved, glutathione-S-transferase (GST)–SCCRO and 
selected UBA and PONY domain mutants were used in a pull-down assay containing ubiquitin 
chains of varying lengths and linkages (K48 or K63). The results showed that SCCRO bound to both 
K48- and K63-linked Ub4 or great length chains with higher affinity than Ub or Ub2 chains (Figure 
1C). Pull down assays were repeated using serial dilutions of equal concentrations of K48- and 
K63-linked polyubiquitin chains showing a higher affinity for binding to K63-linked chains (Figure 
1D). Mutations in conserved hydrophobic residues in the UBA domain of SCCRO (L30A and A40E) 
reduced binding, whereas mutations of nonconserved residues in the UBA domain or of residues in 
the PONY domain did not affect binding to polyubiquitin chains (Figure 1C). Immunoprecipitation 
for Myc in lysates from U2OS cells expressing Myc-tagged SCCRO or SCCRO mutants, followed by 
Western blot analysis for ubiquitin, showed that SCCRO binds to polyubiquitinated proteins in vivo 
and that this interaction requires conserved hydrophobic residues (F18, L30, A40, and F45) but not 
other residues in the UBA domain (Figure 1E). Mutations in two (SCCROF18K/L30A and SCCROL30A/A40E) 
or three conserved residues (SCCROF18K/L30A/A40E) in SCCRO’s UBA domain result in complete loss of 
binding to polyubiquitinated proteins (Figure 1F). These findings confirm the requirement of the 
UBA domain in binding to polyubiquitinated proteins. Previous studies have suggested that UBA 
domain–containing proteins can be sub-classified on the basis of the length and linkage of the 
ubiquitin chains to which they bind (32). Our results show that the UBA domain of SCCRO is best 
included in the class 4 subgroup, although it does not bind to monoubiquitin. 
The UBA domain of SCCRO binds to polyubiquitinated CRL substrates
To determine if SCCRO binds to proteins that are ubiquitinated by CRL complexes activated by 
neddylation, we performed tandem affinity purification to assess for binding to known Cul1 
and Cul3 anchored CRL substrates. GST-SCCRO pull-downs on whole cell lysate from HeLa cells 
pretreated with MG132 were performed to enrich for SCCRO-binding proteins. After thrombin 
cleavage to release these proteins from the glutathione beads, immunoprecipitation was performed 
using anti-ubiquitin antibody to enrich for ubiquitinated proteins. Immunoblotting showed that 
SCCRO bound to polyubiquitinated Aurora B and RhoA, established substrates of Cul3 anchored 
CRL complexes, but not to cyclin E or p21, substrates of Cul1 anchored CRL complexes (Figure 
2A). However, as there is a limited amount of ubiquitinated Aurora B and RhoA in cellular lysates, 
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extended exposure of the Western blot was required to detect binding. To verify these results, we 
repeated binding experiments on HeLa cells transfected with Aurora B or RhoA. Transfected cells 
were treated with MG132 and subjected to tandem affinity purification following the approach 
described above. As an additional control, we also included pull-downs with GST-SCCROL30A on the 
same lysates. We found clear binding of polyubiquitinated Aurora B and RhoA to GST-SCCRO but 
not to GST or GST-SCCROL30A (Figure 2B). Combined, these findings suggest that SCCRO binds to 
Cul3-anchored CRL targets.
Figure 2. The UBA domain of SCCRO binds to polyubiquitinated CRL substrates. 
(A) GST-SCCRO pull-down products from HeLa cell lysate pretreated with MG132 were released by thrombin 
cleavage. SCCRO and SCCRO interacting proteins were further immunoprecipitated with antibody against 
polyubiquitinated proteins and analyzed by Western blotting with antibodies against Aurora B and RhoA (Cul3 
substrates) and Cyclin E and p27 (Cul1 substrates), which showed SCCRO selectively bound to polyubiquitinated 
Aurora B and RhoA. (B) Experiments were performed as described for panel A except that HeLa cells were 
transfected with Aurora B or RhoA before MG132 treatment. Note that GST-SCCRO, but not GST or GST-
SCCROL30A, bound to polyubiquitinated Aurora B and RhoA. IP, immunoprecipitation; IB, immunoblotting; PD, 
pulldown.
The UBA domain does not affect SCCRO’s neddylation activity in vitro
To determine whether the UBA domain modulates SCCRO’s neddylation activity, we performed 
structure-function studies to investigate its effect in in vitro assays. In vitro reactions contained 
recombinant Nedd8, APPBP1/Uba3 (E1), Ubc12 (E2), ATP, and whole-cell lysate from HeLa cells (as 
a source of Cul-ROC1 substrate), in the presence of varying concentrations of SCCRO or selected 
SCCRO mutants. As expected, the addition of SCCRO increased cullin neddylation in a dose-
dependent manner. Deletion or mutation of the UBA domain (SCCRO∆N or SCCROL30A) did not 
alter SCCRO’s neddylation-promoting activity, whereas deletion or mutation of the PONY domain 
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(SCCRO∆C or SCCROD241N) abrogated its activity (Figure 3A) (23). Moreover, the addition of a 20-fold 
molar excess of K48-linked Ub4 did not affect the efficiency with which SCCRO and SCCROL30A 
increased levels of neddylated Cul1 or Cul3 (Figure 3B). These findings are consistent with those 
reported previously for DCN1 in Caenorhabditis elegans and yeast (26), confirming that binding of 
ubiquitin chains to the UBA domain does not affect SCCRO’s neddylation activity in vitro. 
Figure 3. SCCRO’s UBA domain does not affect neddylation activity in vitro. 
(A) In vitro neddylation reaction with concentration gradients of SCCRO or SCCRO mutants. Mutations in the 
PONY domain, but not the UBA domain, blocked the neddylation activity of SCCRO (ΔN: SCCRO with N-terminal 
1-45 amino acids deleted; ΔC: SCCRO with C-terminal 151-259 amino acids deleted). (B) In vitro neddylation 
reaction with purified recombinant SCCRO or SCCROL30A, followed by Western blot analysis for Cul1 and Cul3, 
showing that the presence of a 20-fold molar excess of K48-linked tetraubiquitin failed to inhibit effect of 
SCCRO or SCCROL30A on neddylation. IB, immunoblotting.
The UBA domain affects SCCRO’s neddylation activity in vivo
Given our recent findings showing differential requirements for SCCRO in neddylation in vitro and 
in vivo (27), we next assessed the requirement of the UBA domain for SCCRO’s neddylation activity 
in vivo. To determine whether these effects were caused by binding of polyubiquitinated proteins 
to the UBA domain, HeLa cells were treated with sublethal doses of proteasome inhibitor (MG132), 
which resulted in accumulation of polyubiquitinated proteins, relative to DMSO-treated controls. 
Whereas transfection of either SCCRO or SCCROL30A increased levels of neddylated Cul1 and Cul3 
in DMSO-treated cells, levels of neddylated Cul1 and Cul3 increased only in SCCROL30A transfected 
HeLa cells treated with MG132 (Figure 4A). 
To validate these findings, we expressed Myc-tagged SCCRO, SCCROL30A, SCCRO∆210-259, a 
neddylation-deficient mutant that retains binding to polyubiquitinated proteins, or SCCROL30A/∆210-259, 
a neddylation-deficient mutant with reduced binding to polyubiquitinated proteins in U2OS 
cells and confirmed effects of UBA mutations on binding to polyubiquitinated proteins by 
immunoprecipitation and Western blotting for Ub (Figure 4B). Immunoprecipitation using anti-
HA antibody on lysates co-transfected with HA-SCCRO and Myc-SCCRO∆210-259 or Myc-SCCROL30A/∆210-259 
followed by Western blotting for Ub showed reduced binding of polyubiquitinated proteins to HA-
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SCCRO when it was co-transfected with Myc-SCCRO∆210-259 but not with Myc-SCCROL30A/∆210-259 (Figure 
4C; compare lanes 1-3), even though HA-SCCRO was expressed at equal levels (Figure 4C; see IB: HA). 
This is likely due to sequestration of polyubiquitinated proteins by Myc-SCCRO∆210-259, reducing the 
pool available to bind HA-SCCRO. Co-expression of Myc-SCCRO with Myc-SCCRO∆210-259 increased the 
levels of neddylated Cul3 relative to cell transfected with Myc-SCCRO alone (Figure 4D; lanes 1-2). 
Neither co-transfection of Myc-SCCRO∆210-259 or Myc-SCCROL30A/∆210-259 affected levels neddylated Cul3 
in Myc-SCCROL30A transfected U2OS cells (Figure 4D; lanes 4-6). Combined, our observations suggest 
that binding of polyubiquitinated proteins to the UBA domain of SCCRO inhibits its neddylation 
activity in vivo. These findings suggest that the UBA domain may serve as a sensor and inhibitor of 
SCCRO’s neddylation activity in response to increased levels of polyubiquitinated proteins.
Figure 4. Mutations in the UBA domain augment the neddylation activity of SCCRO in vivo.
(A) Neddylation reaction on HeLa cell lysates, with and without pretreatment with MG132, showing that the 
level of neddylated Cul1 and Cul3 was reduced in cells transfected with HA-SCCRO, but not with HA-SCCROL30A, 
when pretreated with MG132. (B) Immunoblot analysis with antibody against polyubiquitinated proteins 
following immunoprecipitation for Myc on lysates from U2OS cells transfected with Myc-SCCRO mutants, 
showing SCCRO∆210-259, but not SCCROL30A or SCCROL30A/∆210-259, retains binding to ubiquitinated proteins. 
(C) Immunoblot analysis with antibody against polyubiquitinated proteins following immunoprecipitation 
for either HA or Myc on lysates from U2OS cells transfected as indicated, showing SCCRO∆210-259, but not 
SCCROL30A/∆210-259, competes with SCCRO for polyubiquitinated proteins. (D) Western blot analysis of neddylated 
Cul3 in U2OS cells transfected as indicated, showing that coexpression of SCCRO with SCCRO∆210-259, but not 
with SCCROL30A/∆210-259, resulted in increased levels of neddylated Cul3 (lanes 1-3). In contrast, neither of the 
SCCRO mutants affected neddylation of Cul3 promoted by SCCROL30A (lanes 4-6).
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The UBA domain affects SCCRO’s compartmentalization activity
To determine the mechanisms by which the UBA domain modulates SCCRO’s neddylation 
activity, we first investigated whether binding of polyubiquitinated proteins to the UBA domain 
affects interactions between SCCRO and other neddylation components (27). Lysates from HeLa 
cells transfected with HA-Ubc12, HA-Cul1, and Myc-SCCRO or Myc-SCCROL30A were subjected to 
immunoprecipitation using anti-Myc antibody, followed by Western blotting for neddylation 
components. We found no differences between the binding of Myc-SCCRO and Myc-SCCROL30A to 
neddylation components (HA-Cul1 or HA-Ubc12) (Figure 5A). Similar results were obtained from 
GST pull-down assays with no detectable differences in binding to neddylation E3 components 
between GST-SCCRO and GST-SCCROL30A in HeLa cell lysates treated with DMSO or MG132 (Figure 
5B). 
Given the importance of nuclear localization to SCCRO’s function (27), we next investigated 
the effects of MG132 pretreatment on the subcellular localization of Myc-SCCRO or Myc-SCCROL30A 
in U2OS cells. Treatment of U2OS cells with MG132 resulted in increased cytoplasmic localization 
of Myc-SCCRO, compared with treatment with DMSO cells (Figure 5C). In contrast, treatment 
with MG132 had no effect on localization of Myc-SCCROL30A, which remained primarily nuclear. 
Next, we cotransfected U2OS cells with Myc-SCCRO or Myc-SCCROL30A and HA-Cul1∆610-615, a mutant 
that depends on SCCRO for nuclear translocation and neddylation in vivo (27). Both Myc-SCCRO 
and Myc-SCCROL30A promoted nuclear translocation of HA-Cul1∆610-615 in U2OS cells treated with 
DMSO. However, treatment with MG132 blocked Myc-SCCRO, but not Myc-SCCROL30A, promoted 
nuclear translocation of HA-Cul1∆610-615 (Figure 5C). These observations suggest that the subcellular 
localization of SCCRO is regulated by binding of polyubiquitinated proteins to the UBA domain. 
Combined with our previous work showing the importance of SCCRO-promoted nuclear 
translocation of CRL complexes for the neddylation of cullins, these results provide an explanation 
for why the UBA domain of SCCRO differentially affects cullin neddylation in vitro and in vivo.
Binding of polyubiquitinated proteins to the UBA domain promotes monoubiquitination 
and nuclear export of SCCRO
Previous studies have shown that the UBA domain is required for monoubiquitination of SCCRO, 
which promotes its nuclear export (28). We therefore sought to determine whether cytoplasmic 
localization of SCCRO in MG132 treated cells is due to increased monoubiquitination of SCCRO. We 
expressed HA-SCCRO or HA-SCCROL30A in U2OS cells. Whole cell lysates from cells treated with either 
MG132 or DMSO were fractionated and immunoblotted for HA. HA-SCCRO, but not HA-SCCROL30A, 
was monoubiqutinated and was present only in the cytoplasmic fraction of MG132 treated cells 
(Figure 5D). Consistent with previous findings (28), SCCROL30A was not monoubiquitinated under 
any conditions tested (Figure 5D). 
To determine if monoubiquitination is required for nuclear export promoted by binding 
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Figure 5. Binding of ubiquitinated proteins affects SCCRO-promoted nuclear translocation of cullins. 
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of polyubiquitinated proteins to the UBA domain of SCCRO, we cotransfected V5-SCCRO3KR (a 
monoubiquitination-deficient mutant; Figure 5E) and HA-Cul1∆610-615 into U2OS cells. In contrast 
to cells expressing SCCRO, treatment with MG132 had no effect on localization of V5-SCCRO3KR 
or V5-SCCRO3KR promoted nuclear translocation of HA-Cul1∆610-615 (Figure 5C), suggesting 
monoubiquitination is important for nuclear export. We next questioned if the nuclear export of 
SCCRO is important for the inhibitory effects exerted by binding of polyubiquitinated proteins to 
the UBA of SCCRO. Myc-NLS-SCCRO and HA-Cul1∆610-615, when cotransfected into U2OS cells, did 
not translocate to the cytoplasm upon treatment with MG132 in U2OS cells (Figure 5C). Combined 
with the observed changes in localization and neddylation activity of SCCRO that resulted from 
treatment with MG132, these data suggest that binding of polyubiquitinated proteins to the 
UBA domain promotes monoubiquitination and nuclear export of SCCRO, thereby inhibiting its 
neddylation activity. 
Mutation of the UBA domain increases SCCRO’s oncogenic activity
We previously reported that overexpression of SCCRO increases cullin neddylation, which 
promotes malignant transformation in vivo. To determine whether the UBA domain affects SCCRO’s 
function in vivo, we assessed the effects of stable expression of HA-SCCRO, HA-SCCROL30A, or HA-
SCCROF44Y on transformation of NIH 3T3 cells. Independent stable clones, with relatively equal 
levels of transgene expression, were selected for each construct. We first confirmed functional 
effects of SCCRO and SCCRO UBA mutants. Levels of neddylated Cul1 or Cul3 were assessed by 
immunoblot analysis on lysates from at least two independent stable clones for each construct. We 
found that levels of neddylated Cul1 and Cul3 were higher in cells transfected with SCCROL30A than 
(A) Immunoblot analysis of lysates from U2OS cells transfected with indicated constructs, following 
immunoprecipitation for Myc, showing no differences between the binding of SCCRO and SCCROL30A to 
neddylation components. (B) Western blot analysis of the pull-down products of GST-SCCRO and SCCRO 
mutants from HeLa cell extracts probed with indicated antibodies, showing that SCCRO binds to CAND1, 
Cul1, and ROC1. The cullin-binding mutant SCCROΔ210-259 loses binding to CAND1, Cul1, and ROC1; in contrast, 
UBA mutants do not. (C) Immunofluorescence analysis using rhodamine-conjugated anti-Myc or anti-V5 and 
FITC-conjugated anti-HA on U2OS cells transfected with Myc-SCCRO, Myc-SCCROL30A, V5-SCCRO3KR or Myc-NLS-
SCCRO and HA-Cul1Δ610-615 in the presence or absence of MG132. Pretreatment with MG132 caused translocation 
of a significant proportion of Myc-SCCRO, but not Myc-SCCROL30A, V5-SCCRO3KR, or Myc-NLS-SCCRO, from the 
nucleus to the cytoplasm (first row). In addition, pretreatment with MG132 blocked nuclear translocation of 
HA-Cul1∆610-615 promoted by SCCRO, but not by SCCROL30A, V5-SCCRO3KR, or Myc-NLS-SCCRO (second row). (D) 
Fractionation analysis of U2OS cells transfected with HA-SCCRO, showing increased levels of cytosolic SCCRO 
and monoubiquitinated SCCRO, but not SCCROL30A, after treatment with MG132. Results from densitometry 
measurement of Western blots from three independent experiments are shown (C, cytoplasm; N, nucleus; C/N 
stands for ratios of the levels of cytosolic SCCRO or SCCROL30A vs the levels of nuclear SCCRO or SCCROL30A). *, 
P=0.043. (E) Western blot analysis of neddylated Cul1 and Cul3 in U2OS cells transfected as indicated, showing 
that expression of NLS-SCCRO or SCCRO3KR resulted in increased levels of neddylated Cul1 and Cul3 to the extent 
similar to expression of SCCRO. Western blot for SCCRO on the same lysates showed that while both Myc- 
SCCRO and Myc-NLS-SCCRO underwent monoubiquitination, V5-SCCRO3KR did not under identical conditions 
(1, monoubiquitinated SCCRO; 2, endogenous SCCRO).
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in cells transfected with SCCRO or SCCROF44Y (Figure 6A; compare lanes 5, 6, and 7 with the other 
lanes). These observations suggest that the UBA domain modulate SCCRO’s neddylation activity 
in these cells. Next we assessed oncogenicity in stably transfected NIH 3T3 clones by soft agar 
assay, which showed that clones expressing SCCROL30A formed significantly more colonies than NIH 
3T3 clones expressing SCCRO (Figure 6B and 6C). In contrast, no differences in colony formation 
were seen between clones expressing SCCROF44Y (which retains binding to polyubiquitinated 
proteins) and those expressing SCCRO. To confirm that the increase in anchorage-independent 
growth in UBA domain mutants depends on SCCRO’s neddylation activity, we investigated the 
transforming activity of the neddylation-dead mutant (SCCROD241N) and a double mutant (in both 
the UBA domain and the PONY domain: SCCROL30A/D241N). Neither the SCCROD241N mutant nor the 
SCCROL30A/D241N double mutant was able to form colonies in soft agar, which suggests that the 
neddylation activity of SCCRO plays an essential role in its oncogenic activity (Figure 6B and 6C). 
To validate these findings, we performed in vivo xenograft assays in BALB/c nude mice using 
SCCRO- or SCCROL30A-transfected NIH 3T3 clones. We found that there was shortened latency 
and significantly higher growth for SCCROL30A-transfected than SCCRO-transfected NIH 3T3 cells 
(Figure 6D-F). Necropsy of mice and histopathologic analyses showed that tumor xenografts 
resulting from injection of SCCROL30A-expressing NIH 3T3 cells were poorly differentiated and 
metastasized to pelvic lymph nodes in all mice (data not shown). Conversely, tumor xenografts 
resulting from injection of SCCRO-expressing NIH 3T3 cells were more differentiated and rarely 
metastasized to lymph nodes. These results suggest that SCCRO’s oncogenic activity is modulated 
by its UBA domain. To determine the relevance of these findings to human tumors, we screened 47 
lung and head and neck squamous cell carcinomas for mutations, using the Sequenom method, 
and identified one with a frame-shift mutation that putatively produces a truncated SCCRO protein 
with an alternate start site downstream of the mutation and without a UBA domain (Figure 7A). 
However, because of a lack of tumor tissue, we could not confirm the effect of this mutation on the 
production of SCCRO protein. We further screened available whole-genome sequencing results 
from TCGA projects for different human cancers. This analysis showed that, although they are rare, 
mutations in SCCRO cluster in the UBA domain (Figure 7B). To assess whether TCGA identified UBA 
domain mutants bind to ubiquitin chains, we carried out an immunoprecipitation assay to assess 
for their binding to ubiquitin chains of varying lengths and linkages (Lys48 or Lys63). In contrast to 
wild-type SCCRO, we found that none of tumor-derived UBA mutants bound to ubiquitin chains 
(Figure 7C). Moreover, immunoprecipitation for Myc in lysates from U2OS cells expressing Myc-
tagged SCCRO or UBA mutants identified in TCGA, followed by Western blot analysis for ubiquitin, 
showed that all TCGA mutants lost ability to bind to polyubiquitinated proteins in vivo (Figure 7D). 
To determine if UBA mutants identified in the TCGA dataset affect SCCRO’s biochemical and 
oncogenic functions, we assessed their effect on cullin neddylation and transformation. Whereas 
transfection of SCCRO, SCCROR13H, or SCCROQ20A increased levels of neddylated Cul1 and Cul3 
in DMSO treated HeLa cells, neddylated Cul1 and Cul3 only increased in SCCROR13H or SCCROQ20A 
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transfected cells after MG132 treatment (Figure 8A). Next, to assess the transforming activities of 
tumor-derived SCCRO UBA mutants, we stably transfected NIH 3T3 cells and selected stable clones 
with similar transgene expression levels (Figure 8B). These cells were subjected to soft agar assays, 
which showed significantly higher colony formation in NIH 3T3 cells expressing TCGA-identified 
SCCRO UBA mutants relative to those expressing wild-type SCCRO (Figure 8C and 8D). Combined, 
these findings suggest that SCCRO’s UBA domain modulates its neddylation activity and that this 
has functional relevance to tumorigenesis. 
Figure 6. Disruption of ubiquitin binding increases SCCRO’s transforming activity. 
(A) Western blot analysis showing that levels of neddylated Cul1 and Cul3 are higher in NIH 3T3 cells transfected with 
HA-SCCROL30A than in those transfected with HA-SCCRO (WT) or HA-SCCROF44Y. (B) Representative results from soft agar 
assay showing that, in NIH 3T3 cells, stable expression of SCCROL30A resulted in increased colony formation, compared 
with expression of SCCRO. Note that NIH 3T3-expressing PONY domain mutants (SCCROD241N and SCCROL30A/D241N) had 
a similar number of colonies as empty vector (EV) controls did. (C) Graph quantification of colonies for panel B. (D) 
and (E), In vivo xenograft assays in nude mice with NIH 3T3 clones expressing SCCRO or SCCROL30A, showing more 
aggressive tumor growth (D) with a larger tumor diameter (E) for SCCROL30A than for SCCRO. (F) Kaplan-Meier survival 
curves showing that mice transplanted with NIH 3T3 clones expressing SCCROL30A had shorter survival than those 
transplanted with NIH 3T3 clones expressing SCCRO. IB, immunoblotting.
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Figure 7. Mutations in the UBA domain of SCCRO are present in human cancers. 
(A) Frame-shift mutation in the UBA domain identified in 1 case out of 47 lung and head and neck squamous 
cell carcinomas assessed by the use of the Sequenom method. A truncated SCCRO mutant without a UBA 
domain is predicted. (B) Mutations in SCCRO identified in TCGA projects. Red dots represent UBA domain 
point mutations or splice mutations putatively producing truncated SCCRO without a UBA domain; light blue 
dots represent non–UBA domain mutations. Each dot represents a separate cancer. The asterisk (*) indicates 
nonsense mutation. (C) Immunoprecipitation assay using Myc-SCCRO and its TCGA UBA mutants on K48- or 
K63-linked ubiquitin chains, followed by Western blot analysis for ubiquitin, showing that TCGA-identified UBA 
domain mutants do not bind ubiquitin chains. (D) Immunoblot analysis of lysates from U2OS cells transfected 
with Myc-SCCRO or TCGA UBA mutants probed with antibody against ubiquitinated proteins following 
immunoprecipitation for Myc showing all mutants lose the ability to bind to polyubiquitinated proteins.
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Figure 8. Tumor-derived UBA mutations increase SCCRO’s transforming activity.
(A) TCGA-identified mutations in the UBA domain augment the neddylation activity of SCCRO in vivo. 
Neddylation reaction on lysates derived from HeLa cells with and without pretreatment with MG132, 
showing that the levels of neddylated Cul1 and Cul3 are reduced by pretreatment with MG132 in Myc-SCCRO 
transfected but not Myc-SCCROR13H or Myc-SCCROQ20A transfected cells. Results were confirmed by densitometry 
measurement. (B) Western blot analysis of lysates from NIH 3T3 cells stably transfected with the indicated 
SCCRO constructs, probed with anti-Myc antibody, showing equivalent expression. (C) Representative results 
from soft agar assay showing that stable expression of TCGA-identified UBA domain mutants in NIH 3T3 cells 
results in increased colony formation in soft agar relative to expression of SCCRO. (D) Graph showing average 
number of colonies for each NIH 3T3 clone from panel B.
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Discussion
Through its role as an E3 in neddylation, SCCRO promotes CRL activity, which results in an increase 
in cellular levels of polyubiquitinated proteins (27). We found that binding of polyubiquitinated 
proteins to the N-terminal UBA domain of SCCRO inhibits its neddylation activity, suggesting the 
presence of a classical negative-feedback loop that regulates CRL-promoted ubiquitination activity 
(Figure 9). 
Figure 9. Proposed model of UBA domain–mediated regulation of SCCRO.
In this model, SCCRO’s N-terminal UBA domain serves as a sensor of polyubiquitinated proteins, 
as well as an effector by promoting the auto-ubiquitination of SCCRO. The effects of the UBA 
domain do not appear to be allosteric, as the addition of polyubiquitin chains or mutation of 
the UBA domain has no effect on SCCRO’s neddylation function in vitro, whereas accumulation 
of polyubiquitinated proteins shows classical negative-feedback dynamics in vivo. Interestingly, 
the requirement for SCCRO in neddylation is also different in vitro and in vivo, with its essential 
effects in vivo involving compartmentalization of neddylation components. As Ubc12, the E2 for 
neddylation, is primarily located in the nucleus, SCCRO-promoted nuclear translocation of Cullin-
ROC1 complexes is required for neddylation. Consistent with this, we found that the effect that 
binding of polyubiquitinated proteins to the UBA domain had on SCCRO’s function was imparted 
by cytoplasmic translocation of SCCRO: increase in levels of polyubiquitinated proteins increased 
cytoplasmic localization of SCCRO and inhibited nuclear localization of neddylation components, 
whereas mutation in the UBA domain abrogated these effects. 
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These findings raise obvious questions about how binding of polyubiquitinated proteins 
to the UBA domain affects the subcellular localization and function of SCCRO. Recent work by 
Wu et al. shows that the UBA domain of SCCRO is required for its monoubiquitination and that 
monoubiquitination promotes nuclear export of SCCRO. Conversely, mutations in the UBA domain 
block monoubiquitination of SCCRO and, consequently, its nuclear export (Figure 5C and 5D) (28). 
These findings suggest that the binding of polyubiquitinated proteins to the UBA domain serves 
as a signal for the monoubiquitination of SCCRO. A limitation of this work is reliance on SCCRO 
mutants to assess structure-function relationships. It remains possible that the generated mutants 
affect protein function in unanticipated ways. Mitigating this issue, at least in part, we found that 
blocking the monoubiquitination of SCCRO by mutation of ubiquitination residues in SCCRO or 
restricting SCCRO’s nuclear export by NLS tag had identical effects on SCCRO localization and 
function as UBA domain mutants expressed in cells exposed to MG132.
UBD-coupled auto-ubiquitination has been reported for several other proteins, including 
Sts1, Sts2, Eps15, Eps15R, Vps27p/Hrs, Vps9p, and Rabex-5 (9). Although the precise underlying 
mechanisms remain to be defined, a range of functional consequences are known to accompany 
UBD-coupled auto-ubiquitination, including effects on inter- and intra-protein interactions and 
subcellular localization. Various UBDs have been implicated in coupled auto-ubiquitination, 
including UIM, CUE, MIU, and A20 ZnF domains; however, this has not been previously reported 
for UBA domain–containing proteins. In the case of SCCRO, coupled auto-ubiquitination leads to 
its cytoplasmic translocation and functional inhibition in vivo. What remains to be defined is how 
monoubiquitinated SCCRO is translocated and sequestered in the cytoplasm. Given the relatively 
low affinity of the UBA domain in SCCRO for monoubiquitin, it is unlikely that intra-protein 
interaction is the cause of changes in SCCRO’s localization. These effects are also unlikely to be 
caused by changes in interactions with neddylation components, as the presence of polyubiquitin 
chains and/or mutations in the UBA domain does not affect binding between SCCRO and Cul1 
or Ubc12. Given that SCCRO and other neddylation E3 components lack a canonical nuclear 
localization sequence, one possibility for nuclear export is that monoubiquitination of SCCRO 
inhibits interactions with NLS-containing protein partners involved in nuclear import.
In the broader context, the principal presence of the UBA domain in E2s and E3s (33) raises 
the question of whether UBA domains serve as general feedback regulators of the ubiquitination 
pathway. In a related model, the auto-ubiquitination and ubiquitin binding of the UBD in Rabex-5 
affected its ubiquitin ligase activity (34). It remains to be determined whether UBA domains play 
similar roles in other proteins. 
Although specific mechanisms require definition, it is quite clear that mutations in the UBA 
domain that inhibit interactions with ubiquitinated proteins increase SCCRO’s neddylation activity 
in vivo. We have previously shown that increased neddylation activity resulting from overexpression 
of SCCRO promotes oncogenesis in vitro and in vivo (30). In primary tumors, SCCRO’s oncogenic 
activity is promoted by amplification that is present in many types of cancers, including lung, 
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ovarian, head and neck and esophageal cancers (35-37). Interestingly, we found that transgenic 
expression of UBA domain mutants of SCCRO was more oncogenic than wild-type SCCRO. Moreover, 
we found that, although they are rare, somatic mutations cluster in the UBA domain of SCCRO. As 
the spontaneously occurring somatic UBA domain mutations lose binding to polyubiquitinated 
proteins and have increased neddylation and transforming activity, they represent an alternate 
mechanism for activation of SCCRO’s oncogenic activity in human cancers. 
The role of the UBA domain in cancer pathogenesis has been well-established. For example, 
germline mutations in the UBA domain of SQSTM1 are associated with the development of Paget’s 
disease of bone. These mutations impair the ability of SQSTM1 to bind to ubiquitin chains, altering 
proteasome- and/or autophagy-based turnover of the bound ubiquitinated proteins (38-42). 
Although the specific polyubiquitinated proteins involved remain to be identified, the carcinogenic 
effects that result from loss of binding due to mutation in the UBA domain of SQSTM1 are achieved 
through activation of NF-κB signaling (39,40). Moreover, the identification of mutation clusters in 
the UBA domains of other proteins suggests that these domains may play a larger and more direct 
role in oncogenesis than previously appreciated (Supplemental Table 1). In the broader context, 
functional domains typically have similar activities, even when present in different proteins. As 
such, functionally related mutations in cancers may cluster in domains, rather than in individual 
genes or gene families. Domain-based analysis of genome-wide sequencing data may identify 
novel targets for anticancer therapies. For example, the activity of an oncogene may be mitigated 
by agents that bind to or mimic the oncoprotein’s UBA domain. In one such instance, overexpression 
of the UBA domain of hFAF1 significantly promotes cell death by increasing the degradation of 
polyubiquitinated proteins (43). 
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Abstract 
The activity of cullin-RING type ubiquitination E3 ligases (CRLs) is regulated by neddylation, a 
process analogous to ubiquitination that culminates in covalent attachment of the ubiquitin-like 
protein Nedd8 to cullins. As a component of the E3 for neddylation, SCCRO/DCUN1D1 plays a key 
regulatory role in neddylation and, consequently, CRL activity. SCCRO’s essential contribution 
to neddylation is to promote nuclear translocation of the cullin-ROC1 complex. The presence of 
a myristoyl sequence in SCCRO3, one of four SCCRO paralogs present in humans, that localizes 
it to the membrane raises questions about its function in neddylation. We found that although 
SCCRO3 binds to CAND1, cullins, and ROC1, it does not efficiently bind to Ubc12, promote cullin 
neddylation, or conform to the reaction processivity paradigms—suggesting that SCCRO3 does 
not have E3 activity. Expression of SCCRO3 inhibits SCCRO-promoted neddylation by sequestering 
cullins to the membrane, thereby blocking its nuclear translocation. Moreover, SCCRO3 inhibits 
SCCRO’s transforming activity. SCCRO3’s inhibitory effects on SCCRO-promoted neddylation and 
transformation require both an intact myristoyl sequence and PONY domain, confirming that 
membrane localization and binding to cullins are required for in vivo functions. Taken together, our 
findings suggest that SCCRO3 functions as a tumor suppressor by antagonizing the neddylation 
activity of SCCRO. 
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Introduction
Ubiquitination regulates the activity of proteins involved in diverse and essential cellular processes, 
including transcription, differentiation, signal transduction, cell cycle progression, and apoptosis 
(1). Although ubiquitination serves as the primary signal targeting proteins for degradation at the 
proteasome, it can modify protein function in many other ways (2). Ubiquitination results from 
the sequential activity of activating (E1), conjugating (E2), and ligating (E3) enzymes (3,4), with 
substrate-derived signals (e.g., misfolding, mutation, and posttranslational modifications [i.e., 
phosphorylation]) serving as initiators of the cascade (5). E3s provide specificity and serve as the 
rate-limiting step in ubiquitination. Thus, factors regulating assembly of multiprotein complexes 
to constitute functional E3 ligases are the primary regulators of ubiquitination activity. For cullin-
RING ligases (CRLs), the largest class of mammalian ubiquitination E3s, neddylation of cullin serves 
as the key signal for assembly of the E3 complex (6,7). Neddylation is a process analogous to 
ubiquitination, in which a tripartite cascade resulting in covalent modification of the cullin family 
of proteins by the ubiquitin-like protein Nedd8 is regulated by activity of the neddylation E3 (8-10). 
We and others identified SCCRO/DCUN1D1 and showed that it functions as a regulatory component 
in the neddylation E3 (11-15). SCCRO promotes neddylation in three ways: (1) it binds to cullin-ROC1 
complexes in the cytoplasm and promotes their nuclear translocation; (2) it enhances recruitment 
of E2~Nedd8 (Ubc12~Nedd8) thioester to the complex; and (3) it optimizes the orientation of 
proteins in the complex to allow efficient transfer of Nedd8 from the E2 to the cullin substrates. 
SCCRO is not required for neddylation in in vitro assays (14), but studies in yeast and 
Caenorhabditis elegans suggest that SCCRO’s activity is essential for neddylation, as targeted 
inactivation of SCCRO results in lethality (12). In contrast, SCCRO knockout mice are viable, likely 
due to compensation by the SCCRO paralogs, which are exclusively present in higher organisms (14) 
(unpublished data). Bioinformatics analysis shows that SCCRO has four paralogs in mammals, which 
can be classified into three subgroups on the basis of their phylogeny and N-terminal sequences: 
SCCRO and SCCRO2 (DCUN1D2) contain an ubiquitin-associated (UBA) domain, SCCRO3 (DCUN1D3) 
contains a myristoyl sequence, and SCCRO4 (DCUN1D4) and SCCRO5 (DCUN1D5) contain a nuclear 
localization signal in the N-terminus. Although it has been suggested that each of the SCCRO family 
members promotes neddylation, the precise in vivo contributions remain to be defined (11-17) (18). 
Interestingly, N-terminal motifs either directly or indirectly regulate subcellular localization of all 
SCCRO paralogs. The UBA domain of SCCRO and SCCRO2 regulates its nuclear localization (19). We 
recently showed that SCCRO5’s function as an oncogene requires its nuclear localization signal 
(NLS) (16). Given the importance of nuclear localization in the neddylation function of SCCRO family 
members, the presence of a myristoyl sequence in SCCRO3 that localizes it to the membrane raises 
questions about its in vivo activities (17). Moreover, in contrast to the other SCCRO family members, 
SCCRO3 is reported to function as a tumor suppressor (20). In this study, we sought to determine the 
mechanisms underlying SCCRO3’s contributions to neddylation and human cancer pathogenesis. 
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We show that, by sequestering cullins to the membrane to prevent their nuclear translocation, 
SCCRO3 inhibits SCCRO-promoted neddylation and, consequently, CRL-promoted ubiquitination. 
Its inhibitory effects on SCCRO activity endow SCCRO3 with putative tumor-suppressor function. 
The high prevalence of reduced SCCRO3 expression in multiple tumor types suggests that it plays 
a significant role in human cancer pathogenesis. 
Experimental procedures
Tumor tissue, cell lines, antibodies, and plasmids
Primary tumor specimens and adjacent normal tissue from head and neck, lung, oral, ovarian, and 
thyroid neoplasms were collected from patients undergoing surgical resection, after informed 
consent was obtained and in accordance with institutional guidelines. Cell lines H1299, NIH-3T3, 
U2OS, and HeLa were obtained from American Type Culture Collection (Manassas, VA); 16HBE 
was a gift from Dr. Alan Hall (Memorial Sloan-Kettering Cancer Center [MSKCC]). The following 
antibodies were used: anti-DCUN1D3 (Abnova, Taipei City, Taiwan); anti-Cul1 and Alexa Fluor 
488 Phalloidin (Invitrogen, Grand Island, NY); anti-Cul3 (BD Biosciences, San Jose, CA); anti-ROC1 
(Spring Bioscience, Pleasanton, CA); anti-Ubc12 (Rockland, Gilbertsville, MA); anti-CAND1 and 
anti-GST (Upstate, Lake Placid, NY); anti-tubulin (Sigma-Aldrich, St Louis, MO); anti-HA (Covance, 
Princeton, NJ); anti-Aurora B (BD Biosciences); anti-actin and anti-RhoA (Santa Cruz Biotechnology, 
Santa Cruz, CA); Cy3-conjugated anti-Myc and FITC-conjugated anti-HA (Jackson ImmunoResearch 
Laboratories, West Grove, PA); anti-GAPDH (Millipore, Billerica, MA); and secondary antibodies 
conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA), with dilutions 
according to the manufacturers’ specifications. Anti-SCCRO (rabbit polyclonal) antibody was 
produced and used as described previously (21).
All DNA constructs were generated using a standard PCR-ligation technique and verified by 
automated sequencing. Proteins were expressed as glutathione-S-transferase (GST) fusions in 
Escherichia coli strains BL21 (DE3) (Novagen, Madison, WI), were induced overnight at 18oC with 
the addition of 1 mM IPTG, and were purified by passage through Glutathione Sepharose 4B 
beads (GE Healthcare Life Sciences, Piscataway, NJ), followed by thrombin cleavage as required. 
APPBP1/Uba3, Ubc12, and Nedd8 were obtained from a commercial source (Boston Biochem, 
Cambridge, MA). The human SCCRO3 plasmid was obtained from a commercial source (Clontech, 
Mountain View, CA). The human PUM2 construct was a gift from Dr. Judith Kimble (Howard Hughes 
Medical Institute investigator, University of Wisconsin, Madison). SCCRO and SCCRO3 shRNA 
lentiviral constructs were obtained from Sigma-Aldrich through the high-throughput screening 
core facility at MSKCC (see Table 1 for sequences). SCCRO3 cDNAs were cloned into pGEX-4T-3 
(GE Healthcare Life Sciences, Piscataway, NJ), pBABE (Addgene, Cambridge, MA), or pCMV-HA (BD 
Biosciences, San Jose, CA) vectors per the manufacturers’ protocols. Transfections were performed 
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with Lipofectamine 2000 (Invitrogen, Grand Island, NY), in accordance with the manufacturer’s 
protocols. Stable overexpression and shRNA knockdown clones were selected in the presence of 
puromycin. An NIH-3T3 cell line stably expressing SCCRO was derived as described previously (21).
Table 1. Primer sequences for SCCRO3 methylation analysis and SCCRO3 mutations and sequences for 
SCCRO and SCCRO3 knockdown.
Sequence type Primer
DNA methylation primer 
sequences
   Methylated(s) 5 – TGGCGATGATATCGAGTCGTTTC – 3
   Methylated(as) 5 – GACTCCAAACGCGAAAAACTAACG – 3
   Unmethylated(as) 5 – AAAACACCAACTCCAAACACAAAAAAC – 3
   Unmethylated(s) 5 – GTTGGTGGTGATGATATTGAGTTGTTTT – 3
cDNA cloning primer 
sequences
   DCUN1D3 G2A 5 – ATGGCCCAGTGTGTCACCAAGTGTAAG – 3
   DCUN1D3 D241N 5 – CATGTTCCAAGTGTTCCGGGAGATGCCCTT – 3
   DCUN1D3 A265R 5 – AAAGAGACTTGGCCACCGCTCATCTTCACT – 3
   DCUN1D3 D271N 5 – CCACAAAGGTGTTAAAGAGACTTGGCC – 3
   DCUN1D3 deletion 1-26 5 – CGGAATTCCGCCGCCACCATGAAGTCACAT – 3
shRNA primer sequences
   Primer shRNA1 5 – CACTTGGAACATGTTCCTTAA – 3
   Target shRNA1 5 – CCGGCACTTGGAACATGTTCCTTAACTCGAGTTAAGGAACATGTTCCAAGTGTTTTTTG – 3
   Primer shRNA2 5 – CCTTAACTTCACTCAGGTGAT – 3
   Target shRNA2 5 – CCGGCCTTAACTTCACTCAGGTGATCTCGAGATCACCTGAGTGAAGTTAAGGTTTTTTG – 3
Real-time reverse-transcriptase PCR
Total RNA was extracted with Trizol reagent (Life Technologies, Grand Island, NY) and repurified 
using the RNeasy Mini spin column (Qiagen, Valencia, CA). Gene-specific primers were designed 
using the Primer3 program and were purchased from Operon Technologies (Alameda, CA) (for 
primer sequences, see Table 2). The relative quantitative analysis of SCCRO3 mRNA expression, 
normalized to GAPDH, was performed using the 7900HT Sequence Detector System (Applied 
Biosystems, Foster City, CA). PCR cycling conditions for all samples were as follows: denaturation 
(94oC for 5 min) and amplification repeated for 40 cycles (94oC for 15 s, Tm for 20 s, 72oC for 20 
s). Real-time PCR assays were conducted in duplicate for each sample, and each PCR experiment 
included 2 nontemplate control wells. A standard curve for serial dilutions of cDNA of head and 
neck cancer cell lines MDA686 and MDA1186 was similarly generated. The comparative threshold 
cycle method was used to calculate the SCCRO3/DCUN1D3–like gene expression ratio in each 
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sample relative to the value observed in the control standard curve, using GAPDH as a control 
for normalization among samples. Melt curve analysis was performed after amplification. The 
acquisition temperature was set  at 1oC to 2oC below the Tm of the specific PCR product. The 
relative quantification of a target gene, compared with that of a reference gene (GAPDH rRNA), was 
performed as described previously (21).
Table 2. Real-time RT-PCR primer sequences.
Gene
Primer
Forward Reverse
SCCRO1/DCUN1D1 5 – CTGGAGGACACCAACATG – 3 3 – TTCACTAGATTGTGTGAAGATC – 5
SCCRO2/DCUN1D2 5 – GTTCACCTCCATTTCTCAATGTG – 3 3 – CTTAGAAATGGCTGTTGCGT – 5
SCCRO3/DCUN1D3 5 – CACAGAATTTCGAGTGCTG – 3 3 – TGCACTTATTGCTTTGCAG – 5
SCCRO4/DCUN1D4 5 – CTGGCAAATATTCATAAGATCTACC – 3 3 – AAGACCGCAGACTTCCTG – 5
SCCRO5/DCUN1D5 5 – TGCGCTCACAGTTGAATGATATTTCGTC – 3 3 – CAGTGGCCATGTCCTCCCAAGCAG – 5
GAPDH 5 – GCACCACCAACTGCTTAG – 3 3 – CATGGACTGTGGTCATGAG – 5
DNA sequencing and mutational analysis, DNA methylation analysis
Putative exonic regions of the SCCRO3 gene (NCBI Human Genome Build 36.1) were broken into 61 
amplicons of 500 bp or less, and specific primers were designed using Primer3. Sequence reactions 
were run on an ABI PRISM 3730xl sequencing apparatus (Applied Biosystems, Foster City, CA). 
PCR was performed in 384-well plates, in a Duncan DT-24 water bath thermal cycler, with 10 ng of 
whole-genome amplified DNA (Repli-G Midi; Qiagen, Valencia, CA) as template, using a touchdown 
PCR protocol with HotStart Taq (Kapa Biosystems, Cape Town, South Africa). Templates were 
purified using AMPure (Agencourt Biosciences, Beverly, MA). The purified PCR reactions were split 
in 2 and sequenced bidirectionally with M13 forward and reverse primer and Big Dye Terminator 
Kit (version 3.1; Applied Biosystems, Foster City, CA) at Agencourt Biosciences. Dye terminators 
were removed using the CleanSEQ kit (Agencourt Biosciences). Mutations were detected using an 
automated detection pipeline at the Memorial Sloan-Kettering Cancer Center Bioinformatics Core. 
Bidirectional reads and mapping tables (to link read names with sample identifiers, gene names, 
read direction, and amplicon) were subjected to a quality control filter, which excludes reads that 
have an average Phred score of <10 for bases 100 to 200. Passing reads were assembled against 
the SCCRO3 reference sequence, containing all coding and UTR exons, including 5 Kb upstream 
and downstream of the gene, using command line Consed 16.0 (22). Assemblies were passed 
on to Polyphred 6.02b (23) and Polyscan 3.0 (24), generating lists of putative mutations. Putative 
mutation calls were normalized to “+” genomic coordinates and annotated using the Genomic 
Mutation Consequence Calculator (25). The resulting list was loaded into a Postgres database, 
along with select assembly details for each mutation call. To reduce the number of false-positives 
generated by the mutation detection software packages, only point mutations supported by at 
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least 1 bidirectional read pair and at least 1 sample mutation called by Polyphred were considered, 
and only the putative mutations annotated as having nonsynonymous coding effects and that 
occurred within 11 bp of an exon boundary or had a conservation score >0.699 were included in 
the final candidate list. Indels called by any method were manually reviewed and included in the 
candidate list if found to hit an exon. All putative mutations were confirmed by a second PCR and 
sequencing reaction, in parallel with amplification and sequencing of matched normal-tissue DNA.
For DNA methylation analysis, genomic DNA was extracted from primary lung tumors by use 
of All Prep DNA/RNA (Qiagen, Valencia, CA). Bisulfite conversion of genomic DNA was performed 
using the EZ DNA methylation kit (Zymo Research, Irvine, CA). One microgram of genomic DNA 
was used. Methylation-specific PCR was performed using primers designed for methylated and 
unmethylated promoter sequences using the program MSPPrimer. Methylation-specific PCR was 
performed as previously described (26). All PCR products were analyzed by electrophoresis on a 
2.5% agarose gel. Primers are listed in Table 1.
GST pull-down assay
GST-tagged proteins were bound to Glutathione Sepharose beads (GE Healthcare Life Sciences, 
Piscataway, NJ) by gentle rocking at 4°C for 30 min. The beads were washed 4 times with EBC buffer 
(50 mM Tris-HCl [pH 7.5], 2.5 mM MgCl2, 150 mM NaCl, and 0.5% Nonidet P-40) at 20x bead volume. 
The beads were incubated with 500 µg of HeLa cell lysate or purified proteins, as indicated, at 4°C 
for 1 h, followed by 3 washes with EBC buffer at 20x bead volume. Bound proteins were eluted by 
the addition of 6x Laemmli buffer or nonreducing Laemmli buffer (when thioester bonds were 
involved), were resolved on SDS-PAGE gels, and were analyzed by Western blot.
Thioester reactions
Reactions were performed at room temperature in buffer (50 mM Tris-HCl [pH 7.6], 50 mM NaCl, 10 
mM MgCl2, and 0.5 mM DTT) with 4 mM ATP, 80 nM APPBP1/Uba3, 800 nM Ubc12, and 9 µM Nedd8. 
After 10 min, which was previously determined to be the optimal reaction time (15), reactions were 
quenched by the addition of EDTA (to a final concentration of 50 mM) and were purified on a G-50 
micro spin desalting column (GE Healthcare Life Sciences, Piscataway, NJ). Next, 13.1 µL of reaction 
product containing 10 pmol Ubc12 was added to 1 nmol GST-SCCRO binding assay with a gradient 
of purified protein as indicated. The wash and detection sequences were as described above. The 
presence of Ubc12~Nedd8 thioester complexes was verified by Western blot analysis for Ubc12. 
Ponceau S stain was performed as a loading control.
In vivo and in vitro neddylation assay
For in vivo neddylation, cell lysates were directly subjected to immunoblotting for cullin(s). In vitro 
neddylation assays were performed, as described previously (15), using HeLa lysate (as a source of 
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cullin-ROC1) and purified SCCRO/SCCRO3 proteins or lysate from U2OS cells transfected with HA-
SCCRO3 and Myc-Cul1. The reaction mixture also contained recombinant Nedd8 (2 µM), E1 (5 nM), 
E2 (5 µM), and ATP (4 mM).
Cell morphologic analysis
Cells were seeded in chamber slides (Lab-Tek; Thermo-Fisher Scientific, Rochester, NY), incubated 
in appropriate media for 24 h at 37°C with 5% CO2, washed with PBS, and photographed using 
phase-contrast microscopy at 4x and 10x magnification (Olympus IX71). 
Immunofluorescence analysis
H1299 cells, 16HBE cells, and U2OS cells transfected with the indicated plasmids were seeded in 
chamber slides or 6-well plates with cover glass and left overnight at 37°C in 5% CO2. Twenty-four 
hours after seeding or after transfection, cells were washed (PBS) and fixed in 4% formaldehyde 
for 10 min or were fixed with methanol acetone for 20 min at -20°C. Fixed cells were permeabilized 
with 0.5% Triton X-100 (Spectrum Chemicals, Gardena, CA) for 5 min, were stained with Alexa 
Fluor 488 Phalloidin for 30 min at room temperature or incubated in blocking buffer (1% bovine 
serum albumin in PBS-T) for 30 min, were washed (PBS), and were stained overnight in a humid 
chamber at 4°C with fluorochrome-conjugated antibodies. The cells were washed 3 times (PBS), 
were counterstained with DAPI (Vector Laboratories, Burlingame, CA), were washed an additional 
3 times (PBS), were covered by ProLong Gold Antifade Reagent (Invitrogen, Grand Island, NY), 
and were examined with Leica and Olympus IX71 inverted confocal microscopes fitted with 
appropriate fluorescence filters at 20x or 63x magnification. For the subcellular localization assay, 
percentages of nuclear and nonnuclear Cul1 were calculated on the basis of 200 transfected cells 
for each condition.
Cell motility and transformation assays
For scratch assays, cells were plated and grown until they formed a confluent monolayer. Cells were 
then starved of serum for 24 h and treated with mitomycin C for 90 min to arrest cell proliferation, 
using a previously published protocol (27). The monolayer was scratched in a straight line using 
a 20-µL pipette tip. We checked these cells at intervals to ensure that cells were migrating across 
the scratch, rather than broad-front advancement resulting from cell proliferation. The cells were 
washed with PBS and then photographed using a phase-contrast microscope (Olympus IX71) at 
4x magnification. The petri dishes were placed at 37°C in humidified air with 5% CO2 for 24 or 36 h, 
depending on the cell line, and were then photographed in the same location. For soft agar assays, 
vector, SCCRO3, or mutant DNA was stably transfected into H1299 cells, as well as into NIH-3T3 cells 
stably transfected with SCCRO, and the cells were plated in 0.35% agarose-coated 6-well plates, at 
densities of ~1000 and ~5000 cells in agarose. After incubation for 2 to 6 weeks, cells were stained 
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with 0.005% crystal violet (Sigma-Aldrich) and photographed using a dissecting microscope (Leica 
Stereoscope MZ FL-III). Colony counts were obtained using Image J software (NIH, Bethesda, MD). 
Statistical analysis
Descriptive statistics were used to summarize study data. Qualitative (Fisher’s exact test) and 
quantitative (Mann-Whitney U test) comparisons were performed using nonparametric assays. 
Statistical significance was defined as a two-tailed P ≤ 0.05. All statistical analyses were performed 
using a commercially available statistical software package (SPSS, Chicago, IL, or SAS, Durham, NC).
Results
SCCRO3 expression is decreased in human tumors
We and others have shown that amplification and overexpression of SCCRO are common in many 
different types of human cancer and that they underlie its function as an oncogene (21,28-30). To 
determine whether SCCRO3 is also involved in cancer pathogenesis, we assessed its expression 
in lung, oral, ovarian, and thyroid neoplasms and matched normal tissue by real-time PCR (Fig. 
1A). Expression of SCCRO mRNA was increased in many different tumor types studied, which 
is consistent with its known oncogenic activity (Fig. 1B). In contrast, SCCRO3 mRNA levels were 
decreased in a wide range of cancers, including in 58% of lung squamous cell carcinomas (n=40), 
38% of lung adenocarcinomas (n=40), 85% of lung neuroendocrine tumors (n=54), 21% of oral 
squamous cell carcinomas (n=39), 20% of ovarian carcinomas (n=40), and 27% of thyroid tumors 
(n=56). We further subclassified tumors to assess those with an increase of SCCRO only, a decrease 
of SCCRO3 only, or both (Fig. 1B). Interestingly, there was a trend toward mutual exclusivity, with 
127 cases having either an increase of SCCRO or a decrease of SCCRO3 expression and only 31 
tumors having both. Co-dysregulation of SCCRO and SCCRO3 was most common among lung 
squamous cell carcinomas and neuroendocrine carcinomas. It remains to be determined whether 
co-dysregulation of SCCRO paralogs increases oncogenicity. Given that SCCRO and SCCRO5 function 
as oncogenes, the decreased expression of SCCRO3 in human cancers is somewhat unexpected, 
but it is supported by previously published analyses of liver, bladder, and renal tumors (20) (16,31).
PUM2 regulates SCCRO3 levels in human tumors
To determine the cause of the decreased expression of SCCRO3 in human cancers, we assessed 
published genomic screening data. This did not identify any tumor types with recurrent chromosomal 
losses involving the SCCRO3 locus at 16p12.3 (32-34). The absence of chromosomal losses at 16p12.3 
was validated by our analysis of results from array comparative genomic hybridization and/or 
single-nucleotide polymorphism investigations performed on thyroid, head and neck, lung, and 
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neuroendocrine tumors at our institution (data not shown). These findings suggest that genomic 
loss is not a cause of the decreased expression of SCCRO3 in human cancers. To determine whether 
expression of SCCRO3 is altered by mutations, we performed exon sequencing on DNA extracted 
from 216 thyroid, oral, and lung tumors with decreased expression of SCCRO3 mRNA, as well as 
on matched normal tissue. Although several single-nucleotide polymorphisms were detected 
(NCBI nos. rs1858901, rs34248677, rs35094690, and rs7187522), no mutations were identified in the 
coding region of SCCRO3 in these tumors (data not shown). Analysis of large-scale cancer genomics 
data sets using the cBioPortal (www.cbioportal.org) revealed the presence of several mutations 
in SCCRO3. The prevalence of mutation (highest prevalence in melanoma [2.5% in Broad data set 
and 2% in TCGA data set]) was significantly lower than the prevalence of a decrease of expression 
of SCCRO3, suggesting that additional mechanisms may be responsible for changes in expression.
Analysis of the SCCRO3 promoter sequence identified multiple CpG islands, prompting us to 
investigate DNA methylation as a mechanism of SCCRO3 silencing (35). Methylation was assessed by 
PCR using the bisulfate method, with matched normal tissue serving as controls. Hypermethylation 
of the SCCRO3 promoter region was not detected in any of the samples tested (Fig. 1C). These 
findings suggest that the decreased expression of SCCRO3 is likely not caused by changes in 
transcription.
We next investigated the presence of posttranscriptional factors that could affect SCCRO3 
levels in human cancer. Proteins that decrease mRNA stability have emerged as key regulators of 
gene expression in normal and cancerous cells (36). Recent studies identified PUM2 as a SCCRO3 
mRNA–binding protein, raising the possibility that it affects translation (37). PUM2 is a member of 
the PUF family of proteins, which bind to sequence elements in the 3’ UTR of target mRNAs to affect 
stability and/or translation of the message. Immunoblotting analysis showed that PUM2 protein 
levels inversely correlated with levels of SCCRO3 mRNA in tumor and matched normal tissue and 
cancer cell lines, suggesting that an association between PUM2 levels and decreased SCCRO3 
expression exists in human cancers (Fig. 1D). To determine whether PUM2 directly affects SCCRO3 
levels, we expressed PUM2 in 16HBE cells, an immortalized benign human bronchial epithelial cell 
line that has low levels of PUM2 and high levels of endogenous SCCRO3. Western blotting analysis 
of lysates from 16HBE cells transiently transfected with HA-tagged PUM2 showed a decrease in 
levels of SCCRO3, but not SCCRO (Fig. 1E, lane 3). Moreover, knockdown of PUM2 using shRNA in 
H1299 cells (a human non-small cell lung carcinoma cell line that has high levels of PUM2 and low 
levels of SCCRO3) resulted in an increase in levels of SCCRO3, but not SCCRO (Fig. 1F, lanes 3 and 4). 
To begin to elucidate how PUM2 controls SCCRO3 expression, we assessed SCCRO3 mRNA levels, 
using real-time PCR, in 16HBE cells overexpressing PUM2 and H1299 cells after siRNA-knockdown 
of PUM2. We found that overexpression of PUM2 reduced the levels of SCCRO3 mRNA, whereas 
knockdown of PUM2 increased its levels relative to controls (Fig. 1G). These findings suggest that 
PUM2 regulates SCCRO3 at the mRNA level. Next, to determine whether PUM2 regulates SCCRO3 
mRNA at the level of transcription or whether it affects its stability, we treated PUM2-transfected 
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16HBE cells with Actinomycin D to stop transcription. Inhibition of transcription in 16HBE cells 
resulted in a significantly greater decrease in SCCRO3 mRNA levels in PUM2, compared with vector-
transfected cells, suggesting that PUM2 affects SCCRO3 mRNA stability (Fig. 1G). Taken together, 
these findings suggest that SCCRO3 mRNA is a target of PUM2-mediated decay, which may explain 
the decreased SCCRO3 expression in at least some human tumors.
Figure 1. SCCRO3 expression in human tumors has an inverse relationship with PUM2 levels. 
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(A), Box plot showing fold decrease in SCCRO3 mRNA levels as measured by Real-time RT-PCR in lung 
adenocarcinoma (Adeno), squamous cell carcinoma (SCC), neuroendocrine carcinomas (NE), oral squamous 
cell carcinoma (OSCC), ovarian carcinoma (CA), and thyroid tumor samples, compared with those in matched 
normal tissue. (B), Results from quantitative real-time PCR analysis showing percentage of cases with SCCRO 
over-expression and decreased SCCRO3 expression in the indicated tumor types. Columns 4 to 6 represent 
the numbers of cases with an increase of SCCRO only, of a decrease of SCCRO3 only, and of both an increase 
of SCCRO and a decrease of SCCRO3. (C), Bisulfate-treated DNA from 3 representative neuroendocrine 
lung tumor samples (and matched normal samples) with decreased SCCRO3 mRNA expression was PCR 
amplified using SCCRO3 promoter–specific primer pairs for methylated (M) and unmethylated (U) DNA. PCR 
product was obtained (lanes 3, 7, and 11) only in template DNA from normal tissue, using primer pair (M). (D), 
Western blot analysis of lysates from lung adenocarcinoma or neuroendocrine carcinomas (T) and matched 
histologically normal tissue (N) showing inverse correlation between PUM2 protein levels and SCCRO3 mRNA 
expression in tumors by real-time PCR analysis (shown below the blot). (E), Western blot analysis of lysates 
from untransfected (WT), empty vector (EV) or HA-PUM2 transfected 16HBE cells probed with anti-HA (top), 
anti-SCCRO3 (2
nd 
panel), anti-SCCRO (3
rd 
panel), and anti–α-tubulin (loading control; bottom panel) antibodies, 
showing a decrease in SCCRO3 but no change in SCCRO levels in cells expressing HA-PUM2 (lane 3). (F), Western 
blot analysis of lysates from H1299 cells showing a decrease in PUM2 and increase in SCCRO3 levels in cells 
infected with virus expressing shRNA against PUM2 (shRNA1 and shRNA2) compared with uninfected cells or 
those infected with a virus expressing scrambled shRNA. (G), Real-time RT-PCR analysis for SCCRO3 expression 
on RNA extracted from experiments in E (left two panels) and F (right panel). AMD (Actinomycin D) was used 
to inhibit transcription after transfection.
SCCRO3 interacts with CAND1, cullins, and ROC1 via its PONY domain
To begin to define the role of SCCRO3 in cancer pathogenesis, we first assessed its biochemical 
activities. Previous studies have shown that SCCRO interacts with proteins involved in neddylation, 
including CAND1, cullins, ROC1, and Ubc12, via its PONY domain (11,12,15,38). Given the presence 
of a highly conserved PONY domain in SCCRO3, we assessed its binding to components of the 
neddylation E3. Immunoblots of products from GST-SCCRO3 pull-down assays of HeLa lysates 
showed that SCCRO3 interacts with CAND1, Cul1, Cul3, and ROC1 (Fig. 2A, lane 3). To define the 
regions involved in binding, we created mutations in residues in the PONY domain of SCCRO3 
(corresponding to the DAD patch) that are required for binding of SCCRO to neddylation 
components (SCCRO3D241N, SCCRO3A265R, SCCRO3D271N, SCCRO3A265R/D271N, and SCCRO3D241N/A265R/D271N 
[SCCRO3DAD]), as well as in the N-terminal myristoyl sequence (SCCRO3∆1-26 and SCCRO3G2A) (11). GST 
pull-down assays of HeLa lysates showed that the SCCRO3–DAD patch mutants (Fig. 2A, lanes 4-8), 
but not the N-terminal mutants (Fig. 2A, lanes 9 and 10), lost binding to CAND1, cullins, and ROC1. 
These findings confirm that, as with SCCRO, SCCRO3’s interaction with neddylation components 
requires its PONY domain. 
SCCRO3 does not bind to Ubc12
Unlike SCCRO, SCCRO3 had no interactions with Ubc12 detected in GST pull-down assays of HeLa 
lysates (Fig. 2A). These findings contrast results from Meyer-Schaller et al. (17), who found that 
GST-Ubc12 binds to bacterially purified His-SCCRO3. We were also able to detect binding between 
GST-SCCRO3 and Ubc12 using purified proteins, but only when very high concentrations of protein 
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were used for GST pull-down, raising the possibility that the observed interactions are nonspecific 
(data not shown). Selective interaction between E3s and E2s charged with ubiquitin or ubiquitin-
like protein, rather than free E2s, is a key mechanism for maintenance of reaction processivity. 
To determine whether binding to Ubc12 is functionally relevant, we assessed whether SCCRO3 
maintains the reaction processivity paradigms that are conserved in all E3s for ubiquitin and 
ubiquitin-like protein in their interactions with E2s. We previously showed that SCCRO binds to 
Ubc12~Nedd8 thioester with a much higher affinity than to free Ubc12, which is consistent with its 
function as an E3 (11,15) (39). GST pull-down assays of the products of thioester reactions containing 
roughly equal quantities of free Ubc12 and Ubc12~Nedd8 thioester, followed by immunoblotting, 
showed that, whereas GST-SCCRO preferentially bound to Ubc12~Nedd8 thioester, GST-SCCRO3 
did not bind to either Ubc12 or Ubc12~Nedd8 under identical conditions (Fig. 2B). To confirm these 
differences in binding efficiency, we performed the GST-SCCRO pull-down in identical experiments, 
adding either bacterially derived, thrombin-cleaved SCCRO or SCCRO3 to the reaction mix before 
the pull-down. The addition of a 10-fold molar excess of SCCRO, but not SCCRO3, blocked pull-
down of Ubc12~Nedd8 by GST-SCCRO, confirming that SCCRO binds to Ubc12~Nedd8 with much 
higher efficiency than SCCRO3 does (Fig. 2C). These observations suggest that SCCRO3 does not 
conform to the conserved processivity paradigms for E3s in the ubiquitin and ubiquitin-like protein 
pathway, and they raise questions about its function as an E3 in neddylation.
SCCRO3 does not augment cullin neddylation in vitro
Given the limited binding of SCCRO3 to Ubc12~Nedd8, we questioned whether SCCRO3 can 
augment cullin neddylation. In vitro neddylation reactions were performed using HeLa cell lysate 
(as a source of cullin-ROC1 substrate) supplemented with recombinant Nedd8, APPBP1/Uba3 (E1), 
Ubc12 (E2), ATP, and varying amounts of either purified SCCRO or SCCRO3 (Fig. 2D). As expected, 
SCCRO augmented cullin neddylation in a dose-dependent manner. Under identical conditions, 
SCCRO3 was associated with a minimal increase of neddylated Cul3. The changes in the levels of 
neddylated Cul3 were independent of the dose of SCCRO3, suggesting that the observed changes 
may not reflect the physiological activity of SCCRO3. Combined, these findings suggest that 
SCCRO3 does not promote neddylation of cullins with the same efficiency as SCCRO. 
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Figure 2. SCCRO3 does not function as a component of the neddylation E3. 
(A), Western blot analysis of the pull-down products of GST-SCCRO, GST-SCCRO3 or GST-SCCRO3 mutants from HeLa 
extracts probed with indicated antibodies, which showed GST-SCCRO (control; lane 1) binds to all the indicated 
proteins. SCCRO3 and its N-terminal mutants, but not its C-terminal mutants, bind to CAND1, Cul1, Cul3, and ROC1. 
Neither SCCRO3 nor its mutants showed binding to Ubc12. The levels of the various GST-tagged proteins used 
in the pull-down experiment were confirmed by probing a Western blot with anti-GST antibody (bottom panel). 
(B), Western blot analysis probing for Ubc12 on a thioester reaction, which showed generation of Ubc12~Nedd8 
thioester (left panel, left lane 30kD band) and a specific reduction of thioester bonds with the addition of DTT 
(left panel, right lane); and Western blot analysis of the products of GST, GST-SCCRO, and GST-SCCRO3 pull-down 
assays from the same Ubc12 thioester reaction mixture, which showed a preferred interaction of GST-SCCRO with 
Ubc12~Nedd8 (right panel, lane 2) and no interaction of GST or GST-SCCRO3 with Ubc12~Nedd8 or free Ubc12 
(right panel, right lane). Coomassie blue staining showing levels of GST and GST-tagged proteins (bottom panel). 
(C), Western blot analysis of a thioester reaction, showing a generation of UBC12~Nedd8 thioester (left panel, left 
lane, 30kD band) and its reduction with the addition of DTT (left panel, right lane); and Western blot analysis of the 
products of GST-SCCRO pull-down assays (1 nmol GST-SCCRO per assay) from the same Ubc12 thioester reaction 
(right panel) supplemented with 10 nmol of untagged SCCRO or SCCRO3 protein as indicated, which showed 
addition of 10x free SCCRO but not SCCRO3 blocked binding between Ubc12 and GST-SCCRO. Ponceau S staining 
of the blot showed equal loading. (D), Western blot analysis of the products of an in vitro neddylation reaction 
with HeLa lysate (as a source of cullin-ROC1) supplemented with a concentration gradient of either SCCRO (upper 
panel) or SCCRO3 (lower panel) purified proteins, which showed a dose-dependent increase in Cul3 neddylation 
with addition of SCCRO but not SCCRO3.  
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SCCRO3 competes with SCCRO for Cul1 localization
Recent work from our laboratory suggests that subcellular localization plays an important role 
in regulating cullin neddylation (14). To determine whether SCCRO3 affects cullin localization, 
HA-tagged SCCRO, SCCRO3, or selected SCCRO3 mutants were cotransfected with Myc-tagged 
Cul1 into U2OS cells. Localization of proteins expressed from transgenes was assessed by 
immunofluorescence with FITC-conjugated anti-HA and Cy3-conjugated anti-Myc antibodies. We 
found that Cul1 and SCCRO3 were colocalized to the plasma membrane (Fig. 3A, 2nd row and Fig. 
3B) and SCCRO3DAD was localized to the membrane without Cul1, whereas neither SCCRO3G2A nor 
Cul1 localized to the membrane when cotransfected (Fig. 3A, 3rd and 4th rows). These findings show 
that SCCRO3 promotes localization of Cul1 to the membrane and that this requires both an intact 
myristoyl sequence and PONY domain.
Given our previous findings showing that SCCRO-promoted nuclear translocation of Cul1 is 
required for neddylation in vivo, we next questioned whether SCCRO3 competes with SCCRO for 
binding and localization of Cul1. To address this question, we assessed the localization of Myc-
Cul1 while varying the ratio of SCCRO to SCCRO3 by shRNA knockdown or transgene expression 
in U2OS cells. As expected, we found that SCCRO promoted nuclear translocation, resulting in its 
colocalization with Cul1 in the nucleus (Fig. 3A, top row and Fig. 3B). Knockdown of SCCRO using 
shRNA cells led to localization of Cul1 at the cell membrane (Fig. 3C and 3D). In contrast, knockdown 
of SCCRO3 led to an increase of Cul1 in the nucleus (Fig. 3C and 3E). Note that shRNA knockdown 
of SCCRO3 did not result in removal of all Cul1 from the membrane, likely due to incomplete 
knockdown of SCCRO3. When SCCRO3 and SCCRO were coexpressed at equal levels in U2OS cells, 
Cul1 primarily localized to the membrane. Increasing the level of SCCRO expression relative to 
SCCRO3 expression in U2OS cells resulted in a dose-dependent increase in nuclear translocation 
of Cul1 (Fig. 3A, last two rows and Fig. 3B). These findings suggest that SCCRO3 antagonizes the 
SCCRO-promoted nuclear translocation of Cul1.
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Figure 3. SCCRO3 competes with SCCRO for subcellular localization of cullins.
(A), Representative images from fluorescence microscopy (scale bar represents 20 μm) showing U2OS cells 
cotransfected with Myc-Cul1, the indicated HA-tagged constructs and varying concentrations of untagged 
SCCRO (rows 5 and 6) stained with FITC-conjugated anti-HA (column 1) and Cy3-conjugated anti-Myc antibody 
(column 2) or DAPI (Column 3). Merged images are shown (column 4). Myc-Cul1 co-localized with HA-SCCRO 
(row 1) in the nucleus and HA-SCCRO3 at the membrane (row 2). HA-SCCRO3
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and Myc-Cul1 is primarily nuclear in these cells (row 3). HA-SCCRO3
DAD 
retains membrane localization, but 
HA-Cul1 does not co-localizes with it (row 4). Co-transfection of increasing concentrations of SCCRO with HA-
SCCRO3 results in progressive translocation of Myc-Cul1 from the membrane to the nucleus (rows 5 and 6). (B), 
Graph showing subcellular distribution of HA-Cul1 from experiment above at varying concentrations of SCRRO 
and SCCRO3. (C), Representative fluorescence microscopic images of U2OS cells transfected with scrambled 
shRNA, or shRNA against SCCRO or SCCRO3 stained for Cul1 using antibody against Cul1 (column 1) and DAPI 
(column 2) and merged (column 3). Knockdown of SCCRO resulted in localization of a fraction of Cul1 to the cell 
membrane (row 2). Knockdown of SCCRO3 increased the proportion of Cul1 in the nucleus (row 3). (D), Western 
blot analysis of lysates from U2OS cells expressing shRNA against SCCRO (shRNA1 and shRNA2) showing 
reduced levels of SCCRO (row 3), but not SCCRO3 (row 4), and a decrease in the proportion of neddylated 
Cul1 and Cul3. (E), Western blot analysis of lysates from U2OS cells expressing shRNA against SCCRO3 (shRNA1 
and shRNA2) showing decreased SCCRO3, but not SCCRO expression, and an increase in the proportion of 
neddylated Cul1 and Cul3. The numbers below the blots are the ratios of neddylated to nonneddylated cullins.
SCCRO3 antagonizes SCCRO-promoted cullin neddylation
Given that SCCRO3 antagonizes SCCRO-promoted nuclear translocation, we questioned whether 
this activity also affects cullin neddylation in vivo. U2OS cells were transfected with SCCRO3, 
SCCRO3G2A, or SCCRO3DAD, alone or in combination with varying amounts of SCCRO, and the levels of 
neddylated Cul1 in vivo were assessed by immunoblotting. Transfection of vector alone, SCCRO3, 
SCCRO3G2A, or SCCRO3DAD did not enhance Cul1 neddylation beyond basal levels (Fig. 4A, lanes 
1-4). Expression of SCCRO increased levels of neddylated Cul1. Coexpression of SCCRO3, but not 
SCCRO3G2A or SCCRO3DAD, reduced the level to which SCCRO enhanced Cul1 neddylation (Fig. 4A, 
lanes 6 and 7; Fig. 4B). The inhibitory effects of SCCRO3 on Cul1 neddylation could be rescued by 
increasing SCCRO expression in a dose-dependent manner (Fig. 4A, lanes 2, 5, and 6). These results 
suggest that SCCRO3 antagonizes SCCRO-mediated cullin neddylation in vivo.
Figure 4. SCCRO3 antagonizes SCCRO-promoted cullin neddylation. 
(A), Western blot analysis of the products of lysates of U2OS cells transfected with the SCCRO, SCCRO3, and/or SCCRO3 
mutants as indicated. Expression of SCCRO3 or its mutants had no effect on levels of neddylated Cul1 (lanes 2-4). 
Expression of SCCRO increased the fractions of neddylated Cul1 (lane 7). Co-expression of SCCRO3 decreased the 
extent to which SCCRO increased levels of neddylated Cul1 (lane 6). The effect of SCCRO3 on neddylated Cul1 levels 
could be partially rescued by increasing SCCRO expression levels (lanes 2, 5, and 6). (B), Western blot analysis on 
lysates from U2OS cells cotransfected with Ubc12 and the indicated SCCRO/SCCRO3 constructs. Coexpression of 
SCCRO3 (compare lane 1 with 2), and not SCCRO3 mutants, inhibits SCCRO-augmented Cul1 neddylation (compare 
lane 2 with lanes 3 and 4).
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Putative tumor suppressor function of SCCRO3 requires its PONY domain and myristoyl 
sequence.
Because SCCRO is known to function as an oncogene, we questioned if SCCRO3’s putative tumor 
suppressor activity involves its antagonism of SCCRO’s neddylation activity. To confirm SCCRO3 
functions as a tumor-suppressor, we assessed effects of its knock down in 16HBE cells. Knockdown 
of SCCRO3 by virally delivered shRNA resulted in a decrease in levels of SCCRO3 protein (but not 
SCCRO) relative to levels in 16HBE cells infected with virus expressing scrambled shRNA controls 
(Fig. 5A). Microscopic evaluation showed 16HBE cells in which SCCRO3 was stably knocked down 
changed from epitheloid to spindle shaped. These cells also showed alteration in their pattern of 
growth, spreading widely across the plate, rather than growing in islands, as seen in parental 16HBE 
cells or those infected with scrambled shRNA control (Fig. 5B). Scratch assays showed that cells in 
which SCCRO3 was knocked down had more directional motility than scrambled shRNA–infected 
cells (Fig. 5C). Staining for actin, using Alexa Fluor 488 Phalloidin, showed a reduction in stress 
fibers in SCCRO3 knockdown cells, compared with scrambled shRNA–infected cells (Fig. 5D).
To begin to determine the mechanisms underlying SCCRO3’s effects on transformation, 
we performed structure-function studies in H1299 cells. We stably transfected H1299 cells with 
empty vector, HA-SCCRO3, HA-SCCRO3G2A, or HA-SCCRO3DAD and confirmed that transgenes were 
expressed at approximately equal levels by Western blot (data not shown). Microscopic analysis 
showed that SCCRO3-transfected cells acquired an epitheloid shape and grew in nests (Fig. 5E, 
2nd row, first image). In contrast, vector-, SCCRO3G2A-, and SCCRO3DAD-transfected cells were spindle 
shaped and were scattered throughout the plate, resembling features seen in untransfected H1299 
cells (Fig. 5E, 1st, 3rd, and 4th rows). Scratch assays showed that migration across the scratch was 
markedly reduced in H1299 cells expressing SCCRO3, compared with that in vector-, SCCRO3G2A-, 
and SCCRO3DAD-transfected cells (Fig. 5F and 5G). Staining with phalloidin showed rearrangement 
of the actin cytoskeleton, with stress fibers developing in SCCRO3-transfected cells but not in 
vector- or SCCRO3 mutant-transfected cells (Fig. 5H). To determine SCCRO3’s oncogenic activity, we 
performed soft-agar assays, which showed reduced colony formation in SCCRO3-transfected but 
not SCCRO3G2A- or SCCRO3DAD-transfected H1299 clones (Fig. 6A and 6B). These observations suggest 
that SCCRO3 functions as a putative tumor suppressor that requires membrane localization and 
binding to cullins.
Given the significant impact of mutation on SCCRO3’s function, we critically assessed mutations 
occurring in human cancers. Interestingly, we found mutations in both the myristoyl sequence 
(SCCRO3G2S) and the PONY domain, including SCCRO3S239F, which occurred with a loss of the wild-
type allele (www.cbioportal.org). The presence of naturally occurring mutations in human tumors 
that can abrogate SCCRO3’s function supports the role of SCCRO3 as a putative tumor suppressor 
and as well as the requirement of the PONY domain and myristoyl sequence for this activity.
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Figure 5. SCCRO3 has tumor suppressor activity that requires its myristoyl sequence and PONY domain.
(A), Western blot analysis of lysates from 16HBE cells showing a decrease in SCCRO3 levels in cells infected with 
shRNA against SCCRO3 (shRNA1 and shRNA2). Western blot for tubulin is shown as a loading control. (B), Dark 
field microscopic image of 16HBE cells expressing shRNA against SCCRO3 (shRNA1, shRNA2) showing a change 
from epitheloid to spindle shape and decreased clumping, compared with cells expressing scrambled shRNA. 
(C), Scratch assay on the same cells showing enhanced migration in cells with SCCRO3 knocked-down relative 
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to those transfected with scrambled shRNA. (D), Indirect immunofluorescence analysis of 16HBE cells infected 
with shRNA against SCCRO3 and stained with Alexa Fluor 488 Phalloidin for actin, which showed a reduction 
in stress fibers. (E), Representative images form microscopic analysis of H1299 cells stably transfected with the 
indicated constructs. Empty vector (EV) transected cells dispersed throughout the plate. SCCRO3 transfected 
cells (panel 2) shows cells maintained intercellular contact and grew in nests. Cells expressing SCCRO3G2A 
or SCCRO3DAD showed no change in growth characteristics relative to empty vector transfected cells. (F), 
Scratch assay on H1299 cells transfected with the indicated constructs showing decreased migration in cells 
transfected with SCCRO3 and no change in those transfected with SCCRO3G2A, SCCRO3DAD, or empty vector 
(EV). (G), Graph showing the average numbers of cells that migrated into wounded areas from experiments 
above. H, Representative images form fluorescence microscopy of H1299 cells transfected with the indicated 
constructs and stained with: Alexa Fluor 488 Phalloidin showing development of actin containing stress fibers 
in SCCRO3 relative to empty vector transected cells, but not SCCRO3G2A or SCCRO3DAD transfected cells. All 
scale bars represent 20 μm.
Figure 6. SCCRO3 has tumor suppressor activity that requires its myristoyl sequence and PONY domain. 
(A), Western blot analysis of lysates from H1299 cells stably transfected with the indicated SCCRO3 constructs, 
probed with anti-SCCRO3 antibody showing equivalent expression of constructs in selected clones. (B), 
Results from soft agar assay on the same H1299 clones showing decreased colony formation in cells expressing 
SCCRO3, relative to clones expressing SCCRO3 mutants or vector alone (average number of colonies per well of 
a 6-well plate ± SD; P = 0.03 for SCCRO3#12 and P = 0.03 for SCCRO3#20, compared with vector).
SCCRO3 antagonizes SCCRO’s in vivo function
To determine whether SCCRO3’s tumor-suppressor activity results from inhibition of SCCRO’s 
oncogeneic activity, we assessed whether SCCRO3 inhibits SCCRO-promoted transformation 
in vivo. To do this, we established NIH-3T3 clones that stably expressed SCCRO. We found that in 
contrast to vector transected NIH-3T3 cells, SCCRO-expressing NIH-3T3 cells formed colonies in 
soft agar. SCCRO-expressing NIH-3T3 cells were then cotransfected with HA-tagged SCCRO3, 
SCCRO3G2A, or SCCRO3DAD (Fig. 7A). Cotransfection of SCCRO3 induced morphological changes in 
SCCRO-expressing NIH-3T3 cells, from a spindle to an epitheloid shape. The pattern of growth was 
also changed, with cells growing in clusters rather than spreading throughout the plate, as seen in 
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the parental line. No change in shape or growth pattern was seen in SCCRO-expressing NIH-3T3 
cells transfected with SCCRO3G2A or SCCRO3DAD (Fig. 7B). Scratch assays showed reduced directional 
migration of NIH-3T3 cells coexpressing SCCRO and SCCRO3 but not of cells coexpressing SCCRO 
and SCCRO3G2A or SCCRO3DAD (Fig. 7C). Moreover, colony formation in soft agar was significantly 
lower in SCCRO-expressing NIH-3T3 cells transfected with SCCRO3 than in those transfected 
with SCCRO3G2A or SCCRO3DAD (Fig. 7D). Combined, these findings suggest that SCCRO3’s tumor-
suppressor activity involves inhibition of SCCRO-promoted oncogenesis.
Figure 7. SCCRO3 antagonizes SCCRO-induced transformation. 
(A), Western blot analysis of lysates of NIH-3T3 cells stably expressing SCCRO, cotransfected with HA-SCCRO3, 
HA-SCCRO3-G2A, HA-SCCRO3-DAD, or vector alone and probed for the HA tag, which showed equal expression 
of transgenes. (B), Representative dark field microscopic images showing SCCRO3 transfected cells maintaining 
contact and growing in nests while those stably co-expressing SCCRO with empty vector or SCCRO3G2A or 
SCCRO3DAD detached and began to disperse across the plate. (C), Scratch assay on the same set of cells at times 
0 h and at 14 h showing a decrease in migration across the scratch for SCCRO expressing cells co-transfected 
with SCCRO3 relative to empty vector, but not those co-transfected with SCCRO3G2A or SCCRO3DAD. (D), Graph 
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showing the average numbers of cells that migrated into wounded areas from the experiments above. (E), 
Graph showing results from soft agar assays on the same set of cells showing a decrease in colony formation 
in cell cotransfected with SCCRO3 relative to those co-transfected with empty vector. No change in colony 
formation was seen with co-transfection of SCCRO3G2A or SCCRO3DAD (showing the average number per high-
power field [HPF] ± SD; P = 0.002, compared with vector).
Discussion
SCCRO’s role in the neddylation E3 is to promote assembly and optimize complex orientation to 
enhance ligase activity, which it achieves by binding to neddylation components via its PONY 
domain. Although the contributions of SCCRO are important, they are not required for neddylation 
E3 activity in vitro. The essential contribution of SCCRO to neddylation in vivo is the nuclear 
translocation of neddylation components, which is regulated by its UBA domain (19). To compensate 
for the complexities of the expanded genome, SCCRO has evolved in higher organisms to include 
four paralogs that have highly conserved PONY domains but variable N-terminal domains. Previous 
studies have suggested that all SCCRO paralogs can promote neddylation (18). However, as these 
studies used in vitro assays, they do not account for the contributions of N-terminal domains, which 
are all directly or indirectly involved in subcellular localization. Given the requirement of nuclear 
localization of cullins for neddylation, the presence of a myristoyl sequence in SCCRO3 that localizes 
it in the cytoplasm raises questions about its in vivo function. We found that, in sharp contrast to 
other SCCRO family members, SCCRO3 does not function as a component of the E3 or promote 
cullin neddylation. Although SCCRO3 binds to cullins, ROC1, and CAND1 via its PONY domain, it does 
not bind to Ubc12 at levels that are functionally relevant. Similar to previous reports, in the present 
study, we detected binding between SCCRO3 and Ubc12 only when high concentrations of purified 
proteins were used in in vitro pull-down assays (17). However, the affinity of SCCRO3 for Ubc12 is 
significantly lower than that of SCCRO. These findings are supported by recent work from Monda et 
al., who showed a Kd of 21 µM for the interaction between SCCRO3 and Ubc12, compared with 2.0 
µM for SCCRO and Ubc12 (18). Moreover, unlike SCCRO, SCCRO3 does not conform to the reaction 
processivity paradigms for E3s, as it did not preferentially bind to Ubc12~Nedd8. Consistent with 
this, we found that SCCRO3 does not promote Cul1 neddylation in vivo. The lack of conformity with 
reaction processivity paradigms, combined with the absence of neddylation-promoting activity, 
suggests that SCCRO3 does not function as a component of the E3 for neddylation. 
What then is the function of SCCRO3? Previous studies have shown that the Kd for binding 
to Cul1-Cul5 varies between SCCRO paralogs (18). The Kd for binding of Cul1 to SCCRO is 1.8 
µM, compared with 1.1 µM for SCCRO3. Consistent with this, when SCCRO and SCCRO3 were 
coexpressed at relatively equal levels, HA-Cul1 predominately localized to the membrane 
with SCCRO3. As the transgenic expression of SCCRO is increased above that of SCCRO3, Cul1 
translocates to the nucleus. Moreover, the relative levels of SCCRO and SCCRO3 expression also 
affected the level of cullin neddylation. SCCRO3 inhibited SCCRO-promoted Cul1 neddylation, 
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which could be overcome by increasing the level of SCCRO expression in vivo. Mutation of either 
the myristoyl sequence or the PONY domain in SCCRO3 abrogated colocalization and inhibition 
of Cul1 neddylation. These findings suggest that SCCRO and SCCRO3 compete for binding and 
localization of cullins. This competition affects neddylation activity and suggests that SCCRO3 
functions as an antagonist of SCCRO’s neddylation activity. As expected, the PONY domain mutant 
of SCCRO3, which loses binding to the neddylation component, also loses its in vivo functions. That 
SCCRO3G2A, a mutant that is unable to localize to the membrane but retains the ability to bind to 
cullins, also loses its effects on SCCRO function suggests that membrane localization is required 
for SCCRO3 to impart its effects. To confirm these findings, we performed a competition assay by 
transecting U2OS cells with SCCRO and an increasing amount of SCCRO3G2A. We found that, even 
at significantly higher expression levels, SCCRO3G2A had no obvious effect on SCCRO-promoted 
Cul3 neddylation in vivo (data not shown). There are several possible explanations for why the 
SCCRO3G2A mutant has no effect on SCCRO’s neddylation and transformation activity. Although 
the SCCRO3G2A mutant retains binding to neddylation components in the absence of the tether to 
the membrane, neddylation components can still enter the nucleus (Fig. 3A). Once neddylation 
components are in the nucleus, the regulatory effects of compartmentalization are lost, allowing 
neddylation to proceed. It is also possible that co-factors present at the membrane are required for 
SCCRO3 to inhibit neddylation activity. Our findings need to be reconciled with previous published 
results, which show that SCCRO3 promotes Cul3 neddylation at the membrane. It remains possible 
that SCCRO3 has dual activity. Our data and those from Monda et al. clearly show that SCCRO3 has 
limited binding to Ubc12. As such, SCCRO3 is unlikely to be able to participate in a neddylation 
reaction that involves Ubc12. However, Monda et al. showed that SCCRO3 binds more efficiently 
to UBE2F (Kd = 1.1 µM), an alternate E2 in neddylation. Consistent with this finding, the effect of 
SCCRO3 on Cul5 neddylation was significantly more with the addition of UBE2F to the reaction 
than with addition of Ubc12. Interestingly, SCCRO3 complemented the neddylation defect of 
yeast dcn1Δ cells (SCCRO homologue), which does not contain UBE2F, suggesting that SCCRO3 
may interact with yeast Ubc12. Combined, these results suggest that SCCRO3 plays a dual role: (1) 
antagonizing the neddylation activity of the other SCCRO paralogs and (2) promoting neddylation 
at the membrane by using UBE2F as the E2. 
It was previously shown that overexpression of SCCRO3 in HeLa cells leads to inhibition of 
colony formation in soft agar. UVC irradiation increased expression of SCCRO3 in cancer cell 
lines, and knockdown of SCCRO3 by siRNA in HeLa cells inhibited UVC-induced cell death (20) 
suggesting that SCCRO3 functions as a tumor suppressor. We validated SCCRO3’s function as a 
putative tumor suppressor by showing (1) that overexpression of SCCRO3 promotes mesenchymal-
to-epithelial–like changes and is associated with a decrease in oncogenic activity in H1299 cells 
and (2) that knockdown of SCCRO3 by shRNA in 16HBE cells promotes epithelial-to-mesenchymal–
like changes and is associated with an increase in oncogenic activity. SCCRO3’s tumor-suppressor 
activity required both an intact myristoyl sequence and PONY domain, as mutants in these regions 
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abrogate its tumor-suppressor activity in 16HBE cells. Moreover, coexpression of SCCRO3 blocked 
SCCRO-promoted transformation, suggesting that competition between SCCRO and SCCRO3 for 
cullin substrate has functional implications in vivo. 
Consistent with SCCRO3’s role as a putative tumor suppressor, its expression was decreased in 
a large proportion of lung, oral, ovarian, and thyroid tumors. Previous reports have shown that its 
expression is also reduced in liver, bladder, and renal tumors (20), suggesting that SCCRO3 plays a 
role in the pathogenesis of a broad range of human cancers. In contrast to the other SCCRO family 
members, changes in SCCRO3 expression in human cancers cannot be explained by copy number 
changes or by promoter methylation or gene mutation. Screening for the causes of the decreased 
expression of SCCRO3 in human cancers led us to PUM2, an RNA-binding protein. We found that 
expression of PUM2 inversely correlates with levels of SCCRO3 expression in human tumors (37). 
PUM2 is known to bind to SCCRO3 mRNA, and we found that transgenic expression of PUM2 in 
cells resulted in decreased cellular levels of SCCRO3, but not SCCRO. Similarly, knockdown of PUM2 
was associated with increased SCCRO3 expression, suggesting that PUM2 may be a cause of the 
decreased SCCRO3 expression in many human cancers. Moreover, presence of mutations in both 
the PONY domain and myristoyl sequence of SCCRO3 in human tumors suggests that mutation 
may be the cause for SCCRO3 inactivation in some cases.
Combined, our data clearly show an antagonistic relationship between SCCRO and SCCRO3 
in neddylation and oncogenesis. Whether this antagonism is also attributable to competition for 
binding to targets downstream of CRLs remains to be elucidated. In the broader context, our results 
suggest that SCCRO family members play independent and overlapping roles in the regulation of 
cullin neddylation (13). Moreover, CRL targets that mediate the effects of SCCRO and SCCRO3 in 
oncogenesis have yet to be elucidated.
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Abstract
Purpose: To determine mechanisms by which SCCRO5 (aka DCUN1D5) promotes oncogenesis.
Experimental Design: SCCRO5 mRNA and protein expression were assessed in 203 randomly 
selected primary cancer tissue samples, matched histologically normal tissues, and cell lines by use 
of real-time PCR and Western blot analysis. SCCRO5 overexpression was correlated with survival. 
The effect of SCCRO5 knockdown on viability was assessed in selected cancer cell lines. Structure-
function studies were performed to determine the SCCRO5 residues required for binding to the 
neddylation components, for neddylation-promoting activity, and for transformation.
Results: In oral and lung squamous cell carcinomas, SCCRO5 mRNA levels corresponded with protein 
levels and overexpression correlated with decreased disease-specific survival. Knockdown of 
SCCRO5 by RNAi resulted in a selective decrease in the viability of cancer cells with high endogenous 
levels, suggesting the presence of oncogene addiction. SCCRO5 promoted cullin neddylation while 
maintaining conserved reaction processivity paradigms involved in ubiquitin and ubiquitin-like 
protein conjugation, establishing it as a component of the neddylation E3. Neddylation activities 
in vitro required the potentiating of neddylation (PONY) domain but not the nuclear localization 
sequence (NLS) domain. In contrast, both the NLS domain and the PONY domain were required for 
transformation of NIH-3T3 cells.
Conclusions: Our data suggest that SCCRO5 has oncogenic potential and that it imparts its 
oncogenicity as a component of the neddylation E3. Neddylation activity and nuclear localization 
of SCCRO5 are important for its in vivo function.
Translational relevance: The importance of the ubiquitin-proteasome pathway in cancer 
pathogenesis is established by the therapeutic efficacy of agents that target pathway activity in 
treating human cancers. Neddylation, a major regulator of ubiquitin-proteasome pathway activity, 
is itself subject to regulation by SCCRO. SCCRO is commonly activated by amplification in many 
different types of cancer and its overexpression is independently associated with poor clinical 
outcome. Here we show that SCCRO5, a paralog of SCCRO, plays a role in cancer pathogenesis. 
SCCRO5 is commonly overexpressed in human cancers and its overexpression is associated 
with worse outcome in oral and lung squamous cell carcinomas. Establishing its role in cancer 
pathogenesis, we show oncogene addiction associated with SCCRO5 overexpression in cancer 
cell lines. Moreover, we show that SCCRO5’s oncogenic activity requires it function as an E3 in 
neddylation, as well as, its subcellular localization. Combined our findings suggest that like SCCRO, 
SCCRO5 is a putative therapeutic target in oral and lung SCC, as well as, other types of cancer.
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Introduction
Several important anticancer therapies have been discovered by leveraging the knowledge that 
changes in protein homeostasis drive human cancer pathogenesis. In this regard, the ubiquitin/
proteasome system is of significance, as there is a high prevalence of aberrations among the 
components of this pathway (1, 2). In particular, the activity of cullin-RING type ubiquitination E3 
ligases is commonly dysregulated in human cancers (3). Dysregulation often results from aberrations 
in the substrate recognition adaptors (ie, FBX7, SPOP, Skp2, VHL), and rarely from abnormalities 
in core components (eg, Cul4A amplification in breast cancer) (4-7). It has long been established 
that posttranslational modification of cullins by neddylation is a key regulator of cullin-RING ligase 
(CRL) activity (neddylation promotes assembly of the CRL complex and enhances recruitment of 
ubiquitin-charged E2, to facilitate ubiquitin conjugation) (8-13). As is the case with ubiquitination, 
neddylation results from the sequential enzymatic activity of a dedicated E1 (APPBP1-Uba3), 
E2 (Ubc12 [aka Ube2M] and Ube2F), and E3 (14). The link between abnormal CRL activity and 
dysregulation of the proteins involved in neddylation in human cancers has only recently been 
appreciated (15). These observations have led to the development of a small molecule inhibitor of 
neddylation E1, MLN4924, which has shown promise in preclinical and early human trials (3). 
SCCRO (aka DCUN1D1), a key component of the E3 for neddylation, is activated by amplification in 
a wide range of human cancers (16, 17). The role that SCCRO plays in cancer pathogenesis has been 
studied in both in vivo and in vitro experimental systems, establishing its function as an oncogene 
(16, 18). In addition, overexpression of SCCRO in human tumor samples has been independently 
associated with poor survival outcomes (16). Of interest, SCCRO is a member of a protein family 
that contains four other highly conserved paralogs in higher organisms. All family members have 
a conserved C-terminal potentiating of neddylation (PONY) domain with a variable N-terminal 
region. SCCRO paralogs are subdivided into three subfamilies on the basis of the N-terminal 
sequence: SCCRO and SCCRO2 (aka DCUN1D2) contain a ubiquitin-associated (UBA) domain, 
SCCRO3 (aka DCUN1D3) contains a myristoylation sequence, and SCCRO4 (aka DCUN1D4) and 
SCCRO5 (aka DCUN1D5) contain a nuclear localization sequence (NLS). We have previously shown 
that SCCRO is oncogenic and that its oncogenic function requires its neddylation activity (16, 17). 
SCCRO3 has also been shown to play a role in oncogenesis (19). Recent work indicates that SCCRO5 
has oncogenic activity (20). However, the precise mechanisms by which the NLS-containing SCCRO 
paralogs promote oncogenesis remain unknown. 
Like SCCRO (at 3q26), its paralogs are located in chromosomal loci that are recurrently amplified 
in human cancers (SCCRO2 at 13q34, SCCRO4 at 4q12, and SCCRO5 at 11q22) (21-23). Of these, 11q22 
amplification is the second most frequent, occurring in a wide range of human cancers, with the 
highest prevalence in squamous cell carcinomas (SCCs) of the cervix, esophagus, head and neck, and 
lung (24-27). Moreover, there is an independent association between 11q22 amplification and worse 
clinical outcome, suggesting that this locus harbors genes that play a role in cancer pathogenesis 
(15, 28, 29). Although several candidate genes have been identified, including MMPs, Birc2 (cIAP1), 
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Birc3 (cIAP2), and Yap, none has been clearly established as a target that drives selection for 11q22 
amplification (29-31). Finemapping of 11q22.2-q22.3 in cervical, oral, and lung cancers has shown 
that SCCRO5 (MGC2714) is located within the minimal common region of amplification (27, 30, 32). 
SCCRO5 is upregulated in laryngeal SCC and putatively plays a role in its pathogenesis (20). Given 
the established role of SCCRO in oncogenesis, we questioned whether SCCRO5 drives selection for 
11q22 amplification in human cancers and sought to elucidate the mechanisms involved. 
Here, we report the validation of SCCRO5 as a target that drives selection for 11q22 amplification 
in human cancers. We found that SCCRO5 mRNA expression is associated with a corresponding 
increase in protein levels and is correlated with decreased disease-specific survival in oral and 
lung SCCs. Specific knockdown of SCCRO5 in cancer cell lines with high endogenous levels of 
SCCRO5 expression resulted in a significantly higher decrease in viability, compared with that in 
cells with low expression levels, suggesting the presence of an oncogene addiction phenotype. 
The oncogenic potential of SCCRO5 is underscored by its ability to transform fibroblasts (NIH-3T3 
cells) in vitro. Furthermore, we show that, like SCCRO, SCCRO5 functions as a component of the E3, 
promoting cullin neddylation while maintaining reaction processivity paradigms. Although only 
the PONY domain was required for SCCRO5’s neddylation function in vitro, its oncogenic activity in 
vivo requires both the PONY domain and the NLS domain, suggesting that subcellular localization 
plays a role in its function. The precise mechanism involved in SCCRO5’s in vivo neddylation activity 
remains to be defined.
Materials and Methods
Bioinformatic analyses
The ClustalW program (Conway Institute UCD, Dublin, Ireland) was used for multiple sequence 
alignments. Data from The Cancer Genome Atlas (TCGA) projects were accessed and analyzed 
using the cBio Cancer Genomics Portal (http://www.cbioportal.org).
Human tissues, cell lines, and antibodies
A total of 203 randomly selected primary cancer tissue and adjacent matched histologically normal 
tissue samples were obtained from patients undergoing surgical treatment at Memorial Sloan-
Kettering Cancer Center between January 1, 2004, and October 1, 2007. All patients undergoing 
surgical resection of primary cancers were offered an opportunity to participate in the study. 
Only previously untreated patients with adequate tissue stored in our tissue bank were included 
in the study. Informed consent was obtained from all patients, in accordance with the guidelines 
established by the institutional review board, and use of patient samples was approved by the 
institutional Human Biospecimen Utilization Committee. Histopathologic confirmation of all 
specimens was established by an experienced pathologist. Tissues were frozen in liquid nitrogen 
immediately after resection and stored at -80°C until use. Demographic and tumor data for the 
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oral SCC, lung SCC, thyroid cancer, and lung neuroendocrine carcinoma patients are described in 
Supplemental Tables S1-S4.
The origins, cytogenetic characteristics, maintenance, and growth of the cell lines used in this 
study were as previously described (16, 33). The following antibodies were used in this study: 
anti-SCCRO (developed and validated as previously described [16]), anti-SCCRO5 (developed and 
validated in our laboratory [data not shown]), anti-Cul1 (Invitrogen, Grand Island, NY), anti-Cul2 
(Abcam, Cambridge, MA), anti-Cul3 (BD Biosciences, San Jose, CA), anti-ROC1 (Abcam), anti-Ubc12 
(Rockland, Gilbertsville, PA), anti-CAND1 (BD Biosciences, San Jose, CA), anti-α-tubulin and anti-
GAPDH (Millipore, Billerica, MA), and anti-actin and secondary antibodies conjugated to horseradish 
peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA).
RNA isolation, cDNA synthesis, and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cell lines and tissue by use of Trizol reagent (Life Technologies, Grand 
Island, NY), repurified using RNeasy Mini spin columns (Qiagen, Valencia, CA), and treated with 
DNase I to eliminate residual genomic DNA. One microgram of total RNA was reverse-transcribed 
using MultiScribe Reverse Transcriptase (Applied Biosystems, Foster City, CA). Primers were 
designed for SCCRO5 and GAPDH (Supplemental Table S5), by use of the Primer3 program (Howard 
Hughes Medical Institute, Chevy Chase, MD), to generate PCR products 75–300 bp in length 
and were obtained from a commercial source (Operon Technologies, Alameda, CA). To confirm 
specificity for SCCRO5, the SCCRO5 primer set was tested on plasmids for all SCCRO paralogs. qRT-
PCR for SCCRO5 was performed, at least in duplicate, in two separate experiments, on the 203 tumor 
and paired normal samples and on appropriate controls by use of a Sequence Detector System 
7900HT device (Applied Biosystems, Foster City, CA), as previously described (16). To ensure the 
presence of a single PCR product, melting curve analysis was performed after each experiment. A 
standard curve was generated using serial dilutions of cDNA from MDA686 and MDA1186 cell lines. 
The comparative threshold cycle method was used to calculate the SCCRO5 expression ratio in each 
sample relative to the value observed in the control standard curve, with GAPDH used as a control 
for normalization among samples (34). GAPDH was determined to be the most stable housekeeping 
gene in the tissues studied, on the basis of geNorm analysis (M < 0.298) (35, 36). Overexpression was 
defined as at least 2-fold higher levels of mRNA expression in the tumor sample relative to the 
matched normal sample and the mean of all normal tissue samples for each cancer type.
Mutation profiling
Primers were designed, using Primer3, to cover putative exon regions of SCCRO5 (National Center 
for Biotechnology Information Human Genome Build 36.1), yielding products ≤500 bp in length 
(Supplemental Table S6) (37). Tumor DNA was extracted using the DNeasy kit (Qiagen, Valencia, CA) 
and was subjected to whole-genome amplification, as previously described (38). High-throughput 
bidirectional dideoxynucleotide sequencing of PCR-amplified gene products was performed using 
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the Sanger sequencing platform, as previously described (39). PolyPhred and PolyScan software 
were used to generate an initial automated report of sequence variations (39). For each respective 
exon, tumor sequences were compared against reference sequences listed in the National Center 
for Biotechnology Information (RefSeq) database. After visual inspection of the individual forward 
and reverse chromograms, for confirmation of nonsynonymous sequence variations and insertions 
or deletions (including duplications), a manual review list of potential nucleotide changes was 
produced. Synonymous variants and those with corresponding entries in the Single Nucleotide 
Polymorphism Database (http://www.ncbi.nlm.nih.gov/projects/SNP/) were excluded from 
analysis. 
cDNA cloning, mutagenesis, and short hairpin RNA (shRNA) knockdown
Human SCCRO5 cDNA was obtained from Clontech Laboratories (Clontech, Mountain View, CA). 
Mutations were generated in SCCRO5 by standard PCR mutagenesis, as previously described (17). 
Primers were designed using Primer3 (Supplemental Table S7). SCCRO5 and its mutated forms were 
cloned into pEGFP-N2 (Clontech, Mountain View, CA), pBABE (BD Biosciences, San Jose, CA), and 
pGEX-4T-3 (GE Healthcare Life Sciences, Piscataway, NJ) vectors. Plasmid and protein purifications 
were performed as previously described (16, 17). shRNA against human SCCRO5 (obtained from the 
Genome Sequencing Center at Memorial Sloan-Kettering Cancer Center) or lacZ shRNA (negative 
control) was transfected – along with packaging plasmids pLP1, pLP2, and pVSVG – into HEK293 
cells by use of Lipofectamine 2000, in accordance with the manufacturer’s protocol (Invitrogen, 
Grand Island, NY). Lentiviral particles were harvested 48 h and 72 h after transfection and were 
filtered, pelleted, and resuspended in media for retroviral delivery in the presence of polybrene 
(Millipore, Billerica, MA). Twenty-four hours after infection, cells were cultured in media containing 
puromycin, to select for infected cells.
Molecular and biochemical assays
Glutathione S-transferase (GST) pull-down assays, in vitro neddylation assays, in vitro thioester 
reactions, transfections, and immunoblotting were performed as previously described (16, 17). 
Proliferation and colony formation assays
MTS proliferation assays and colony formation assays were performed as previously described (16, 
17). For the soft agar assay, colonies were counted using ImageJ software (National Institutes of 
Health, Bethesda, MD), to analyze images captured from four 6-well plate wells per construct, from 
two independent experiments.
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Statistical analysis
Descriptive statistics were used to summarize study day. Continuous variables were compared 
across groups using Student’s t-test or Mann-Whitney U-test. Categorical comparisons were 
performed using the Fisher’s exact test. Survival curves were generated using the Kaplan-Meier 
method and compared using the log-rank test. Time to recurrence was defined as the time between 
completion of primary treatment of cancer and the development of recurrent cancer at any site 
(local, regional, or distant). Survival outcomes were censored for patients who died of causes other 
than cancer, were lost to follow-up or survived to the end of the study. Statistical significance was 
defined as a two tailed p-value less than or equal to 0.05. All statistical analyses were performed 
using state-of-the-art statistical packages (SPSS, Chicago, IL; or SAS, Durham, NC).
Results
SCCRO5 binds to neddylation components
In silico analysis showed that SCCRO has four paralogs in higher organisms, all with a highly 
conserved C-terminal PONY domain with variable N-terminal domains (Supplemental Fig. S1A). 
The established role of the PONY domain in neddylation raised the possibility that, like SCCRO, 
SCCRO’s paralogs participate in neddylation E3 activity. To determine the role that SCCRO5 plays in 
neddylation, we assessed the binding of SCCRO5 to neddylation components. GST pull-down assays 
using HeLa cell extracts, followed by Western blot analysis for neddylation components, showed 
that, like SCCRO, SCCRO5 binds to CAND1, Ubc12, Cul1, Cul2, Cul3, and ROC1 (Table 1 and Fig. 1A). 
Previous biochemical and structural studies have established that SCCRO binds to its neddylation 
components through its PONY domain, which contains four residues that are critical for binding 
interactions (Supplemental Fig. S1B) (17, 40, 41). To map the binding domains, we created a series 
of SCCRO5 deletions and point mutants as GST fusions, including those involving the N-terminal 
NLS and C-terminal PONY domains, and used them in pull-down assays on HeLa lysates. Deletion 
of the PONY domain (SCCRO5_Δ189-237) or mutation in critical residues (SCCRO5_D195N, SCCRO5_
A219R, SCCRO5_D225N, SCCRO5_E226A, SCCRO5_A219R/D225N, and SCCRO5_D195N/A219R/
D225N) resulted in loss of binding to CAND1 and Cul1-ROC1 (Table 1). Binding to Ubc12 was lost only 
with larger deletion of the C-terminal region of SCCRO5 (SCCRO5_Δ189-237), which is consistent 
with the location of the binding site of Ubc12 in SCCRO (17). Previous studies have shown that the 
UBA domain in SCCRO is not required for binding to neddylation components (17, 40, 41). SCCRO5 
contains an NLS in its N-terminus. We found that the NLS is functional, as transiently expressed 
GFP-SCCRO5 was exclusively present in the nucleus, whereas NLS-deletion mutant GFP-SCCRO5 
(SCCRO5_Δ1-10 and SCCRO5_Δ1-46) had a pan-cellular distribution on fluorescence microscopy 
(data not shown).
As with the UBA domain of SCCRO, deletion of the NLS or the entire N-terminus in SCCRO5 
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(SCCRO5_Δ1-10 and SCCRO5_Δ1-46, respectively) had no effect on binding to Cullin-ROC1, Ubc12, 
or CAND1 (Table 1). These results show that binding with the neddylation components and residues 
involved in the interactions are conserved between SCCRO and SCCRO5. 
Table 1. Results from GST pull-downs.
SCCRO5 Mutants Cul1-ROC1 CAND1 Ubc12
WT + + +
∆1-10 + + +
∆1-46 + + +
∆189-237 - - -
A219R - - +
D195N - - +
D225N - - +
E226A - - +
A219R/ D225N - - +
D195N/ A219R/ D225N - - +
SCCRO5 interacts with components of the neddylation pathway.
NOTE: The table shows a summary of results from pull-down assays using GST-SCCRO5 and selected mutants to 
recombinant Cul1-ROC1, Ubc12, and CAND1, which confirmed that binding to Cul1-ROC1 and CAND1 requires 
an intact PONY domain but not the NLS domain. In contrast, binding to Ubc12 was only lost with deletion of 
the C-terminus (SCCRO5_ Δ189–237).
SCCRO5 preferentially binds to Ubc12~Nedd8 thioester
The mechanisms that maintain the processivity of the reactions that result in the conjugation of 
ubiquitin and ubiquitin-like proteins are highly conserved. Central to maintenance of processivity 
is a differential affinity between E1 and E3 for free and conjugated E2, respectively. Differences in 
affinity ensures that an E2 must dissociate from its cognate E1 after it accepts transfer of ubiquitin 
or ubiquitin-like proteins and before it can bind to the E3. SCCRO has greater affinity for E2~Nedd8 
thioester than for free E2, which is consistent with its role as a component of the E3 for neddylation 
(17). To determine whether SCCRO5 also conforms to the established processivity paradigm for 
E3s, we performed GST pull-down assays on products from a Ubc12 thioester reaction, followed 
by Western blot analysis for Ubc12. Even in the presence of molar-excess free Ubc12, SCCRO5 
preferentially bound to Ubc12~Nedd8 thioester (Fig. 1B; compare lanes 1 and 3). Moreover, the 
results of GST pull-down assays showed that, as with SCCRO, critical residues involved in binding 
of SCCRO5 to Cul1-ROC1 (lanes 3 and 4) and the N-terminal region (lane 5) were not involved in 
binding to Ubc12~Nedd8 (Fig. 1C). These findings confirm that, in its interactions with Ubc12, 
SCCRO5 maintains reaction processivity paradigms. 
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Figure 1. SCCRO5 interacts with components of the neddylation pathway. 
(A), Western blot analysis of the products of GST-SCCRO, GST-SCCRO5, and selected GST-SCCRO5 mutants 
after pull-down assays from HeLa lysates probed with the indicated antibodies, which shows that, like SCCRO, 
SCCRO5 binds to CAND1, Cul1, Cul2, Cul3, and ROC1. Mutations in the PONY domain (SCCRO5_D225N and 
SCCRO5_E226A), but not the N-terminal NLS (SCCRO5_ Δ1–46), result in loss of binding. The dividing line 
between lane 1 and lane 2 indicates the position of omitted lanes from the same gel. (B), Western blot analysis 
of Ubc12 after GST and GST-SCCRO5 pulldown assays on products from a thioester reaction (lane 1), which 
shows preferential binding to Ubc12~Nedd8, even in the presence of excess free Ubc12. C, Western blot 
analysis of Ubc12 after pull-down assays on products of thioester reaction, which shows that GST-SCCRO5 and 
PONY and NLS mutants bind equally to Ubc12~Nedd8.
SCCRO5 promotes cullin neddylation
Structural and biochemical studies have shown that SCCRO promotes cullin neddylation by 
promoting complex assembly, nuclear translocation of neddylation E3 components, enhanced 
E2 recruitment, and structural orientation to optimize the efficiency of the transfer of Nedd8 
from Ubc12 to cullin (42, 43). To determine whether SCCRO5 also promotes cullin neddylation, 
we performed in vitro neddylation reactions containing Nedd8, recombinant APPBP1/Uba3 (E1), 
Ubc12 (E2), ATP, and whole-cell lysate from HeLa cells (as a source of Cullin-ROC substrates), with 
and without SCCRO5. Western blotting of reaction products for cullins showed a dose-dependent 
increase in neddylation of Cul1, Cul2, and Cul3 with the addition of SCCRO5 (Fig. 2A). A time-course 
in vitro neddylation reaction showed that SCCRO5 enhanced the rate of cullin neddylation (Fig. 2B). 
To determine the domains required for the observed effects on neddylation, we supplemented in 
vitro reactions with SCCRO5 or selected SCCRO5 mutants. PONY domain mutants (SCCRO5_D225N 
and SCCRO5_E226A) failed to augment Cul3 neddylation beyond basal levels, whereas N-terminus 
deletion mutants (SCCRO5_ Δ1–46) enhanced Cul3 neddylation to levels similar to those observed 
in reactions supplemented with wild-type SCCRO5 (Fig. 2C). Combined, these findings suggest 
that, as with SCCRO (17), the effect of SCCRO5 on cullin neddylation in vitro requires its interaction 
with neddylation E3 components through its PONY domain but not its NLS domain.
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Figure 2. SCCRO5 augments cullin neddylation. 
(A), Western blot analysis of the indicated cullins on products of an in vitro neddylation reaction using HeLa 
lysates as a source for Cullin-ROC1 complexes supplemented with a gradient of SCCRO5, which shows a 
dose-dependent increase in neddylation of Cul1, Cul2, and Cul3 with the addition of recombinant SCCRO5. 
(B), Western blot analysis of Cul1 on products of an in vitro neddylation reaction with (lanes 5–8) or without 
(lanes 1–4) the addition of SCCRO5, which shows enhanced efficiency of Cul1 neddylation by SCCRO5. (C), 
Western blot analysis of Cul3 on products of an in vitro neddylation reaction with concentration gradients 
of SCCRO5, SCCRO5_∆1–46, SCCRO5_D225N, or SCCRO5_E226A (quantities in pmol), which shows a dose-
dependent increase in neddylation of Cul3 with SCCRO5 and SCCRO5_∆1–46 but not with SCCRO5_D225N or 
SCCRO5_E226A.
SCCRO5 promotes cell proliferation and anchorage-independent cell growth
With SCCRO5’s function in cullin neddylation established, we next asked whether this activity is 
required for transformation. To determine this, we transfected NIH-3T3 cells with pBABE-SCCRO5, 
selected pBABE-SCCRO5 mutants or empty vector, and developed two stably expressing clones for 
each construct by use of puromycin selection. Equal expression of SCCRO5 and SCCRO5 mutants 
in selected clones was confirmed by qRT-PCR and Western blot analysis (Supplemental Fig. S2A 
and S2B). The results of MTS assays showed that the proliferation rate was significantly higher 
in SCCRO5-expressing clones than in SCCRO5_D195N/A219R/D225N, SCCRO5_ Δ1–10, or empty 
vector transfected NIH-3T3 cells (Fig. 3A). NIH-3T3 clones were then subjected to soft agar colony 
formation assay to assess transforming ability, which showed that SCCRO5-transfected clones 
had significantly higher anchorage-independent growth, compared with SCCRO5_D195N/A219R/
D225N, SCCRO5_ Δ1–10, or empty vector transfected cells (Fig. 3B). Combined, these findings 
suggest that SCCRO5’s oncogenic activity requires its neddylation-promoting activity as well as its 
compartmentalization to the nucleus. 
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SCCRO5 overexpression is associated with an oncogene addiction phenotype
Consistent with the concept of oncogene addiction, we previously reported that cancer cell lines 
with amplification and high levels of SCCRO expression are more susceptible to apoptosis with 
RNAi knockdown of SCCRO, compared with cell lines with normal copy numbers and low levels 
of SCCRO expression (16, 44). To validate the role that SCCRO5 plays in cancer pathogenesis, we 
sought to determine whether an oncogene addiction to SCCRO5 was present in cancer cell lines. 
Results of qRT-PCR and Western blot analysis showed a wide range of SCCRO5 expression in a panel 
of head and neck cancer cell lines, with the highest levels of expression in SCC15 and MDA1483 
and the lowest level in MDA1386 (Fig. 3C). Representative cell lines with low (MDA1386) and high 
(MDA1483) endogenous SCCRO5 expression were transfected with two independent anti-SCCRO5 
shRNA constructs and with anti-lacZ shRNA as a control. Western blot analysis, after transfection 
with anti-SCCRO5 shRNA constructs, showed efficient knockdown of SCCRO5 levels, compared 
with those in the anti lacZ shRNA-transfected cells (Fig. 3D). SCCRO levels were not affected by 
transfection with any of the shRNA constructs, which confirmed specificity. Results of MTS assays 
showed a more significant decrease in the viability of MDA1483 cells, compared with MDA1386 
cells, after SCCRO5 knockdown (Fig. 3E and F). These results indicate the presence of an oncogene 
addiction phenotype and validate the role of SCCRO5 in cancer pathogenesis. 
Figure 3. Transgenic expression of SCCRO5 promotes proliferation and anchorage-independent 
growth. 
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(A), graph showing results from an MTS assay on NIH-3T3 cells stably expressing SCCRO5 and indicated 
mutants, which shows increased proliferation in cells expressing SCCRO5 but not NLS (SCCRO5_∆1–10) or PONY 
(SCCRO5_D195N/A219R/D225N) domain mutants. (B), results from a soft agar assay, which shows increased 
colony formation in NIH-3T3 cells stably transfected with SCCRO5, compared with that in cells transfected 
with empty vector and SCCRO5 NLS and PONY domain mutants (bars represent the mean _ SD number of 
colonies per well of 6-well plates; P < 0.001). (C), Western blot analysis, which shows SCCRO5 protein levels and 
corresponding mRNA levels, on the basis of real-time PCR, in head and neck cancer cell lines. (D), Western blot 
analysis of SCCRO5, with GAPDH as a loading control, on lysates fromMDA1386 (low endogenous SCCRO5) and 
MDA1483 (high endogenous SCCRO5), before and after transfection of two independent shRNA constructs 
against SCCRO5 or lacZ control, which shows efficient and specific knockdown of SCCRO5. (E) and (F), graphs 
from MTS assays showing a more pronounced decrease in the viability of MDA1483 cells, compared with 
MDA1386 cells, with knockdown of SCCRO5.
SCCRO5 overexpression is associated with an aggressive clinical course
To establish the clinical significance of SCCRO5 overexpression, we sought to identify mutations and 
to determine the prevalence of SCCRO5 overexpression, as well as the association of mutations and 
overexpression with outcome in a panel of randomly selected human tumors. Sequenome-based 
mutational screening of all cases did not identify any mutations in SCCRO5 (data not shown). To 
investigate the presence and frequency of overexpression, SCCRO5 mRNA levels were determined 
by qRT-PCR in cancer tissue and matched histologically normal tissue for each case. The highest 
prevalence of SCCRO5 mRNA overexpression was observed in cancer types known to harbor 11q22 
amplification, including gliomas (4/10; 40%), lung SCCs (14/30; 47%), and oral cavity SCCs (16/40; 
40%). SCCRO5 mRNA overexpression was less common in cancer types with a lower prevalence of 
11q22 amplification, including lung adenocarcinomas (2/27; 7%), lung neuroendocrine carcinomas 
(6/54; 11%), ovarian carcinomas (1/40; 3%), and thyroid carcinomas (5/56; 9%; Fig. 4A; refs. 26, 27, 
30). Moreover, in the cohort of lung SCCs and oral cavity SCCs, SCCRO5 mRNA levels correlated with 
SCCRO5 protein levels (Fig. 4B). 
To validate the prevalence of SCCRO5 dysregulation, we analyzed interim results from TCGA 
projects, which showed that the highest prevalence of SCCRO5 dysregulation (amplification and/or 
overexpression) was in head and neck SCCs (11.6%), followed by ovarian serous cystadenocarcinomas 
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(3%; copy number change only; expression data not available), cervical carcinomas (8.7%; copy 
number change only; expression data not available), and bladder urothelial carcinomas (7%), 
with a significant correlation between copy number and mRNA expression in head and neck SCCs 
(Supplemental Fig. S3). The difference in the prevalence of dysregulation between our tumor cohort 
and that in the TCGA likely represents differences in the sensitivity of the analytic techniques used 
to assess SCCRO5 mRNA levels (cDNA array vs. qRT-PCR) and in the type of control tissue used for 
analysis (matched normal tissue vs. blood). 
To determine clinical relevance, we performed a post hoc analysis to determine the association 
between SCCRO5 overexpression and disease-free survival. We limited survival comparisons 
to patients undergoing treatment for head and neck or lung SCC as these datasets had: (i) 
reasonable power (more than 10 cases with SCCRO5 over expression), (ii) had sufficient events (only 
2 recurrences were observed in the thyroid cancer cohorts; Supplemental Table 3), and (iii) had 
uniform histology (thyroid cohort included papillary, follicular and Hurthle cell carcinomas and lung 
neuroendocrine carcinomas included large cell carcinomas, small cell carcinomas, and carcinoid 
tumors; Supplemental Table S4). All patients in the study cohort underwent uniform treatment that 
included primary surgery with or without adjuvant treatment (on the basis of the extent of disease), 
in accordance with established institutional protocols. Clinicopathologic parameters, including 
age, sex, tumor node metastasis stage, and tobacco use, were not significantly different according 
to SCCRO5 expression status for either cancer cohort (Supplemental Tables S1 and S2). We found 
that SCCRO5 overexpression (SCCRO5+), which is defined in the Materials and Methods section, 
compared with normal expression of SCCRO5 (SCCRO5-), negatively correlated with disease-free 
survival for both head and neck SCCs and lung SCCs (P = 0.05; Fig. 4C and D). Interestingly, time to 
survival analysis for lung neuroendocrine carcinomas also shows worse outcome in tumors with 
SCCRO5 over expression (Supplemental Fig. S4; P = 0.05). However, the differences in outcome in 
the lung neuroendocrine carcinoma need to be considered with caution given the limited sample 
size and variable behavior of histologic subtypes of neuroendocrine carcinomas. Moreover, 
limitation of sample size and number of events in the study cohorts do not support multivariate 
analyses. Nonetheless, the correlation of overexpression with an aggressive clinical course supports 
SCCRO5’s clinical relevance. 
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Figure 4. SCCRO5 overexpression is common in human tumors and correlates with outcomes. 
(A), box plot showing fold increase in SCCRO5 mRNA expression, analyzed by qRT-PCR, in 10 gliomas, 30 
lung SCCs, 27 lung adenocarcinomas (AC), 54 lung neuroendocrine (NEC) tumors, 40 oral SCCs, 40 ovarian 
carcinomas, and 56 thyroid carcinomas, compared with matched normal tissues (boxes represent the lower 
through the upper quartile; the median is shown as a horizontal line; whiskers represent minimum and 
maximum levels). The percentage of cases with overexpression is given below each plot. (B), Western blot 
analysis showing SCCRO5 protein expression in representative head and neck and lung SCCs (T) and matched 
normal (N) samples. The corresponding fold change in mRNA levels, determined by real-time PCR, is noted 
below. (C), Kaplan–Meier survival curves from post-hoc analysis showing recurrence-free survival based on 
SCCRO5 mRNA expression status in primary oral SCCs. (D), Kaplan–Meier survival curves showing recurrence-
free survival from post hoc analysis based on SCCRO5 mRNA expression status in primary lung SCCs.
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Discussion
SCCRO and its paralogs are commonly dysregulated in human cancers, with aberrations of 
one or more paralogs present in 50% of head and neck cancers, in 70% of lung SCCs, in 55% of 
ovarian serous cystadenocarcinomas, in 34% of cervical and endometrial carcinomas, in 26% of 
lung adenocarcinomas, and in 15% of glioblastomas, on the basis of analysis of interim data from 
respective TCGA projects. Of the SCCRO paralogs, SCCRO and SCCRO5 are the most commonly 
dysregulated and have a tendency toward mutual exclusivity, which suggests that they act 
independently in oncogenesis. It is well established that overexpression of SCCRO promotes its 
function as an oncogene (16, 18). By showing that overexpression of SCCRO5 has transforming 
activity and by associating it with an aggressive clinical course in human cancers, our data support 
the position that SCCRO5 may function as an oncogene as well (20). Its role in cancer pathogenesis is 
further validated by our findings, which indicate the presence of an oncogene addiction phenotype 
in cancer cell lines that have high endogenous levels of SCCRO5 expression. Structure-function 
analyses show that, as with SCCRO, SCCRO5’s conserved PONY domain is required for binding to 
neddylation components, as well as for its neddylation and transforming activities (16, 17, 41, 42). 
Of interest, SCCRO5’s N-terminal NLS was not required for neddylation- promoting activity in vitro, 
which is similar to the case for the UBA domain in SCCRO (41). 
Given that SCCRO’s subcellular localization is important to its neddylation activity, the direct 
or indirect association of the N-terminal motifs with subcellular localization of the SCCRO 
paralogs suggests that they may regulate neddylation activity in vivo (43–45). Consistent with 
this finding, SCCRO’s UBA is involved in monoubiquitination by Nedd4-1, which promotes  nuclear 
export, thereby inhibiting its neddylation activity (unpublished data; refs. 43, 45). Similarly, 
the myristoylation sequence localizes SCCRO3 to the membrane, which affects its neddylation 
promoting activity (unpublished data; ref. 46). Our finding showing that the NLS is required for 
SCCRO5’s transforming activity suggests that, as with the UBA, the NLS may modulate neddylation 
activity in vivo. However, these findings raise a question about SCCRO5’s role in neddylation. Our 
previous work showed that SCCRO promotes nuclear translocation of Cullin-ROC1, which is required 
for neddylation in vivo. Given that SCCRO5 is present almost exclusively in the nucleus, it is unclear 
how cytoplasmic Cullin-ROC1 complexes are delivered to the nucleus to allow for interaction with 
SCCRO5. Several possibilities exist, including cooperative activity between other SCCRO paralogs 
and NLS-containing variants, presence of alternative mechanisms for nuclear translocation of 
Cullin-ROC1 complexes, and selective activity on cullins situated in the nucleus. The functional 
effects of neddylation are mediated by downstream targets that CRLs activate. 
The recent publication by Monda and colleagues showing that SCCRO and its paralogs have 
overlapping affinity to E2s (Ube2M and Ube2F) and cullins (42) suggests that they may have 
redundant effects on CRL activity in vivo. This idea is supported by the differential requirements of 
SCCRO for viability in yeast, whose genome does not contain other SCCRO paralogs, and in higher 
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organisms, where paralogs can compensate for SCCRO loss (unpublished data; refs. 40, 43). As 
SCCRO5 promotes neddylation of all cullins (with the possible exception of Cul4A), it putatively 
can regulate the ubiquitination of a myriad of proteins, resulting in diverse cellular effects (42). Guo 
and colleagues suggest that SCCRO5 may be involved in regulating ubiquitination of the proteins 
involved in DNA damage repair (20). Consistent  with this suggestion, SCCRO5 was found to be 
part of a panel of seven genes whose expression score predicts radiation response in patients 
with cervical cancer (47). Further work is required to define the CRLs and protein targets that are 
dependent on SCCRO5 in the DNA damage response, cellular activities, and oncogenesis.
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Supplemental figure 1. 
(A), Schematic representation of domain structures of SCCRO and its paralogs. (B), Alignment of PONY domain 
of SCCRO and its paralogs. SCCRO5 residues critical for binding to neddylation components are shown.
A
B
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Supplemental figure 2. 
(A), Western blot analysis of lysates of NIH-3T3 cells stably transfected with vector alone, SCCRO5, SCCRO5_Δ1-
10 or SCCRO5_D195N/A219R/D225N and probed with antibody against SCCRO5 or tubulin as a loading control. 
SCCRO5_Δ1-10 is not detected as the antibody recognizes an epitope that included this region. (B), Bar graph 
depicting results of qRT-PCR on the same cells as in A showing expression of transgenes.
A B
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Supplemental figure 3. 
Correlation between SCCRO5 copy number alterations and mRNA expression measured by RNA seq (deep 
sequencing for RNA), in head and neck squamous cell carcinomas from The Cancer Genome Atlas, normalized 
by z-score transformation. Het, heterozygous; Hom, homologous; RPKM, reads per kilobase for million mapped 
reads.
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Supplemental figure 4. 
Kaplan-Meier survival curves from post-hoc analysis showing recurrence-free survival based on SCCRO5 mRNA 
expression status in primary lung neuroendocrine carcinomas.
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Supplemental Table S1. Oral squamous cell carcinoma- patient and tumor characteristics.
Characteristic Total (N=40) SCCRO5 overexpression P
Present  (N=16) Absent  (N=24)
Median age (range), years 57 (26-89) 57 (36-89) 58 (26-80)       NS*
Gender NS#
   Male 24 9 15
   Female 16 7 9
TNM Stage NS#
   Early (I-II) 29 12 17
   Advanced (III-IV) 11 4 7
Tumor site in oral cavity NS#
   Tongue 24 11 13
   Other 16 5 11
Tobacco use NS#
   Yes 25 10 15
   No 15 6 9
*Mann-Whitney U test.
#Fisher’s exact test.
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Supplemental Table S2. Lung squamous cell carcinoma –patient and tumor characteristics.
Characteristic Total (N=30) SCCRO5 overexpression P
Present (N=15) Absent (N=15)
Median age (range), years  67 (43-84) 67 (43-84) 65 (48-76)  NS*
Gender NS#
   Male 21 9 12
   Female 9 6 3
TNM Stage NS#
   Early (I-II) 25 12 13
   Advanced (III-IV) 5 3 2
Tobacco use NS#
   Yes 29 15 14
   No 1 0 1
*Mann-Whitney U test.
#Fisher’s exact test.
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Supplemental Table S3. Thyroid carcinoma –patient and tumor characteristics.
Characteristic 
SCCRO5 overexpression P Value
Present  (N=5) Absent  (N=51)
Age NS#
     <45 years 3 23
     >45 years 2 28
Gender NS#
     Female 4 41
     Male 1 10
Type of operation NS#
     Total 4 31
   Lobectomy 1 20
Tumor size NS#
     0-2 cm 2 29
     >2.1 cm 3 22
Lymph node metastasis NS#
     Present 3 41
     Absent 2 10
Capsular invasion NS#
     Present 1 29
     Absent 4 22
Tumor encapsulation NS#
     Present 4 31
     Absent 1 20
Extrathyroidal extension NS#
     Present 2 33
     Absent 3 18
Recurrence NS#
     Present 1 1
     Absent 4 50
#Fisher’s exact test.
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Supplemental Table S4. Lung neuroendocrine carcinoma –patient and tumor characteristics.
Characteristic 
SCCRO5 overexpression P Value
Present  (N=6) Absent  (N=48)
Median age (range), years 58.5 (48-79) 63.5 (31-83) NS*
Gender NS#
     Female 3 20
     Male 3 28
Tobacco use NS#
   Yes 39 6
   No 9 0
Tumor type NS+
   Carcinoid 2 16
   Large cell carcinoma 3 25
   Small cell carcinoma 1 7
TNM Stage NS#
   Early (I-II) 5 45
   Advanced (III-IV) 1 3
Recurrence 0.05#
     Present 3 6
     Absent 3 42
*Mann-Whitney U test.
#Fisher’s exact test.
+Chi Square Test
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Supplemental Table S5. Sequences of the real-time PCR primers for SCCRO5 and housekeeping gene 
GAPDH (in 5’-3’ direction).
Gene Forward primer Reverse primer
SCCRO5 ‘TGCGCTCACAGTTGAATGATATTTCGTC’ ‘CAGTGGCCATGTCCTCCCAAGCAG’
GAPDH ‘GCACCACCAACTGCTTAG’ ‘CATGGACTGTGGTCATGAG’
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Supplemental Table S6. Sequences of the DNA mutation analysis primers for SCCRO5.
DNA mutation analysis primer Sequence
SCCRO5_450608_L_13706892_chr11_102467638_20 GTAAAACGACGGCCAGTGGGGAAGCGCAATTTACATA
SCCRO5_450608_R_13706893_chr11_102468531_20 CAGGAAACAGCTATGACCAGTTTCACTTTTTGGCGGTG
SCCRO5_450609_L_13160312_chr11_102465192_20 GTAAAACGACGGCCAGTTCAGCCTAAATTGGCAACAA
SCCRO5_450609_R_13160313_chr11_102465562_20 CAGGAAACAGCTATGACCACAATGCCAACCGAAGAAAA
SCCRO5_450610_L_chr11_102459030 GTAAAACGACGGCCAGTCATTTGCCCAACTTAAACTGA
SCCRO5_450610_R_chr11_102459353 CAGGAAACAGCTATGACCTGGTGTGTTCATGGGTACCTT
SCCRO5_450611_L_13158842_chr11_102458527_20 GTAAAACGACGGCCAGTCTGCCCAACGAACATACTCC
SCCRO5_450611_R_13158843_chr11_102458999_20 CAGGAAACAGCTATGACCTGCTGACTTTTCCCCTATCC
SCCRO5_450612_L_12038772_chr11_102442443_20 GTAAAACGACGGCCAGTATGTCCTCCCAAGCAGAAGA
SCCRO5_450612_R_12038773_chr11_102442863_20 CAGGAAACAGCTATGACCATTGGTAGATGCAGGGCAAG
SCCRO5_450613_L_15099538_chr11_102442179_20 GTAAAACGACGGCCAGTCTTTTATTTGGGGGACTGGG
SCCRO5_450613_R_15099539_chr11_102442597_20 CAGGAAACAGCTATGACCATGCCTTTGATTTTGCAAGG
SCCRO5_450614_L_14044750_chr11_102440195_20 GTAAAACGACGGCCAGTGTTGCCGAGGAACTGAAAAC
SCCRO5_450614_R_14044751_chr11_102440890_20 CAGGAAACAGCTATGACCGCCAAACTCAAAATGTGGCT
SCCRO5_450615_L_12063632_chr11_102438024_20 GTAAAACGACGGCCAGTAAGGCCAACAGTCTTCCAAA
SCCRO5_450615_R_12063633_chr11_102438925_20 CAGGAAACAGCTATGACCGCTGATCCCTCTCAACAAGC
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Supplemental Table S7. Sequences of the primers used for SCCRO5 PCR for deletion and mutagenesis.
Mutation primer Sequence
Δ1-10 CGCGGATCCATGGGGGTG
Δ1-46 CGCGGATCCATGTCAAGCAAGAAGT
Δ189-237 CTTTGATTGCTCCAGGTACTGGTAAAATAC
A219R ACAGGCCAACGACCATCTTCAT
D195N CATTGTACCATTGATTTTTGTTCATAACACGATAC
D225N GCCACTCAACAAATTCATTAAGAAGAACAGG
E226A CACTCAACAAATGCATCAAGAAGAACAGG
Oncogenic function of SCCRO5 requires its neddylation E3 activity and nuclear localization
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Abstract
Background: SCCRO is now established as an oncogenic driver in many types of cancer. Recently, 
SCCRO’s paralogs were shown to play a role in cancer pathogenesis. The focus of this work was to 
determine the prevalence of dysregulation of SCCRO and its family members and to assess their 
clinical and biological significance in human cancers.
Methods: Expression of SCCRO and its family members was assessed in a cohort of 257 human 
cancer samples and in interim results from The Cancer Genome Atlas (TCGA) for head and neck 
cancers. Expression of SCCRO and its family members was then correlated with clinical outcomes 
and biochemical activity in neddylation and ubiquitination, using selected cohorts.
Results: SCCRO and its family members were commonly dysregulated in many types of cancer, 
with the highest prevalence in squamous cell carcinomas (SCCs) of the lung and oral cavity and 
neuroendocrine carcinomas of the lung. The prevalence of dysregulation was similar in the interim 
TCGA data. Expression of SCCRO and its paralogs was associated with poorer survival outcomes 
for oral SCC in our study cohort and for head and neck cancer in the TCGA data. Moreover, levels 
of endogenous SCCRO correlated with neddylation and ubiquitination activity in representative 
tumor samples of oral cavity and thyroid cancers. 
Conclusions: SCCRO and its paralogs are commonly dysregulated in human cancers. Given the 
biochemical functions of SCCRO and its family members in neddylation, targeting their function 
may have therapeutic benefit. 
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Introduction
Our group previously identified squamous cell carcinoma related oncogene (SCCRO, aka DCUN1D1) 
within an amplification peak at 3q that is present with a high prevalence in head and neck cancers, 
lung squamous cell carcinomas (SCCs), and many other cancer types.(1-6) Its role as a cancer 
driver was validated by (1) independent correlation of SCCRO overexpression with worse clinical 
outcomes, (2) the presence of oncogenic activity in vitro and in vivo, and (3) the presence of an 
oncogene addiction phenotype.(7, 8) A subsequent analysis of The Cancer Genome Atlas (TCGA) data 
for lung SCC validated our findings by showing that SCCRO is a driver within the 3q amplicon in 
lung SCC.(9, 10) In addition, SCCRO was identified as one of the top 42 druggable cancer driver genes 
amplified across multiple TCGA datasets.(11) Combined, these data established the role of SCCRO as 
an oncogenic driver in a wide range of cancer types. 
We and others found that SCCRO functions in neddylation, a process analogous to ubiquitination, 
in which a tripartite enzymatic cascade results in covalent modification of primarily cullin family 
members with the ubiquitin-like protein Nedd8.(12) Neddylation of cullins promotes assembly and 
activity of cullin-RING-ligase (CRL) type ubiquitination E3s. As such, neddylation regulates the 
activity of the largest class of E3s involved in ubiquitination.(13-15) Dysfunction of the ubiquitin-
proteasome pathway contributes to deregulated cell-cycle control and aberrant cell proliferation 
and has been implicated in the pathogenesis of numerous human diseases, including cancer.(16-18) 
Although SCCRO was not required for neddylation in vitro, our findings suggest that its subcellular 
localization of neddylation components is essential for in vivo neddylation activity. 
Starting as a single gene in one-cell organisms, SCCRO has evolved to include four additional 
paralogs in mammals: SCCRO2, SCCRO3, SCCRO4, and SCCRO5. Each of these paralogs has a highly 
conserved potentiation of neddylation (PONY) domain in common, which is required for binding 
to neddylation components and for promoting neddylation activity. We have shown that SCCRO, 
SCCRO2, SCCRO4, and SCCRO5 all promote neddylation and function as oncogenes.(8, 10, 12, 19) In 
contrast, the expression of SCCRO3 is decreased, compared with its expression in matched adjacent 
normal tissues, and it functions as a tumor suppressor gene.(20) The frequency of dysregulation of 
each of all these genes in head and neck and other cancers remains to be determined. 
Materials and methods
Bioinformatic analyses
The ClustalW program (Conway Institute UCD, Dublin, Ireland) was used for multiple sequence 
alignments (Supplemental Figure S1, Supplemental Table S1).  Data from TCGA projects were 
accessed and analyzed using the cBio Cancer Genomics Portal (http://www.cbioportal.org). 
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Human tissues, cell lines, and antibodies 
A total of 257 randomly selected primary cancer tissue and adjacent matched histologically normal 
tissue samples were obtained from patients undergoing surgical treatment at Memorial Sloan 
Kettering Cancer Center between January 1, 2004, and October 1, 2007, as previously described. 
(19) The study group included 30 lung SCCs, 27 lung adenocarcinomas, 54 lung neuroendocrine 
carcinomas, 40 oral SCCs, 10 oligodendromas, 40 ovarian carcinomas, 9 benign nodular 
hyperplasias, 9 follicular adenomas, 10 Hürthle cell carcinomas, 18 well-differentiated papillary 
thyroid carcinomas, and 10 tall cell variant papillary thyroid carcinomas. Demographic and tumor 
data for all patients are described in Supplemental Tables S2 and S3. 
The origins, maintenance, and growth of the cell lines used in this study have been described 
previously.(1,8) The following antibodies were used in this study: anti-SCCRO (developed and 
validated as previously described)(8), anti-Cul1 (Invitrogen, Grand Island, NY), anti-Ponceau S 
(Millipore, Billerica, MA), and anti-ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA).
RNA isolation, cDNA synthesis, and quantitative real-time PCR (qRT-PCR)
RNA isolation and, cDNA synthesis in this study were performed, as previously described.(19) Primers 
were designed for all SCCRO paralogs and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) 
(Supplemental Table S4). To confirm their specificity, the primer sets were tested on plasmids for 
all SCCRO paralogs. qRT-PCR for all SCCRO paralogs was performed on the 257 tumor and paired 
normal samples and the comparative threshold cycle method was used to calculate the expression 
ratio in each sample relative to the value observed in the control standard curve, as previously 
described.(8,19, 21, 22, 23) 
Mutation profiling
Primers were designed, using Primer3, to cover putative exon regions of all SCCRO paralogs 
(National Center for Biotechnology Information Human Genome Build 36.1); products were ≤500 
bp in length.(24) Tumor DNA extraction and mutation analysis were performed in this study, as 
described previously.(19, 25,26) 
Protein extraction and Western blot analysis 
For protein extraction, primary tumor tissues were mechanically homogenized in 1× cell lysis 
buffer (Cell Signaling Technology, Danvers, MA). Protein concentrations were determined using 
the standard Bradford assay. Twenty-five micrograms of primary tissue extracts (25 μg) in 6× 
Laemmli buffer were loaded onto 4% to 12% Bis-Tris polyacrylamide gel, and Western blotting was 
performed in accordance with the standard protocol. 
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Activated neddylation assay and global ubiquitination
A biochemical assay was developed to assess neddylation activity in tissue lysates. The assay has 
been validated to accurately represent neddylation activity, using lysates from murine embryonic 
fibroblasts (MEFs) harvested from wild-type and SCCRO-/- mice in which levels of endogenous 
SCCRO, basal neddylation, and ubiquitination are known. Tumor tissue extracts served as a source 
of Cullin-ROC1 substrate for activated neddylation reactions. In total, 50 μg of wild-type MEF lysates 
or 200 μg of tumor tissue extracts were added to reactions containing 10 nM APPBP1/Uba3, 200 
nM Ubc12, 2 μM Nedd8, and 100 mM ATP. All reactions were performed in 1× neddylation buffer 
(50 mM Tris-HCl [pH 7.6], 1 Mm NaF, 55 mM NaCl, and 5mM MgCl2) and incubated at 30°C for the 
indicated times. Reactions were stopped by the addition of 6× Laemmli buffer, loaded onto 7.5% 
Tris-HCl polyacrylamide gel, and Western blotting was performed in accordance with the standard 
protocol. The antibodies used were rabbit anti-Cul1 (1:1000; Invitrogen) and mouse anti-ubiquitin 
(1:1000; Santa Cruz Biotechnology). The blots were visualized using a chemiluminescent detection 
kit (Millipore). To quantify protein levels on Western blots, densitometric analysis was performed 
using ImageJ software. Ponceau-S was used as loading control, Ponceau-S levels were quantified 
using ImageJ, and protein levels were normalized against Ponceau-S levels. To assess global levels 
of ubiquitinated proteins, Western blots from the neddylation assays were stripped and reprobed 
with anti-ubiquitin antibody. 
Statistical analysis
All statistical analyses were performed using the SPSS statistical software package (version 19; IBM, 
Armonk, NY). qRT-PCR results were expressed as means ± SD, and only tumor samples with values 
at least 2-fold different from the matched normal samples and at least 2-fold different from the SD 
of the mean of all normal samples of the same histologic profile were considered to overexpress 
or underexpress a particular gene. The nonparametric Wilcoxon test was used to compare the 
levels of mRNA expression between tumor and normal samples and to compute the relationship 
between SCCRO expression and neddylation activity. Survival curves were generated using the 
Kaplan-Meier method, by use of GraphPad Prism software for Windows (San Diego, California), 
and were compared using the log-rank test. A p level ≤0.05 was considered to indicate statistical 
significance, and all tests were two-sided. 
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Results
SCCRO paralogs are commonly dysregulated in human cancers
To determine the prevalence of dysregulation of SCCRO and its family members in various human 
cancers, we first assessed mRNA expression levels using qRT-PCR analysis in a variety of human 
cancer and matched normal tissues. The most commonly dysregulated paralogs in human cancers 
were SCCRO (27%), SCCRO3 (41%), and SCCRO5 (14%). SCCRO was most commonly overexpressed 
in lung SCCs, oral SCCs, and oligodendromas. SCCRO2 was most commonly overexpressed in lung 
SCCs and oligodendromas. A decrease in SCCRO3 expression was common in multiple cancer types, 
with the highest prevalence of dysregulation observed in SCCs, adenocarcinomas, neuroendocrine 
carcinomas of the lung, and Hürthle cell carcinomas. Although overexpression of SCCRO4 was not 
common, it occurred with the highest frequency in all SCCs and Hürthle cell carcinomas. SCCRO5 
overexpression was most common in oral SCCs and oligodendromas (Table 1). 
Table 1. Expression of SCCRO1-5 in primary human cancers, analyzed by RT-PCR.
Tumor type SCCRO SCCRO2 SCCRO3 SCCRO4 SCCRO5
Lung squamous cell carcinoma (n=30) 57 23 57 7 11
Lung adenocarcinoma (n=27) 4 11 48 0 7
Lung neuroendocrine carcinoma (n=54) 35 13 85 7 11
Oral squamous cell carcinoma (n=40) 44 3 17 17 42
Oligodendroma (n=10) 60 70 0 10 40
Ovarian carcinoma  (n=40) 18 6 20 5 3
Thyroid benign nodular hyperplasia (n=9) 11 11 22 0 0
Thyroid follicular adenoma (n=9) 0 0 22 0 0
Thyroid Hürthle cell carcinomas (n=10) 10 10 60 20 10
Thyroid papillary carcinoma (n=18) 5 5 11 5 11
Thyroid tall cell variant (n=10) 0 20 10 10 20
Shown are the percentages of cases with mRNA overexpression; for SCCRO3, the percentage of cases in which 
expression was decreased is shown. 
To validate the prevalence of dysregulation of SCCRO and its family members, we analyzed 
interim results from TCGA projects using the BioPortal for all available tumors. In the TCGA data 
set, copy number changes in SCCRO and its paralogs were common; the highest prevalence for 
SCCRO was in lung SCC (79 of 178; 44.3%), ovarian carcinoma (187 of 570; 32.8%), and head and 
neck SCC (75 of 279; 26.8%) (Figure 1A). Copy number changes were less common for other SCCRO 
paralogs (data not shown). A strong correlation was found between SCCRO copy number and 
mRNA expression in head and neck cancers (Figure 1B), as well as other cancers (data not shown). 
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Combined, these findings suggest that SCCRO and its paralogs are commonly dysregulated in 
human cancers. Moreover, the common codysregulation of SCCRO paralogs suggests that they 
may play cooperative roles in oncogenesis; these roles remain to be determined.
Mutations in SCCRO paralogs are rare in human cancers
Mutations are a mechanism for activation of oncogenes. To begin to determine whether mutations 
contribute to the oncogenic activation of SCCRO and its paralogs, we subjected our tumor cohort 
to exon sequencing. We identified only 1 case with a mutation in the UBA domain of SCCRO (data 
not shown). Exon sequencing revealed several single nucleotide polymorphisms (SNPs), shown in 
Supplemental Table S5. The significance of these SNPs, if any, has yet to be determined. In the 
TCGA data set, mutations of SCCRO and its paralogs were present in many cancer types, with 
the highest prevalence in melanomas (12 of 228; 5.2%), uterine carcinomas (10 of 248; 4%), lung 
adenocarcinomas (8 of 229; 3.5%), and head and neck SCCs (4 of 306; 1.3%) (Figure 1C). We have 
previously shown that mutations found in the UBA domain of SCCRO (and identified in the TCGA 
data set) enhance its oncogenic activity.(27) The effects that mutations in SCCRO’s paralogs have on 
their function remain to be determined.
Figure 1. TCGA data analysis. 
A 
B C
A
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(A), Results from analysis of the TCGA data set for all tumors for SCCRO, showing copy number alterations. (B), 
Correlation between SCCRO expression and copy number for head and neck cancers in the TCGA data set. (C), 
Mutations in SCCRO1-5 identified in the TCGA data set.
Correlation between expression of SCCRO and its family members and outcomes
To assess the effects of dysregulation of SCCRO and its family members on clinical factors, we 
focused our analyses on oral SCCs, owing to the availability of outcomes data, a sufficient sample 
size, and the high frequency of 3q amplification in these tumors. Dysregulation of any SCCRO 
paralog was significantly correlated with worse outcomes in the oral SCC cohort (p=0.05) (Figure 
2A). In the TCGA data set, a correlation between SCCRO overexpression and worse outcomes was 
present in the data set for head and neck cancers (Figure 2B). However, the presence or the number 
of SCCRO paralogs dysregulated did not correlate with outcomes (data not shown). These findings 
suggest that a complex interaction may exist between the dysregulation of SCCRO and its paralogs 
in their contributions to tumor behavior.
Figure 2. SCCRO dysregulation correlates with an aggressive clinical course. 
A 
B 
P=0.05
A 
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(A), Kaplan-Meier survival curve from post hoc analysis, showing recurrence-free survival based on SCCRO1-5 
expression status in oral SCCs. (B), Correlation between SCCRO expression and outcomes for head and neck 
cancers in the TCGA data set, red: cases with SCCRO overexpression, blue: cases without  SCCRO overexpression.
SCCRO levels correlate with biochemical activity
We next aimed to determine whether dysregulation of SCCRO has functional consequences in 
human cancers. To determine this, we assessed Hürthle cell carcinomas, as these tumors had the 
cleanest profile of misexpression of SCCRO and its paralogs. We screened for levels of endogenous 
SCCRO protein in Hürthle cell carcinomas and matched normal samples by Western blotting. 
We quantified SCCRO protein levels using densitometric analysis and found samples with low, 
intermediate, and high SCCRO levels (Figure 3A and Supplemental Table S6A). To assess the 
biochemical effects of SCCRO expression, we measured neddylation activity in these samples 
using a novel neddylation assay developed and validated in our laboratory.(12) Western blotting 
with Cul1 antibody, quantified using densitometric analysis, was used to determine the ratio of 
neddylated Cul1 (representing the active form of the protein) to unneddylated Cul1 (representing 
the inactive form of the protein). This showed that SCCRO protein expression levels correlated with 
Cul1 neddylation (Figure 3B). Specifically, the ratios of neddylated to unneddylated Cul1 in the 
low, intermediate, and high SCCRO groups were 0.25, 0.47, and 0.74, respectively (Figure 3C and 
Supplemental Table S6B). 
Neddylation of cullins promotes their activity in CRL complexes, which is expected to lead 
to increases in protein ubiquitination. We next asked whether SCCRO protein expression levels 
were also associated with ubiquitination in this set of tumors. We assessed the levels of global 
ubiquitination in these primary tissue lysates, after subjecting them to activated neddylation 
assays, and found that increasing SCCRO protein expression corresponded with an increase in 
A 
B 
P=0.05
B
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global levels of ubiquitinated proteins in primary Hürthle cell carcinoma tissue lysates (Figure 3D). 
These findings show that increased SCCRO expression in tumors is associated with an increase 
in the level of neddylated cullins and CRL activity, suggesting that SCCRO overexpression has 
functional consequences.
Figure 3. SCCRO overexpression correlates with activation of neddylation. 
(A), Bar graph showing the ratio of tumor to normal levels of endogenous SCCRO protein in 6 tumor and 
matched normal tissue specimens from patients with Hürthle cell carcinoma. (B), Western blot analysis of 
Cul1 on products of an in vivo neddylation reaction using tumor tissue lysates with low (1999T), intermediate 
(1776T), and high (1303T) levels of endogenous SCCRO, with Ponceau-S as a loading control, which shows a 
time-dependent increase in neddylation of Cul1 that correlates with higher levels of endogenous SCCRO; 
the upper band is neddylated Cul1, the lower band is unneddylated Cul1. (C), Bar graph showing an increase 
in the ratio of Cul1-Nedd8 to Cul1 in Hürthle cell carcinomas containing low, intermediate, and high levels 
of endogenous SCCRO. (D), Ubiquitination signaling was assessed by probing the same blot from activated 
neddylation in panel B with ubiquitin antibody; there is a pattern of increased global ubiquitination with 
increasing levels of endogenous SCCRO. 
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Discussion
SCCRO amplification supports oncogenesis by promoting neddylation of cullins. The conservation 
of functional domains, and their locations on chromosomal loci that are aberrant in human cancers, 
suggests that all SCCRO paralogs may contribute to human cancer pathogenesis. We have shown 
that all SCCRO paralogs are dysregulated in human cancers. The most commonly dysregulated 
paralogs were SCCRO (27%) and SCCRO3 (41%), followed by SCCRO5 (14%), SCCRO2 (13%), and 
SCCRO4 (7%). One or more SCCRO paralog was dysregulated in 75% of oral and 80% of lung SCCs. 
The prevalence of dysregulation of SCCRO paralogs in the TCGA data sets was similar to that in our 
findings. These findings suggest that SCCRO and its paralogs play a role in the pathogenesis of a 
wide range of cancers.
We and others have previously shown that SCCRO’s primary role is to promote neddylation 
as part of the E3 complex. Similar to ubiquitination, the activity of the E3 complex serves as the 
rate-limiting step in neddylation. Consistent with the importance of SCCRO’s role in neddylation, 
we found that overexpression of SCCRO was associated with an increase in neddylation activity 
in primary tumors. Interestingly, the PONY domain is required for neddylation, and its mutation 
abrogates SCCRO’s oncogenic activity. While PONY domains are present in all SCCRO paralogs, 
it is quite evident that their various N-terminal domains have a significant impact on functional 
activity. We have shown that subcellular localization is a major mechanism by which SCCRO affects 
neddylation activity. The restriction of SCCRO3 to the membrane, caused by its myristoyl sequence 
in the N-terminus, is a key mechanism by which it inhibits neddylation and promotes oncogenesis. 
Consistent with the role of SCCRO3 as a tumor suppressor,. SCCRO3’s effect on neddylation results 
from its inhibition of SCCRO-promoted neddylation.(20) Interestingly, the SCCRO paralogs were 
commonly codysregulated, suggesting that they may have cooperative activity in human cancers. 
However, the oncologic and clinical significance of codysregulation of SCCRO paralogs remains to 
be determined.
We and others have shown that SCCRO can promote the neddylation of multiple cullins. As 
such, it can affect the activity of a myriad of CRL complexes. CRL complexes are the most common 
class of E3s in ubiquitination. Consistent with its role in regulating CRL activity, overexpression of 
SCCRO correlated with an increase in the global pool of ubiquitinated proteins in primary tumors. 
Although many CRL E3 complex targets are known, specific targets regulated by SCCRO-promoted 
neddylation remain to be determined. Combined, our data suggest that SCCRO and its paralogs are 
commonly dysregulated and may be targetable for therapeutic benefit in many types of human 
cancers.
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Supplemental Table 1. Chromosomal loci of the SCCRO family.
Gene Entrez gene name Gene bank sequence 
accession no.
Locus ORF AA
hDCNL1/SCCRO DCUN1D1 NM_020640 3q26.3 780bp 259
hDCNL2/SCCRO2 DCUN1D2 NM_001014283 13q34 780bp 259
hDCNL3/SCCRO3 DCUN1D3 NM_173475 16p12.3 915bp 304
hDCNL4/SCCRO4 DCUN1D4 NM_001040402 4q12 879bp 292
hDCNL5/SCCRO5 DCUN1D5 NM_032299 11q22.3 714bp 237
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Supplemental Table 2. Demographic characteristics of patients with thyroid cancer.
Characteristics No. of patients (N=56)
Age, years
   ≤45 27
   >45 29
   Median 47.4
   Range 22-87
Sex
   Male 12
   Female 44
Histologic diagnosis
   Nodular hyperplasia 9
   Follicular adenoma 9
   Hürthle cell carcinoma 10
   Well-differentiated papillary thyroid carcinoma 18
   Tall cell variant papillary thyroid carcinoma 10
Tumor size
   0-2.0 31
   >2.0 25
Capsular invasion
   Negative 30
   Positive 26
Lymph node metastasis
   Negative 44
   Positive 12
Distant metastasis
   Negative 55
   Positive 1
Extent of surgical resection
    Lobectomy 21
   Total thyroidectomy 35
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Supplemental Table 3. Demographic characteristics of patients with oral squamous cell carcinoma.
Characteristics No. of patients (N=40)
Age, years
   Median 57
   Range 26-89
Sex
   Male 24
   Female 16
TNM stage
   Early (I-II) 29
   Advanced (III-IV) 11
Tumor site in oral cavity
   Tongue 24
   Other 16
Tobacco use
   Yes 25
   No 15
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Supplemental Table 4. Sequences of the real-time PCR primers for SCCRO1-5 and housekeeping gene 
GAPDH (in the 5’-3’ direction).
Gene of interest Forward primer Reverse primer
SCCRO ‘CTGGAGGACACCAACATG’ ‘TTCACTAGATTGTGTGAAGATC’
SCCRO2 ‘GTTCACCTCCATTTCTCAATGTG’ ‘CTTAGAAATGGCTGTTGCGT’
SCCRO3 ‘CACAGAATTTCGAGTGCTG’ ‘TGCACTTATTGCTTTGCAG’
SCCRO4 ‘CTGGCAAATATTCATAAGATCTACC’ ‘AAGACCGCAGACTTCCTG’
SCCRO5 ‘TGCGCTCACAGTTGAATGATATTTCGTC’ ‘CAGTGGCCATGTCCTCCCAAGCAG’
GAPDH ‘GCACCACCAACTGCTTAG’ ‘CATGGACTGTGGTCATGAG’
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Supplemental Table 5. SNPs in thyroid and oral squamous cell carcinoma samples from the present 
study.
Sample SCCRO SCCRO3 SCCRO4
rs4859146 rs4859147 rs7187522 rs1858901 rs34248677rs35094690 rs13531 rs2271046
Thyroid
   FA 880 X X X X
   WDPTC 493 X X X X
   WDPTC 550 X X X
   WDPTC 228 X X
   WDPTC 256 X X X X X
   TCVPTC 662 X X X X X
   TCVPTC 696 X X X X
   TCVPTC 726 X X X X X
   TCVPTC 960 X X X X X
   HCC 416 X X X X X X
   HCC 526 X X X X X
   HCC 637 X X X X X
   HCC 892 X X X X X
   HCC 895 X X X X X
   HCC 1039 X X X X X
Oral SCC X X X X X X X X
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Supplemental Table 6. Raw data used for Figure 3A and 3C.
A
Endogenous SCCRO 
protein level
Low Intermediate High
Sample name 1999T 1791T 1776T 1432T 1303T 1585T
Normalized SCCRO 
densitometry
279.164 738.087 1054.688 1265.886 2135.076 2431.475
Sample name 1999N 1791N 1776N 1432N 1303N 1585N
Normalized SCCRO 
densitometry
1123.773 2009.617 482.342 129.435 377.672 365.451
B
Cul1 Cul1-Nedd8 Cul1-Nedd8 : Cul1
Low (1999T) 2265.84 Low (1999T) 569.75 0.25
Intermediate (1776T) 3004.89 Intermediate (1776T) 1411.16 0.47
High (1303T) 5374.94 High (1303T) 3977.41 0.74
(A) shows data on the normalized SCCRO densitometry protein levels in tumor and matched normal tissue 
samples. (B) shows data on Cul1 and Cul1-Nedd8 densitometry in tumor samples with low, intermediate, and 
high levels of endogenous SCCRO protein; in the last column, the ratio of Cul1-Nedd8 to Cul1 in these samples 
is shown.
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Supplemental Figure 1. Alignment of the PONY domain of SCCRO1-5.
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Genomic abnormalities
The genome of cancer cells is characterized by various forms of aberrations such as copy-number 
alterations, loss of heterozygosity, and epigenetic changes (1). Earlier studies aimed on development 
of genome-wide screening tools, such as comparative genomic hybridization (CGH) and spectral 
karyotyping (SKY). This allowed to determine common genomic copy number alterations and their 
frequency in a wide range of tumors. In head and neck squamous cell carcinomas (HNSCC), this low 
resolution mapping refined a region of frequent amplification to 3q25-27 (2,3). Further analysis, 
in a systemic, positional cloning approach, identified Squamous Cell Carcinoma Related Oncogene 
(SCCRO, aka DCUN1D1) as a candidate oncogene within this region of frequent amplification, 
located on 3q26.3 (4-6).
New technologies
Technology advancement resulted in the development of world-wide appraised assays that are able 
to detect abnormalities at the gene and nucleotide level, like whole genome sequence analysis. In 
2003 the Human Genome Project was declared complete (7). Also for head and neck cancers more 
and more information is coming into the world about mutation status (8). For example tumors from 
patients with a history of tobacco use have more mutations than tumors from patients who did 
not use tobacco, and tumors that are negative for HPV have twice as many mutations compared to 
HPV-positive tumors (9). One of the latest successes in new technologies was The Cancer Genome 
Atlas (TCGA), a platform for researchers to search, download, and analyze data sets with the goal of 
comprehensively mapping cancer genomes (10). 
Gateway to targeted therapies
These novel technologies make us able to now move to an era in which integrating several 
types of data from high-throughput biological assays will be essential to understand complex 
diseases such as cancer. The last years tremendous steps have been made in tumor DNA and RNA 
sequencing and the subsequent development of novel drugs targeting the mutated pathways. In 
an attempt to improve outcomes for head and neck cancers, new targeted therapeutic strategies 
have been developed, including new anti-EGFR monoclonal antibodies (mAb), tyrosine kinase 
inhibitors (TKI) targeting other members of the erbB/HER family besides EGFR, other nodes along 
the EGFR- mitogen-activated protein kinase, MAPK pathway, or oncogenic pathways, such as the 
phosphoinositide 3-kinase (PI3K), insulin-like growth factor 1 receptor and MET pathways (11). This 
novel drug development has led to improved outcome survival, for example in head and neck 
cancer by Cetuximab targeting EGFR, Vumerafenib, targeting the V600E activating mutation in the 
BRAF gene (12,13). Recently the BRAF V600E mutation has been appraised in aggressive papillary 
thyroid cancer and Pembrolizumab, an antibody against the anti-programmed-death-receptor-1 
(PD-1) has been shown to have activity in PD-1 positive HNSCC (14,15). 
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Understanding the function of SCCRO- implications for cancer
The genomic complexity of human cancers and perpetual genetic evolution in cancer cells has 
made characterization of the cancer genome difficult. But, as described above, developments in 
basic science research has led to a broad range of new therapeutic strategies and the function of 
many cellular pathways involved in carcinogenesis are revealed. Every piece of the puzzle solved, 
is needed to, in the future, be able to better treat cancer patients and improve clinical outcomes.
In further elucidating the molecular biology behind cancer, we focused in this thesis on the 
function of SCCRO, an established oncogene in HNSCC (6). As known, dysregulation of DCN-1, the 
C. elegans ortholog of SCCRO, results in severe developmental defects, and dysregulation of SCCRO 
leads to tumor formation in mice (6,16). Taken together, this made the elucidation of the exact 
molecular function of SCCRO very interesting, both for unravelling the normal cellular function of 
SCCRO and for the implications in carcinogenesis. In chapter 2, we describe that SCCRO is part of a 
complex that functions as the E3 for neddylation. We showed that SCCRO binds to the components 
of the neddylation pathway (Cullin-ROC1, Ubc12, and CAND1), that SCCRO helps to recruit the 
Ubc12~Nedd8 thioester to the neddylation E3 complex, SCCRO promotes cullin neddylation and is 
necessary to dissociate CAND1. 
The completion of the human genome sequencing project and analysis of sequence databases 
revealed a variety of vertebrate genes with sequence homology to SCCRO; four highly conserved 
members of the defective in cullin neddylation domain containing (DCUN1D) proteins. As SCCRO 
was found to be a novel oncogene that functions as an oncogene by its function in the cullin 
neddylation pathway, we sought to elucidate whether these four other paralogs function in the 
neddylation pathway and whether they play a role in carcinogenesis as well.
CRL systems
Due to the complexity of the Cullin Ring ubiquitin Ligase (CRL) system, and the neddylation pathway, 
it is difficult to make a priori hypotheses about the mechanism by which SCCRO overexpression 
and increased neddylation activity contributes to tumor development. There are a wide variety 
of potentially oncogenic and tumor-suppressing pathways which are known to be affected by 
specific CRL E3 complexes, and an even greater number likely remain uncharacterized. Further 
work is required to define the CRL’s and protein targets that are dependent on the SCCRO family in 
cellular activities, specifically what is downstream for each individual paralog as CRL’s regulate the 
ubiquitination of a myriad of proteins, resulting in diverse cellular effects (18). The identification of 
CRL targets downstream of SCCRO is more complex given the presence of 7 Cullins in eukaryotic 
species, each forming a part of a multi-subunit ubiquitin complex modified by Nedd8, regulating 
many different processes. Moreover, the identification of CRL targets downstream of SCCRO is even 
more complex given the multiple SCCRO’s that have neddylation activity and probably different 
General discussion
155
Ch
ap
te
r
7
affinity for each Cullin. 
One strategy for approaching the mechanism of SCCRO-mediated oncogenicity would be 
to individually assay each of the many “candidate” CRL complexes and ubiquitination targets 
for altered activity in SCCRO-overexpressing tumors or SCCRO-transformed cell lines. Another 
approach would be to further identify specific cellular processes or tissues in vertebrates which are 
dependent on the SCCRO family for their normal function. By learning more about the endogenous 
role of the SCCRO family, it may help to further determine the focus of studies of SCCRO family’s 
role in carcinogenesis. 
Elucidating factors that control SCCRO
Since SCCRO promotes cullin neddylation, which serves as a signal for assembly of ubiquitination 
E3 complexes, factors controlling SCCRO likely regulate ubiquitination. As noted by Kurz and 
colleagues, the UBA domain is lost in one of two isoforms of C. elegans DCN-1, and we showed that 
the UBA domain is not necessary for the neddylation-enhancing function of SCCRO proteins, since 
the UBA-lacking proteins SCCRO4 and SCCRO5 enhance in-vitro neddylation reactions with roughly 
the same efficiently as the UBA-containing SCCRO (24). In chapter 3 we describe the finding that 
binding of polyubiquitinated proteins to the N-terminal UBA domain of SCCRO inhibits neddylation 
activity, suggesting the presence of a classical negative feedback loop that regulates CRL-promoted 
ubiquitination activity (25). The effects of the UBA domain do not appear to be allosteric, often 
resulting in a conformational change, as the addition of polyubiquitin chains or mutation of the 
UBA domain has no effect on SCCRO’s neddylation function in vitro, whereas accumulation of 
polyubiquitinated proteins shows classical negative-feedback dynamics in vivo. We suggest that 
binding of polyubiquitinated proteins to the UBA domain affect the subcellular localization and 
function of SCCRO by serving as a signal for the monoubiquitination of SCCRO (26,27). How SCCRO is 
translocated from the nucleus to the cytoplasm and vice versa is very interesting. A possibility is that 
monoubiquitination of SCCRO inhibits interactions with NLS-containing protein partners involved 
in nuclear import. Another possibility is that monoubiquitination of SCCRO leads to an interaction 
with an unknown protein that inhibits nuclear translocation. The role of the UBA domain in cancer 
pathogenesis is well-established and the activity of an oncogene may be mitigated by agents 
that bind to or mimic the oncoprotein’s UBA domain (28-32). Future research should therefore be 
focused on further elucidating the effects of polyubiquitination and monoubiquitination of SCCRO. 
Because SCCRO3, SCCRO4 and SCCRO5 do not contain a UBA domain and do not possess any 
other novel functional domains than the myristoyl sequence and the NLS in comparison to SCCRO 
and SCCRO2, it is tempting to infer that these genes perform a restricted subset of the functions 
performed by the UBA subfamily, that they do not require UBA-mediated interactions and they are 
not likely to replicate all functions of the UBA containing SCCRO proteins in vivo. As we suggest that 
binding of polyubiquitinated proteins to the UBA domain affect the subcellular localization and 
function of SCCRO, it remains a question how the two other subfamilies of the SCCRO family are 
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controlled. The myristoyl sequence of SCCRO3 that localizes to the membrane does not serve as a 
negative feedback loop domain. Neither does the NLS in SCCRO4 and SCCRO5. What controls these 
subfamilies might be useful to identify as it may add information on factors that control the UBA 
domain containing SCCRO proteins. Further experiments with chimeric SCCRO genes containing 
both the UBA and NLS domains, or containing a nuclear export sequence, could help clarify these 
possibilities. But keeping in mind the following restrictions; in vitro studies of the neddylation 
pathway are useful for determining the basic molecular mechanisms of proteins in this system, but 
do not fully capture the complexity of the system in vivo.
Interaction of the five SCCRO family members
One of the puzzling features of the SCCRO family is why there is such a great conservation of five 
separate genes in three subfamilies, given their nearly identical structure and similar functional 
properties. The various expression of the SCCRO family in various human tissues as in human 
cancers suggests that certain tissues have a higher need for neddylation activity than others, and 
that the diversification of SCCRO genes in higher organisms may be related to the need for more 
complex regulation of this system.
The question is if the five SCCRO family members also have functional interaction, overlapping 
or indirect, in the nuclear translocation of Cullin-ROC1 and such in the regulation of cullin 
neddylation. We showed that SCCRO promotes nuclear translocation of Cullin-ROC1, which is 
required for neddylation in vivo (26). In chapter 4 we show that co-expression of SCCRO3 blocked 
SCCRO-promoted transformation of a benign transformed cell line, suggesting that competition 
between SCCRO and SCCRO3 for cullin substrate had functional implications in vivo (33). These 
findings led us to propose that SCCRO3 functions as a tumor suppressor by sequestering Cul1 to the 
membrane and antagonizing SCCRO-mediated nuclear translocation and neddylation of cullins. 
Another reason to hypothesize that the SCCRO’s functionally interact in the nuclear translocation 
of Cullin-ROC1 is shown in chapter 5; our finding showing that the NLS is required for SCCRO5’s 
transforming activity suggests that, as with the UBA, the NLS may modulate neddylation activity 
in vivo (24). However, these findings raise a question about SCCRO5’s role in neddylation. Given 
that SCCRO5 is present almost exclusively in the nucleus, it is unclear how cytoplasmic Cullin-ROC1 
complexes are delivered to the nucleus to allow for interaction with SCCRO5. Several possibilities 
exist, including cooperative activity between the other SCCRO paralogs and the NLS-containing 
variants, presence of alternative mechanisms for nuclear translocation of Cullin-ROC1 complexes, 
and selective activity on cullins situated in the nucleus. 
Targeting the neddylation pathway
Nedd8-activating enzyme (NAE) is the E1 of the neddylation pathway. MLN4924 is a selective 
inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading 
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to apoptotic death in human tumour and has proven successful in the treatment of human 
malignancies (34-38). The success of MLN4924 highlights the benefits of targeting neddylation 
pathway components in anticancer treatment (39). As SCCRO is frequently dysregulated in various 
human cancers and SCCRO is the E3 ligase of cullin neddylation, targeting the activity of SCCRO 
and its paralogs may prove beneficial in the treatment of a significant proportion of patients with 
HNSCC, as well as many other cancers. Several findings suggest that inhibiting SCCRO activity may 
be an effective way to target the neddylation pathway activity in human cancers: (i) in contrast 
with NAE, which is rarely dysregulated in human cancers, SCCRO dysregulation is common and is 
associated with an oncogene addiction phenotype, which was confirmed by results from Wang 
and colleagues (40), (ii) although knocking out other core components of neddylation is associated 
with lethality in mice, SCCRO knockout mice are viable and have no appreciable defects in essential 
functions (26). This suggests that inhibiting SCCRO may have limited detrimental effect on normal 
cells. (iii) SCCRO's molecular interactions and crystal structure are suitable for inhibition by small 
molecules (17, 26, 41, 42).
Towards multiple approach therapies
The treatment of cancer is continuing to evolve, and physicians who are treating patients with 
locally advanced disease have multiple treatment options. The treatment team should consider the 
patient’s overall condition and his or her ability to tolerate aggressive therapy. The risk of local and 
distant recurrence needs to be considered as a treatment is implemented, and a multi-disciplinary 
approach is crucial. However, the next goal, in the near future, is to be able to clinically test each 
patients’ tumor genome and the search for new molecularly targeted agents for head and neck 
cancers will lead to the ability to treat each individual specifically, based on its tumor genetics 
and epigenetics. The incorporation of such therapies into current treatment regimens is priority, in 
conjunction with a good understanding of the underlying mechanisms of action of such targeted 
agents. 
Conclusion
Little was known about the significance and function of the SCCRO family in vertebrates. To our 
knowledge, the Laboratory of Epithelial Cell Biology under supervision of dr. Singh is the first 
to provide functional and clinical data about the protein products of these genes. Our original 
interest in SCCRO arose from evidence that SCCRO is a gene-amplified, overexpressed oncogene 
in human squamous cell cancers of mucosal origin. The discovery of four additional human genes 
with many similar molecular properties raised the question whether they might also be involved in 
the neddylation pathway and carcinogenesis which we have shown in chapter 4 and 5. We hope, 
with elucidating the function of the SCCRO family, to provide important knowledge in the cure 
of cancer. The shown molecular function, oncogenic activity and aggressive clinical course of the 
Chapter 7
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SCCRO family support their clinical relevance in cancer pathogenesis. Innovative molecular targets, 
like the human SCCRO gene family, may add improved outcomes in the treatment of (head and 
neck) cancer in the future and provide much hope (43).
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Summary
SCCRO (a.k.a. DCUN1D1) is an oncogene that is commonly activated by amplification in human 
cancers, especially in head and neck squamous cell carcinomas. The identification of highly 
conserved paralogs that like SCCRO are located in chromosomal loci that are recurrently amplified 
in human cancers (SCCRO2 at 13q34, SCCRO4 at 4q12, and SCCRO5 at 11q22) raised the possibility 
that these paralogs also play a role in cancer pathogenesis. In this thesis the molecular function 
of the SCCRO gene family is described, focusing on their role in the neddylation pathway and in 
carcinogenesis.
First, we wanted to investigate SCCRO’s function in the neddylation pathway, a pathway highly 
relevant to cancer pathogenesis. The neddylation pathway is an enzymatic cascade involving the 
sequential activity of a dedicated E1 (APPBP1/Uba3), E2 (Ubc12), and E3 enzyme. Nedd8, a ubiquitin 
like protein (UBL), is transferred from the E1, E2 to the E3 enzyme. Covalent modification of cullins 
by the ubiquitin-like protein Nedd8 regulates protein ubiquitination by promoting the assembly of 
cullin-RING ligase (CRL) E3 complexes. We show that SCCRO functions as a component of the E3 in 
neddylation; SCCRO binds to the components of the neddylation pathway (Cullin-ROC1, Ubc12, and 
CAND1) in its C-terminal PONY domain and augments, but is not required for, cullin neddylation in 
reactions using purified recombinant proteins. 
In its N-terminal, SCCRO contains a ubiquitin associated (UBA) domain. We found that the UBA 
domain of SCCRO preferentially binds to polyubiquitin chains in a linkage-independent manner. 
Binding of polyubiquitin chains to the UBA domain inhibits SCCRO’s neddylation activity in vivo 
by inhibiting SCCRO-promoted nuclear translocation of neddylation components and results in 
a corresponding decrease in cullin-RING-ligase promoted ubiquitination. Mutations in the UBA 
domain lead to loss of inhibitory control, which results in increased biochemical and oncogenic 
activity, which may be a mechanism of oncogene activity in human cancers.
The specific characteristics of the four paralogs of SCCRO had not yet been studied and the next 
purpose of the research described in this thesis was to screen the role of the SCCRO paralogs in 
human cancers. SCCRO3 and SCCRO5 were shown to be frequently dysregulated in human cancers. 
Therefore, we further elucidated the role of SCCRO3 and SCCRO5 in cancer pathogenesis. SCCRO3 
contains a myristoyl sequence which localizes it to the membrane. We found that SCCRO3 binds 
to components of the neddylation pathway, but contrary to the other SCCRO paralogs, it does not 
efficiently bind to Ubc12 nor does it promote cullin neddylation and so, does not seem to have E3 
activity. We found that SCCRO3 inhibits SCCRO’s transforming activity by sequestering cullins to 
the membrane and we suggest that, in that way, SCCRO3 may function as a tumor suppressor by 
antagonizing SCCRO’s neddylation activity by sequestering cullins. 
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In chapter 5 the role of SCCRO5 in human cancers and the neddylation pathway is described. SCCRO5 
contains a nuclear localization sequence (NLS). Correlation between copy number, mRNA, and 
protein expression and association with clinical outcome was performed showing that increased 
expression of SCCRO5 correlates with a worse clinical outcome. Further on, transforming activity in 
vitro and in vivo, its function in the neddylation pathway and the role of its NLS are elucidated. We 
found that SCCRO5’s NLS is essential for in vivo neddylation activity. 
In chapter 6 we further analyzed the translational importance for this basic science research as we 
examined the role of the SCCRO family of genes in various cancers and describe a novel biochemical 
assay to look for ubiquitination activities in human tissue and use this in a subset of thyroid cancer.
In conclusion, in this thesis we have set the first steps in understanding the molecular function 
and mechanisms of the human SCCRO gene family in neddylation and cancer pathogenesis by 
correlation between copy number, mRNA, and protein expression, association with clinical 
outcome, presence of oncogene addiction in cancer cell lines, transforming activity in vitro and in 
vivo, and by analyzing its function in the neddylation pathway, a pathway highly relevant to cancer 
pathogenesis.  The high frequency of dysregulation, association with a worse clinical outcome, 
combined with an oncogene addiction phenotype, function in a targetable pathway and crystal 
structure suggesting that their activity is amenable to inhibition by small molecules, SCCRO family 
members represent ideal targets for drug development efforts. 
The main goal of this research is to develop therapeutic targets, targeting the neddylation pathway, 
in the treatment of human cancers.
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In dit proefschrift wordt de functie beschreven van de SCCRO gen familie. De SCCRO gen familie 
bestaat uit Squamous Cell Carcinoma Related Oncogene (SCCRO) èn vier genen die in de evolutie 
verwand zijn aan elkaar en functionele gelijkenissen hebben, genaamd SCCRO2, SCCRO3, SCCRO4 
en SCCRO5. SCCRO is een gen dat betrokken is bij de ontwikkeling van tumoren, o.a. in hoofd-hals 
plaveiselcelcarcinomen. In het onderzoek beschreven in dit proefschrift wordt gekeken naar de 
functie van de SCCRO gen familie, naar hun klinische relevantie en naar hun rol in de ontwikkeling 
van kanker. 
Ten eerste werd de moleculaire functie van SCCRO bestudeerd. Er waren aanwijzingen dat SCCRO 
functioneert in de ‘neddylation’ cascade. De neddylation cascade is een enzym-cascade waarbij 
Nedd8, een op ubiquitine lijkend eiwit, wordt opeenvolgend verplaatst van een bepaalde E1 
(APPBP1/Uba3), naar een E2 (Ubc12), naar een E3 enzym. Cullin Ring ligases (CRL) zijn het doel van 
deze Nedd8. Modificatie van cullins door Nedd8 reguleert ubiquitinatie van eiwitten; ubiquitinatie 
is een proces in de cel wat leidt tot eiwitafbraak of het veranderen van de functie van eiwitten. 
Wij tonen in hoofdstuk 2 aan dat SCCRO functioneert als een component van de E3 in cullin 
neddylation. 
SCCRO bevat een ubiquitin geassocieerd (UBA) domein in zijn N-terminus welke wij omschrijven 
en ontrafelen in hoofdstuk 3. Wij tonen aan dat het UBA domein van SCCRO bij voorkeur bindt 
aan polyubiquitine ketens. Binding van polyubiquitine ketens aan het UBA domein van SCCRO 
verhindert SCCRO’s neddylation activiteit in vivo doordat door SCCRO gepromote translocatie van 
componenten van de neddylation cascade wordt verhinderd wat resulteert in een afname van 
cullin-RING ligase gepromote ubiquitinatie. Mutaties in het UBA domein leiden tot verlies van een 
remmende werking op SCCRO’s neddylation activiteit, wat mogelijk een van de onderliggende 
mechanismen is in de ontwikkeling van tumoren door SCCRO.
De volgende stap in ons onderzoek was het verder specificeren van het moleculair mechanisme 
van de aan SCCRO verwante genen en hun rol in de ontwikkeling van tumoren, waarbij we ons 
richten op SCCRO3 en SCCRO5, omdat deze twee paralogen het meest frequent gedereguleerd 
zijn in tumoren. SCCRO3 bevat een ‘myristoylation’ signaal waardoor SCCRO3 aan de celmembraan 
gebonden is. SCCRO3 bindt ook aan de componenten van de neddylation cascade, maar in 
tegenstelling tot de andere SCCRO paralogen, bindt SCCRO3 niet aan Ubc12 en versnelt het niet 
de neddylation van cullins. Tevens wordt bij het screenen van genexpressie levels in verscheidene 
humane tumoren gezien dat SCCRO3 expressie is verlaagd in tumoren. Wij tonen aan dat SCCRO3 
cullins naar de celmembraan sekwestert en zo de neddylation activiteit van SCCRO verhindert. Wij 
suggereren dat hierdoor SCCRO3 als een tumor suppressor functioneert.
Chapter 8
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In hoofdstuk 5 wordt de rol van SCCRO5 beschreven. SCCRO5 bevat een nuclear localization 
sequence (NLS). Gekeken wordt naar de correlatie tussen copy number, mRNA en eiwit expressie 
en klinische parameters. Dit laat zien dat overexpressie van SCCRO5 correleert met een slechtere 
overleving. De in vivo en in vitro eigenschappen van SCCRO5, de functie in de neddylation cascade 
en de rol van de NLS worden bestudeerd waaruit blijkt dat SCCRO5 als een E3 in de neddylation 
cascade functioneert en hiervoor in vivo de NLS nodig heeft.
In hoofdstuk 6 analyseren we het translationele belang van dit basaal wetenschappelijk onderzoek 
door de rol van de SCCRO familie in verscheidene humane tumoren in kaart te brengen. We 
introduceren een nieuwe biochemische test waarmee de ubiquitinatie activiteit in weefsel kan 
worden gemeten en passen deze toe in Hürthle cell carcinomen.
Tot slot, in dit proefschrift hebben we de eerste stappen gezet in het ontrafelen van de moleculaire 
functie en de klinische relevantie van de SCCRO familie in de neddylation cascade en in de 
ontwikkeling van tumoren, o.a. hoofd-hals plaveiselcelcarcinomen. 1) De hoge frequentie van 
deregulatie, 2) de associatie met een slechtere overleving, 3) het 'oncogene' addiction phenotype, 
4) de functie in een te behandelen cascade en 5) een bekende kristalstructuur suggereren dat de 
SCCRO familie in aanmerking komt voor behandeling met ‘small molecules’. 
Het doel van het onderzoek is om uiteindelijk therapieën te ontwikkelen die aangrijpen op de 
SCCRO gen familie in de neddylation cascade teneinde de behandeling van (hoofd-hals) kanker en 
daarmee de prognose voor (hoofd-hals) kanker patiënten te verbeteren.
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List of abbreviations
List of abbreviations
a.k.a. also known as
CA carcinoma
CAND1 cullin associated Nedd8 dissociated-1
CGH comparative genomic hybridization
CRL cullin-RING ubiquitin ligase
DCUN1D1/DCN-1 defective in cullin neddylation 1
DTT dithiothreitol
E1  ubiquitin (or Nedd8)-activating enzyme
E2  ubiquitin (or Nedd8) carrier protein
E3  ubiquitin (or Nedd8)-protein isopeptide ligase
EGFR epidermal growth factor receptor
EV  empty vector
FCS fetal calf serum
FISH fluorescent in situ hybridization
GST glutathione-Sepharose transferase
HA  hemagglutinin
HECT homologous to E6-AP carboxy terminus
HNSCC head and neck squamous cell carcinoma
IB  immunoblotting
IP immunoprecipitation
mAB monoclonal antibodies
MALDI-reTOF matrix-assisted laser desorption/ionization reflectron time-of-flight
MEF murine embryonic fibroblasts
MEM minimal essential media
NAE Nedd8 activating enzyme
NE(C) neuroendocrine carcinoma
NLS nuclear localization sequence
NSCLC non-small-cell lung cancer 
PCAF  p300/CBP-associated factor
PD  pulldown
PCR polymerase chain reaction
PONY potentiating of neddylation
RING really interesting new gene; part of the E3 ligase CRL complex
RNAi  RNA-mediated interference
RT radiotherapy
SCC squamous cell carcinoma
SCCRO squamous cell carcinoma related oncogene
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List of abbreviations
SCF complex SKP1 cullin1 F-box
SKP1  S-phase kinase-associated protein 1
SKP2  S-phase kinase-associated protein 2
SKY spectral karyotyping
TCGA the cancer genome atlas
TKI tyrosine kinase inhibitor
Ub ubiquitin
UBA ubiquitin associated
UBD ubiquitin binding domain
UBL or Ublp ubiquitin like protein
UPS ubiquitin proteasome system
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Summary of PhD training and teaching activities
Name PhD student: C.C. Bommeljé
Erasmus MC Department: KNO-heelkunde
PhD period: 2006-2014
Promotor(s): prof.dr. B. Singh and 
prof.dr. R.J. Baatenburg de Jong
1. PhD training
Year Workload
(Hours/ECTS)
General academic skills 
 Desiderius Education: discipline overstijgend onderwijs 2008-2014  4 ECTS
Research skills
 Research fellowship with weekly basic science training 2006-2008 8 ECTS
 In-depth courses (e.g. Research school, Medical Training)
 Head and neck anatomy (dissection)
 Skillslab Course Hands-on in Otology
2008-2014
2014
4 ECTS
4 ECTS
Presentations
 Poster AAES, Monterey 
 Poster AHNS, San Francisco (best poster)
 KNO vergadering (april)
 KNO vergadering (november)
 Poster AHNS, Arlington 
 KNO vergadering (april) 
 Poster AHNS-IFHNOS, New York City 
     KNO vergadering (november)
2008
2008
2009
2009
2010
2012
2014
2014
3 ECTS
3 ECTS
1 ECTS
1 ECTS
3 ECTS
1 ECTS
4 ECTS
1 ECTS
International conferences
 AAES, Monterey
 AHNS, San Francisco 
 European Skull Base Society, Rotterdam
 AHNS, Arlington
 AHNS-IFHNOS, New York City 
 KNO vergadering (2 / year) 
2008
2008
2009
2010
2014
>2008
0,5 ECTS
1 ECTS
Lecturing
 Onderwijs verpleegkundigen KNO “chirurgische ingrepen”. 2008 0,5 ECTS
Seminars and workshops
 Module: “Knopen en hechten”.
  Workshop: “Geavanceerde beeldvormende technieken voor dokters” 
 Workshop: “Otology course”
2008
2009
2014
0.5 ECTS
0.5 ECTS
1 ECTS
Other
 Refereeravond KNO (4 / year) >2008 1 ECTS
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